ID;Description;GeneRatio;BgRatio;RichFactor;FoldEnrichment;zScore;pvalue;p.adjust;qvalue;geneID;Count
GO:0051254;positive regulation of RNA metabolic process;22/67;312/2237;0,0705128205128205;2,35428626100268;4,53018394674056;5,09185055722451e-05;0,0412448699016448;0,0368826741909334;NLRP3/SERTAD2/ARID5A/NR4A2/INO80D/CTNNB1/APBB2/ELL2/IRF1/IRF4/HSPA1A/PLAGL1/TFEC/JAK2/KLF4/ARID5B/NR1D1/STAT3/JUNB/ELL/ZFP36/ATF4;22
GO:0071214;cellular response to abiotic stimulus;9/67;64/2237;0,140625;4,69519589552239;5,26915561306895;8,36060436090185e-05;0,0412448699016448;0,0368826741909334;GADD45A/SDE2/ADSS2/NLRP3/IRF1/FAS/BCL2L1/ATF4/TIMP1;9
GO:0104004;cellular response to environmental stimulus;9/67;64/2237;0,140625;4,69519589552239;5,26915561306895;8,36060436090185e-05;0,0412448699016448;0,0368826741909334;GADD45A/SDE2/ADSS2/NLRP3/IRF1/FAS/BCL2L1/ATF4/TIMP1;9
GO:0045893;positive regulation of DNA-templated transcription;20/67;289/2237;0,069204152249135;2,3105923668853;4,19435816825462;0,000166783321506587;0,0412448699016448;0,0368826741909334;NLRP3/SERTAD2/ARID5A/NR4A2/INO80D/CTNNB1/APBB2/ELL2/IRF1/IRF4/PLAGL1/TFEC/JAK2/KLF4/ARID5B/NR1D1/STAT3/JUNB/ELL/ATF4;20
GO:1902680;positive regulation of RNA biosynthetic process;20/67;289/2237;0,069204152249135;2,3105923668853;4,19435816825462;0,000166783321506587;0,0412448699016448;0,0368826741909334;NLRP3/SERTAD2/ARID5A/NR4A2/INO80D/CTNNB1/APBB2/ELL2/IRF1/IRF4/PLAGL1/TFEC/JAK2/KLF4/ARID5B/NR1D1/STAT3/JUNB/ELL/ATF4;20
GO:0012501;programmed cell death;26/67;439/2237;0,0592255125284738;1,97742494815218;4,01295482129228;0,000175849319756575;0,0412448699016448;0,0368826741909334;GADD45A/GBP5/MCL1/NLRP3/HK2/NR4A2/TMBIM1/CTNNB1/CCNL1/APBB2/IRF1/HSPA1A/PLAGL1/GGCT/TNFRSF10D/JAK2/KLF4/NEK6/FAS/UBB/PHLPP1/ZFP36/BCL2L1/TGM2/ATF4/TIMP1;26
GO:0008219;cell death;26/67;440/2237;0,0590909090909091;1,97293080054274;4,00016297730448;0,000182908529823968;0,0412448699016448;0,0368826741909334;GADD45A/GBP5/MCL1/NLRP3/HK2/NR4A2/TMBIM1/CTNNB1/CCNL1/APBB2/IRF1/HSPA1A/PLAGL1/GGCT/TNFRSF10D/JAK2/KLF4/NEK6/FAS/UBB/PHLPP1/ZFP36/BCL2L1/TGM2/ATF4/TIMP1;26
GO:0051402;neuron apoptotic process;8/67;56/2237;0,142857142857143;4,76972281449893;5,0190212299682;0,000191972593860956;0,0412448699016448;0,0368826741909334;MCL1/NR4A2/CTNNB1/JAK2/FAS/UBB/BCL2L1/ATF4;8
GO:0045935;positive regulation of nucleobase-containing compound metabolic process;22/67;342/2237;0,064327485380117;2,14776992231823;4,05141488751846;0,000211157599695116;0,0412448699016448;0,0368826741909334;NLRP3/SERTAD2/ARID5A/NR4A2/INO80D/CTNNB1/APBB2/ELL2/IRF1/IRF4/HSPA1A/PLAGL1/TFEC/JAK2/KLF4/ARID5B/NR1D1/STAT3/JUNB/ELL/ZFP36/ATF4;22
GO:0045944;positive regulation of transcription by RNA polymerase II;17/67;227/2237;0,0748898678414097;2,50042737852587;4,18960726619894;0,000229310584850459;0,0412448699016448;0,0368826741909334;NLRP3/ARID5A/NR4A2/CTNNB1/APBB2/ELL2/IRF1/IRF4/PLAGL1/TFEC/JAK2/KLF4/NR1D1/STAT3/JUNB/ELL/ATF4;17
GO:0051726;regulation of cell cycle;15/67;185/2237;0,0810810810810811;2,70713997579669;4,25902071378813;0,000242658411170149;0,0412448699016448;0,0368826741909334;GADD45A/SDE2/INO80D/CTNNB1/CCNL1/APBB2/IRF1/DUSP1/HSPA1A/PLAGL1/KLF4/NEK6/STAT3/JUNB/BCL2L1;15
GO:0000122;negative regulation of transcription by RNA polymerase II;14/67;166/2237;0,0843373493975904;2,81586045675238;4,27159333187635;0,000268697385750182;0,0412448699016448;0,0368826741909334;GADD45A/ARID5A/NR4A2/CTNNB1/APBB2/HSPA1A/PLAGL1/TFEC/KLF4/ARID5B/NR1D1/STAT3/ZFP36/ATF4;14
GO:0043523;regulation of neuron apoptotic process;7/67;45/2237;0,155555555555556;5,19369817578773;4,99259786535867;0,000289712718113067;0,0412448699016448;0,0368826741909334;MCL1/NR4A2/CTNNB1/JAK2/UBB/BCL2L1/ATF4;7
GO:0006915;apoptotic process;25/67;427/2237;0,0585480093676815;1,95480443217169;3,85329723137341;0,000304872322398642;0,0412448699016448;0,0368826741909334;GADD45A/MCL1/NLRP3/HK2/NR4A2/TMBIM1/CTNNB1/CCNL1/APBB2/IRF1/HSPA1A/PLAGL1/GGCT/TNFRSF10D/JAK2/KLF4/NEK6/FAS/UBB/PHLPP1/ZFP36/BCL2L1/TGM2/ATF4/TIMP1;25
GO:0009791;post-embryonic development;5/67;22/2237;0,227272727272727;7,58819538670285;5,45549773453492;0,000367885933133649;0,0464517304903421;0,0415388397482134;NR4A2/TIPARP/JAK2/KLF4/ARID5B;5
GO:0043524;negative regulation of neuron apoptotic process;5/67;24/2237;0,208333333333333;6,95584577114428;5,15349419201996;0,000566764723736944;0,0596110180211345;0,0533063569143586;NR4A2/CTNNB1/JAK2/BCL2L1/ATF4;5
GO:0072538;T-helper 17 type immune response;5/67;24/2237;0,208333333333333;6,95584577114428;5,15349419201996;0,000566764723736944;0,0596110180211345;0,0533063569143586;ARID5A/IRF4/JAK2/STAT3/JUNB;5
GO:0006357;regulation of transcription by RNA polymerase II;22/67;367/2237;0,0599455040871935;2,00146406929928;3,68630304594714;0,000597208452171188;0,0596110180211345;0,0533063569143586;GADD45A/NLRP3/ARID5A/NR4A2/CTNNB1/CCNL1/APBB2/ELL2/IRF1/IRF4/HSPA1A/PLAGL1/TFEC/JAK2/KLF4/ARID5B/NR1D1/STAT3/JUNB/ELL/ZFP36/ATF4;22
GO:2001233;regulation of apoptotic signaling pathway;10/67;100/2237;0,1;3,33880597014925;4,20373534911125;0,000597998596832923;0,0596110180211345;0,0533063569143586;MCL1/NR4A2/TMBIM1/CTNNB1/HSPA1A/JAK2/FAS/UBB/BCL2L1/ATF4;10
GO:0006366;transcription by RNA polymerase II;22/67;374/2237;0,0588235294117647;1,9640035118525;3,58881791106608;0,000782348914475286;0,0740884422008096;0,0662526001784598;GADD45A/NLRP3/ARID5A/NR4A2/CTNNB1/CCNL1/APBB2/ELL2/IRF1/IRF4/HSPA1A/PLAGL1/TFEC/JAK2/KLF4/ARID5B/NR1D1/STAT3/JUNB/ELL/ZFP36/ATF4;22
GO:0008637;apoptotic mitochondrial changes;5/67;26/2237;0,192307692307692;6,42078071182549;4,88424652001588;0,000837257404474289;0,0755126440035383;0,0675261736240166;MCL1/HK2/HSPA1A/GGCT/BCL2L1;5
GO:0010557;positive regulation of macromolecule biosynthetic process;26/67;487/2237;0,053388090349076;1,78252474792363;3,42994354315138;0,000990444709763618;0,0793901506838386;0,0709935821987975;GBP5/TENT5C/NLRP3/SERTAD2/ARID5A/NR4A2/INO80D/CTNNB1/APBB2/ELL2/IRF1/IRF4/HSPA1A/PLAGL1/TFEC/JAK2/KLF4/ARID5B/PNP/ADORA2B/NR1D1/STAT3/JUNB/ELL/ZFP36/ATF4;26
GO:0001659;temperature homeostasis;6/67;40/2237;0,15;5,00820895522388;4,49374842226115;0,000991214644456086;0,0793901506838386;0,0709935821987975;IRF4/JAK2/PTGES/NR1D1/STAT3/ATF4;6
GO:0048871;multicellular organismal-level homeostasis;13/67;167/2237;0,0778443113772455;2,59907051568505;3,77384546708398;0,00100599979747208;0,0793901506838386;0,0709935821987975;CTNNB1/APBB2/IRF4/HSPA1A/SH2B2/JAK2/PTGES/FAS/UBB/NR1D1/STAT3/ZFP36/ATF4;13
GO:0008631;intrinsic apoptotic signaling pathway in response to oxidative stress;4/67;17/2237;0,235294117647059;7,85601404741001;4,98497639589326;0,00130431250938042;0,0988147157106607;0,0883637401091831;MCL1/CTNNB1/JAK2/ATF4;4
GO:0071478;cellular response to radiation;5/67;29/2237;0,172413793103448;5,75656201749871;4,52935188227318;0,00140972714020239;0,102693200136282;0,0918320230196617;GADD45A/SDE2/BCL2L1/ATF4/TIMP1;5
GO:0043067;regulation of programmed cell death;20/67;341/2237;0,0586510263929619;1,95824397076203;3,37658395467769;0,00154693912807137;0,108514915132117;0,0970380139207341;GADD45A/GBP5/MCL1/NR4A2/TMBIM1/CTNNB1/CCNL1/APBB2/HSPA1A/TNFRSF10D/JAK2/KLF4/FAS/UBB/PHLPP1/ZFP36/BCL2L1/TGM2/ATF4/TIMP1;20
GO:0051253;negative regulation of RNA metabolic process;16/67;247/2237;0,0647773279352227;2,16278929240437;3,40381851550932;0,00185397711893576;0,120160082266436;0,107451549139497;GADD45A/TENT5C/ARID5A/NR4A2/CTNNB1/APBB2/IRF1/HSPA1A/PLAGL1/TFEC/KLF4/ARID5B/NR1D1/STAT3/ZFP36/ATF4;16
GO:2001234;negative regulation of apoptotic signaling pathway;7/67;61/2237;0,114754098360656;3,83141668705652;3,93897018269998;0,00190371057703261;0,120160082266436;0,107451549139497;MCL1/NR4A2/TMBIM1/CTNNB1/HSPA1A/BCL2L1/ATF4;7
GO:0045892;negative regulation of DNA-templated transcription;15/67;225/2237;0,0666666666666667;2,22587064676617;3,40616240337511;0,0019836384726151;0,120160082266436;0,107451549139497;GADD45A/ARID5A/NR4A2/CTNNB1/APBB2/IRF1/HSPA1A/PLAGL1/TFEC/KLF4/ARID5B/NR1D1/STAT3/ZFP36/ATF4;15
GO:0007049;cell cycle;17/67;273/2237;0,0622710622710623;2,07910994478159;3,34287171623737;0,0020112811089375;0,120160082266436;0,107451549139497;GADD45A/SDE2/INO80D/CTNNB1/CCNL1/APBB2/IRF1/DUSP1/HSPA1A/PLAGL1/KLF4/NEK6/NDEL1/UBB/STAT3/JUNB/BCL2L1;17
GO:0007098;centrosome cycle;4/67;19/2237;0,210526315789474;7,02906520031422;4,63649124552492;0,00203015978486059;0,120160082266436;0,107451549139497;GADD45A/CTNNB1/CCNL1/NDEL1;4
GO:0046634;regulation of alpha-beta T cell activation;6/67;46/2237;0,130434782608696;4,35496430889033;4,03914147900924;0,0020998828054618;0,12052054647105;0,107773889441405;NLRP3/IRF1/IRF4/JAK2/PNP/JUNB;6
GO:1902679;negative regulation of RNA biosynthetic process;15/67;228/2237;0,0657894736842105;2,19658287509819;3,34937421269499;0,00226833815804163;0,123803210226668;0,110709367673378;GADD45A/ARID5A/NR4A2/CTNNB1/APBB2/IRF1/HSPA1A/PLAGL1/TFEC/KLF4/ARID5B/NR1D1/STAT3/ZFP36/ATF4;15
GO:0009628;response to abiotic stimulus;14/67;205/2237;0,0682926829268293;2,28016017473608;3,37849145710467;0,00228781011506514;0,123803210226668;0,110709367673378;GADD45A/SDE2/ADSS2/NLRP3/HK2/NR4A2/CTNNB1/IRF1/HSPA1A/TFEC/FAS/BCL2L1/ATF4/TIMP1;14
GO:0001764;neuron migration;5/67;33/2237;0,151515151515152;5,05879692446857;4,12659579694471;0,00256760744899103;0,129541724388989;0,115840957340012;NR4A2/CTNNB1/APBB2/NDEL1/STAT3;5
GO:0032784;regulation of DNA-templated transcription elongation;3/67;10/2237;0,3;10,0164179104478;5,0201576831069;0,00265150243668175;0,129541724388989;0,115840957340012;CTNNB1/ELL2/ELL;3
GO:0034243;regulation of transcription elongation by RNA polymerase II;3/67;10/2237;0,3;10,0164179104478;5,0201576831069;0,00265150243668175;0,129541724388989;0,115840957340012;CTNNB1/ELL2/ELL;3
GO:0034097;response to cytokine;18/67;305/2237;0,059016393442623;1,97044286762907;3,20375845366461;0,00266743783060749;0,129541724388989;0,115840957340012;GBP5/MCL1/HK2/IRF1/DUSP1/HSPA1A/SH2B2/JAK2/KLF4/ARID5B/FAS/CDC42EP2/NR1D1/STAT3/CDC42EP4/ZFP36/BCL2L1/TIMP1;18
GO:0031023;microtubule organizing center organization;4/67;21/2237;0,19047619047619;6,35963041933191;4,33513919626526;0,00299626150835565;0,133670965305994;0,119533475894706;GADD45A/CTNNB1/CCNL1/NDEL1;4
GO:0038034;signal transduction in absence of ligand;4/67;21/2237;0,19047619047619;6,35963041933191;4,33513919626526;0,00299626150835565;0,133670965305994;0,119533475894706;MCL1/HSPA1A/FAS/BCL2L1;4
GO:0097192;extrinsic apoptotic signaling pathway in absence of ligand;4/67;21/2237;0,19047619047619;6,35963041933191;4,33513919626526;0,00299626150835565;0,133670965305994;0,119533475894706;MCL1/HSPA1A/FAS/BCL2L1;4
GO:0042981;regulation of apoptotic process;19/67;334/2237;0,0568862275449102;1,89932076146215;3,13048691491886;0,00303476848371582;0,133670965305994;0,119533475894706;GADD45A/MCL1/NR4A2/TMBIM1/CTNNB1/CCNL1/APBB2/HSPA1A/TNFRSF10D/JAK2/KLF4/FAS/UBB/PHLPP1/ZFP36/BCL2L1/TGM2/ATF4/TIMP1;19
GO:0045934;negative regulation of nucleobase-containing compound metabolic process;16/67;261/2237;0,0613026819923372;2,04677760622176;3,1610010547638;0,00330822583905431;0,14240408498111;0,127342951555942;GADD45A/TENT5C/ARID5A/NR4A2/CTNNB1/APBB2/IRF1/HSPA1A/PLAGL1/TFEC/KLF4/ARID5B/NR1D1/STAT3/ZFP36/ATF4;16
GO:1902175;regulation of oxidative stress-induced intrinsic apoptotic signaling pathway;3/67;11/2237;0,272727272727273;9,10583446404342;4,73450878815139;0,00356810467684245;0,150177561287547;0,134294278948292;MCL1/CTNNB1/ATF4;3
GO:2001242;regulation of intrinsic apoptotic signaling pathway;6/67;52/2237;0,115384615384615;3,85246842709529;3,65628660393829;0,00396298432466105;0,163171571976261;0,145913999505255;MCL1/CTNNB1/HSPA1A/UBB/BCL2L1/ATF4;6
GO:0038066;p38MAPK cascade;4/67;23/2237;0,173913043478261;5,80661907852044;4,0705983263835;0,00423741631049697;0,165194900230631;0,147723333780406;GADD45A/DUSP1/PHLPP1/ZFP36;4
GO:0071310;cellular response to organic substance;24/67;480/2237;0,05;1,66940298507463;2,9071391293267;0,00436288212413171;0,165194900230631;0,147723333780406;GBP5/NLRP3/HK2/ARID5A/NR4A2/CTNNB1/TIPARP/IRF1/DUSP1/HSPA1A/SH2B2/JAK2/KLF4/ARID5B/FAS/CDC42EP2/NDEL1/NR1D1/STAT3/CDC42EP4/ZFP36/BCL2L1/TGM2/ATF4;24
GO:0046631;alpha-beta T cell activation;7/67;71/2237;0,0985915492957746;3,29178053394997;3,44759632040177;0,00457640966420739;0,165194900230631;0,147723333780406;NLRP3/IRF1/IRF4/JAK2/PNP/STAT3/JUNB;7
GO:0010574;regulation of vascular endothelial growth factor production;3/67;12/2237;0,25;8,34701492537313;4,48311595032487;0,00465618666124404;0,165194900230631;0,147723333780406;ADORA2B/STAT3/ATF4;3
GO:0010575;positive regulation of vascular endothelial growth factor production;3/67;12/2237;0,25;8,34701492537313;4,48311595032487;0,00465618666124404;0,165194900230631;0,147723333780406;ADORA2B/STAT3/ATF4;3
GO:1901099;negative regulation of signal transduction in absence of ligand;3/67;12/2237;0,25;8,34701492537313;4,48311595032487;0,00465618666124404;0,165194900230631;0,147723333780406;MCL1/HSPA1A/BCL2L1;3
GO:2001240;negative regulation of extrinsic apoptotic signaling pathway in absence of ligand;3/67;12/2237;0,25;8,34701492537313;4,48311595032487;0,00465618666124404;0,165194900230631;0,147723333780406;MCL1/HSPA1A/BCL2L1;3
GO:0051258;protein polymerization;5/67;38/2237;0,131578947368421;4,39316575019639;3,70619010610957;0,00483635692618504;0,165194900230631;0,147723333780406;HSPA1A/JAK2/CDC42EP2/NDEL1/CDC42EP4;5
GO:0008585;female gonad development;4/67;24/2237;0,166666666666667;5,56467661691542;3,94973868324387;0,00497154662784897;0,165194900230631;0,147723333780406;TIPARP/ARID5B/UBB/BCL2L1;4
GO:0032731;positive regulation of interleukin-1 beta production;4/67;24/2237;0,166666666666667;5,56467661691542;3,94973868324387;0,00497154662784897;0,165194900230631;0,147723333780406;GBP5/NLRP3/JAK2/STAT3;4
GO:0032732;positive regulation of interleukin-1 production;4/67;24/2237;0,166666666666667;5,56467661691542;3,94973868324387;0,00497154662784897;0,165194900230631;0,147723333780406;GBP5/NLRP3/JAK2/STAT3;4
GO:0097190;apoptotic signaling pathway;11/67;154/2237;0,0714285714285714;2,38486140724947;3,12871116632923;0,00508199543189706;0,165953437034707;0,148401645189154;MCL1/NR4A2/TMBIM1/CTNNB1/HSPA1A/GGCT/JAK2/FAS/UBB/BCL2L1/ATF4;11
GO:0043066;negative regulation of apoptotic process;13/67;201/2237;0,0646766169154229;2,1594267468627;3,02688478836929;0,00540526630156046;0,173518209748398;0,155166342180389;MCL1/NR4A2/TMBIM1/CTNNB1/APBB2/HSPA1A/TNFRSF10D/JAK2/KLF4/FAS/BCL2L1/ATF4/TIMP1;13
GO:0046545;development of primary female sexual characteristics;4/67;25/2237;0,16;5,34208955223881;3,83547938868007;0,00578666776001956;0,180978661232152;0,161837751304692;TIPARP/ARID5B/UBB/BCL2L1;4
GO:0001819;positive regulation of cytokine production;11/67;157/2237;0,0700636942675159;2,33929080711094;3,05728890754978;0,00588934692554291;0,180978661232152;0,161837751304692;GBP5/NLRP3/ARID5A/IRF1/IRF4/HSPA1A/JAK2/PNP/ADORA2B/STAT3/ATF4;11
GO:0045646;regulation of erythrocyte differentiation;3/67;13/2237;0,230769230769231;7,70493685419059;4,25934100043407;0,00592432787560371;0,180978661232152;0,161837751304692;HSPA1A/STAT3/ZFP36;3
GO:0062197;cellular response to chemical stress;7/67;75/2237;0,0933333333333333;3,11621890547264;3,27496611468071;0,00621183019751759;0,183659582271483;0,164235129147345;NLRP3/NR4A2/HSPA1A/KLF4/FAS/OSER1/ATF4;7
GO:0046632;alpha-beta T cell differentiation;6/67;57/2237;0,105263157894737;3,51453260015711;3,37839079848841;0,00628075066646509;0,183659582271483;0,164235129147345;NLRP3/IRF1/IRF4/PNP/STAT3/JUNB;6
GO:0010564;regulation of cell cycle process;9/67;115/2237;0,0782608695652174;2,6129785853342;3,11995453911608;0,00630299516771195;0,183659582271483;0,164235129147345;SDE2/CTNNB1/CCNL1/APBB2/DUSP1/HSPA1A/KLF4/NEK6/BCL2L1;9
GO:0033554;cellular response to stress;17/67;306/2237;0,0555555555555556;1,85489220563847;2,82764163598935;0,00680180366375537;0,18543290620471;0,165820900396476;GADD45A/MCL1/SDE2/NLRP3/HK2/NR4A2/INO80D/HSPA1A/TFEC/JAK2/KLF4/NEK6/FAS/JUNB/BCL2L1/OSER1/ATF4;17
GO:0043069;negative regulation of programmed cell death;13/67;207/2237;0,0628019323671498;2,09683466724349;2,9101927630059;0,00694433407215681;0,18543290620471;0,165820900396476;MCL1/NR4A2/TMBIM1/CTNNB1/APBB2/HSPA1A/TNFRSF10D/JAK2/KLF4/FAS/BCL2L1/ATF4/TIMP1;13
GO:0032870;cellular response to hormone stimulus;9/67;117/2237;0,0769230769230769;2,5683122847302;3,06126537095923;0,00705650124639989;0,18543290620471;0,165820900396476;ARID5A/NR4A2/HSPA1A/SH2B2/JAK2/NDEL1/NR1D1/STAT3/ZFP36;9
GO:0071417;cellular response to organonitrogen compound;9/67;117/2237;0,0769230769230769;2,5683122847302;3,06126537095923;0,00705650124639989;0,18543290620471;0,165820900396476;NR4A2/CTNNB1/SH2B2/JAK2/KLF4/NDEL1/STAT3/BCL2L1/TGM2;9
GO:0022402;cell cycle process;12/67;184/2237;0,0652173913043478;2,17748215444517;2,92895166413161;0,00712195451673009;0,18543290620471;0,165820900396476;GADD45A/SDE2/CTNNB1/CCNL1/APBB2/DUSP1/HSPA1A/KLF4/NEK6/NDEL1/UBB/BCL2L1;12
GO:0001836;release of cytochrome c from mitochondria;3/67;14/2237;0,214285714285714;7,1545842217484;4,05822796878296;0,00737991180706296;0,18543290620471;0,165820900396476;MCL1/GGCT/BCL2L1;3
GO:0010573;vascular endothelial growth factor production;3/67;14/2237;0,214285714285714;7,1545842217484;4,05822796878296;0,00737991180706296;0,18543290620471;0,165820900396476;ADORA2B/STAT3/ATF4;3
GO:0046902;regulation of mitochondrial membrane permeability;3/67;14/2237;0,214285714285714;7,1545842217484;4,05822796878296;0,00737991180706296;0,18543290620471;0,165820900396476;HK2/HSPA1A/BCL2L1;3
GO:2000316;regulation of T-helper 17 type immune response;3/67;14/2237;0,214285714285714;7,1545842217484;4,05822796878296;0,00737991180706296;0,18543290620471;0,165820900396476;ARID5A/JAK2/JUNB;3
GO:2001239;regulation of extrinsic apoptotic signaling pathway in absence of ligand;3/67;14/2237;0,214285714285714;7,1545842217484;4,05822796878296;0,00737991180706296;0,18543290620471;0,165820900396476;MCL1/HSPA1A/BCL2L1;3
GO:0052548;regulation of endopeptidase activity;6/67;59/2237;0,101694915254237;3,3953959018467;3,27580321157232;0,00744081355414888;0,18543290620471;0,165820900396476;NLRP3/JAK2/KLF4/FAS/STAT3/TIMP1;6
GO:0001701;in utero embryonic development;7/67;80/2237;0,0875;2,9214552238806;3,0746354019866;0,00883074071860078;0,200738370404206;0,179507607391968;TENT5C/CTNNB1/KLF4/NDEL1/JUNB/ELL/BCL2L1;7
GO:0006354;DNA-templated transcription elongation;3/67;15/2237;0,2;6,67761194029851;3,87599083818867;0,00902920255201301;0,200738370404206;0,179507607391968;CTNNB1/ELL2/ELL;3
GO:0006368;transcription elongation by RNA polymerase II;3/67;15/2237;0,2;6,67761194029851;3,87599083818867;0,00902920255201301;0,200738370404206;0,179507607391968;CTNNB1/ELL2/ELL;3
GO:0016525;negative regulation of angiogenesis;3/67;15/2237;0,2;6,67761194029851;3,87599083818867;0,00902920255201301;0,200738370404206;0,179507607391968;GADD45A/CTNNB1/KLF4;3
GO:0021954;central nervous system neuron development;3/67;15/2237;0,2;6,67761194029851;3,87599083818867;0,00902920255201301;0,200738370404206;0,179507607391968;NR4A2/NDEL1/UBB;3
GO:1901343;negative regulation of vasculature development;3/67;15/2237;0,2;6,67761194029851;3,87599083818867;0,00902920255201301;0,200738370404206;0,179507607391968;GADD45A/CTNNB1/KLF4;3
GO:2000181;negative regulation of blood vessel morphogenesis;3/67;15/2237;0,2;6,67761194029851;3,87599083818867;0,00902920255201301;0,200738370404206;0,179507607391968;GADD45A/CTNNB1/KLF4;3
GO:2000242;negative regulation of reproductive process;3/67;15/2237;0,2;6,67761194029851;3,87599083818867;0,00902920255201301;0,200738370404206;0,179507607391968;DUSP1/BCL2L1/TIMP1;3
GO:0062207;regulation of pattern recognition receptor signaling pathway;5/67;44/2237;0,113636363636364;3,79409769335142;3,28845605997698;0,00910938704905733;0,200738370404206;0,179507607391968;GBP5/IRF1/IRF4/HSPA1A/NR1D1;5
GO:2000026;regulation of multicellular organismal development;17/67;315/2237;0,053968253968254;1,80189528547738;2,69736476068491;0,00911483624855422;0,200738370404206;0,179507607391968;GADD45A/NLRP3/HK2/INO80D/CTNNB1/SGMS2/IRF1/IRF4/HSPA1A/KLF4/PNP/NR1D1/STAT3/JUNB/ZFP36/TGM2/ATF4;17
GO:0046660;female sex differentiation;4/67;29/2237;0,137931034482759;4,60524961399897;3,4330350503488;0,00993020875656827;0,215536595848573;0,192740722903548;TIPARP/ARID5B/UBB/BCL2L1;4
GO:0031330;negative regulation of cellular catabolic process;5/67;45/2237;0,111111111111111;3,70978441127695;3,22599846251031;0,0100143719296064;0,215536595848573;0,192740722903548;TENT5C/MCL1/STAT3/ZFP36/TIMP1;5
GO:1903706;regulation of hemopoiesis;9/67;124/2237;0,0725806451612903;2,42332691381801;2,86489816755544;0,0102530993068216;0,218195169518203;0,195118116909236;NLRP3/CTNNB1/IRF1/IRF4/HSPA1A/PNP/STAT3/JUNB/ZFP36;9
GO:0021536;diencephalon development;3/67;16/2237;0,1875;6,26026119402985;3,70968005707269;0,0108774176532397;0,21875993477238;0,195623150696804;NR4A2/CTNNB1/UBB;3
GO:0034644;cellular response to UV;3/67;16/2237;0,1875;6,26026119402985;3,70968005707269;0,0108774176532397;0,21875993477238;0,195623150696804;SDE2/ATF4/TIMP1;3
GO:0090559;regulation of membrane permeability;3/67;16/2237;0,1875;6,26026119402985;3,70968005707269;0,0108774176532397;0,21875993477238;0,195623150696804;HK2/HSPA1A/BCL2L1;3
GO:0071345;cellular response to cytokine stimulus;15/67;269/2237;0,0557620817843866;1,86178771569661;2,64732539764151;0,0109951939076546;0,21875993477238;0,195623150696804;GBP5/HK2/IRF1/DUSP1/HSPA1A/SH2B2/JAK2/KLF4/ARID5B/FAS/CDC42EP2/NR1D1/STAT3/CDC42EP4/ZFP36;15
GO:1901701;cellular response to oxygen-containing compound;15/67;269/2237;0,0557620817843866;1,86178771569661;2,64732539764151;0,0109951939076546;0,21875993477238;0,195623150696804;GBP5/NLRP3/ARID5A/NR4A2/CTNNB1/SH2B2/JAK2/KLF4/NDEL1/NR1D1/STAT3/ZFP36/BCL2L1/TGM2/OSER1;15
GO:0052547;regulation of peptidase activity;6/67;64/2237;0,09375;3,13013059701493;3,03745455157916;0,0110113451833436;0,21875993477238;0,195623150696804;NLRP3/JAK2/KLF4/FAS/STAT3/TIMP1;6
GO:0120161;regulation of cold-induced thermogenesis;4/67;30/2237;0,133333333333333;4,45174129353234;3,34380646331618;0,0112036503024925;0,21875993477238;0,195623150696804;IRF4/JAK2/NR1D1/ATF4;4
GO:2001237;negative regulation of extrinsic apoptotic signaling pathway;4/67;30/2237;0,133333333333333;4,45174129353234;3,34380646331618;0,0112036503024925;0,21875993477238;0,195623150696804;MCL1/TMBIM1/HSPA1A/BCL2L1;4
GO:0050793;regulation of developmental process;23/67;490/2237;0,0469387755102041;1,56719463904965;2,49589975798539;0,0120952265998445;0,224164269764678;0,200455905102744;GADD45A/TENT5C/NLRP3/HK2/INO80D/TMBIM1/CTNNB1/SGMS2/IRF1/IRF4/HSPA1A/JAK2/KLF4/CDC42EP2/PNP/NR1D1/STAT3/CDC42EP4/JUNB/ZFP36/BCL2L1/TGM2/ATF4;23
GO:0097193;intrinsic apoptotic signaling pathway;7/67;85/2237;0,0823529411764706;2,7496049165935;2,88916106677919;0,0121884715740296;0,224164269764678;0,200455905102744;MCL1/CTNNB1/HSPA1A/JAK2/UBB/BCL2L1/ATF4;7
GO:0043068;positive regulation of programmed cell death;10/67;150/2237;0,0666666666666667;2,22587064676617;2,73069053565529;0,0121957285590853;0,224164269764678;0,200455905102744;GADD45A/GBP5/MCL1/CTNNB1/APBB2/JAK2/FAS/UBB/TGM2/ATF4;10
GO:0010950;positive regulation of endopeptidase activity;4/67;31/2237;0,129032258064516;4,30813673567646;3,25840436529598;0,0125781952727697;0,224164269764678;0,200455905102744;NLRP3/JAK2/FAS/STAT3;4
GO:0046661;male sex differentiation;4/67;31/2237;0,129032258064516;4,30813673567646;3,25840436529598;0,0125781952727697;0,224164269764678;0,200455905102744;CTNNB1/ARID5B/UBB/BCL2L1;4
GO:0106106;cold-induced thermogenesis;4/67;31/2237;0,129032258064516;4,30813673567646;3,25840436529598;0,0125781952727697;0,224164269764678;0,200455905102744;IRF4/JAK2/NR1D1/ATF4;4
GO:2001243;negative regulation of intrinsic apoptotic signaling pathway;4/67;31/2237;0,129032258064516;4,30813673567646;3,25840436529598;0,0125781952727697;0,224164269764678;0,200455905102744;CTNNB1/HSPA1A/BCL2L1/ATF4;4
GO:0009895;negative regulation of catabolic process;6/67;66/2237;0,0909090909090909;3,03527815468114;2,9485551907823;0,0127334596662377;0,224164269764678;0,200455905102744;TENT5C/MCL1/AZIN1/STAT3/ZFP36/TIMP1;6
GO:0045444;fat cell differentiation;6/67;66/2237;0,0909090909090909;3,03527815468114;2,9485551907823;0,0127334596662377;0,224164269764678;0,200455905102744;NR4A2/SH2B2/KLF4/ARID5B/NR1D1/ZFP36;6
GO:1900744;regulation of p38MAPK cascade;3/67;17/2237;0,176470588235294;5,89201053555751;3,55695844255567;0,0129287973269238;0,224164269764678;0,200455905102744;GADD45A/DUSP1/PHLPP1;3
GO:0042592;homeostatic process;16/67;300/2237;0,0533333333333333;1,78069651741294;2,55282763801509;0,0129427676211799;0,224164269764678;0,200455905102744;MCL1/HK2/CTNNB1/APBB2/IRF4/HSPA1A/SH2B2/JAK2/PTGES/FAS/UBB/NR1D1/STAT3/ZFP36/TGM2/ATF4;16
GO:0010628;positive regulation of gene expression;15/67;274/2237;0,0547445255474453;1,82781348730799;2,5697511174951;0,012956092772401;0,224164269764678;0,200455905102744;GBP5/TENT5C/NLRP3/ARID5A/CTNNB1/IRF1/IRF4/HSPA1A/JAK2/KLF4/PNP/ADORA2B/STAT3/ZFP36/ATF4;15
GO:1901699;cellular response to nitrogen compound;9/67;129/2237;0,0697674418604651;2,32939951405762;2,73248949885201;0,0131373991255962;0,224164269764678;0,200455905102744;NR4A2/CTNNB1/SH2B2/JAK2/KLF4/NDEL1/STAT3/BCL2L1/TGM2;9
GO:1902532;negative regulation of intracellular signal transduction;9/67;129/2237;0,0697674418604651;2,32939951405762;2,73248949885201;0,0131373991255962;0,224164269764678;0,200455905102744;NLRP3/RNF149/CTNNB1/DUSP1/HSPA1A/NR1D1/PHLPP1/BCL2L1/ATF4;9
GO:0030522;intracellular receptor signaling pathway;7/67;87/2237;0,0804597701149425;2,68639560816607;2,81866389740695;0,0137623119605012;0,232730525474904;0,208116164891414;GBP5/NLRP3/NR4A2/HSPA1A/JAK2/NR1D1/STAT3;7
GO:0098781;ncRNA transcription;4/67;32/2237;0,125;4,17350746268657;3,17653503897586;0,0140565521243826;0,232825190354791;0,208200817696248;ELL2/KLF4/STAT3/ELL;4
GO:0051172;negative regulation of nitrogen compound metabolic process;19/67;384/2237;0,0494791666666667;1,65201337064677;2,46619741572908;0,014236428036066;0,232825190354791;0,208200817696248;GADD45A/TENT5C/ARID5A/NR4A2/CTNNB1/APBB2/IRF1/DUSP1/HSPA1A/PLAGL1/TFEC/AZIN1/KLF4/ARID5B/NR1D1/STAT3/ZFP36/ATF4/TIMP1;19
GO:0007548;sex differentiation;5/67;49/2237;0,102040816326531;3,40694486749924;2,99284315728938;0,0142541276219258;0,232825190354791;0,208200817696248;CTNNB1/TIPARP/ARID5B/UBB/BCL2L1;5
GO:0006508;proteolysis;15/67;277/2237;0,0541516245487365;1,80801767336602;2,52392324164679;0,0142596209509798;0,232825190354791;0,208200817696248;SDE2/NLRP3/RNF149/CTNNB1/FEM1C/HSPA1A/JAK2/KLF4/FAS/UBC/UBB/NR1D1/STAT3/TGM2/TIMP1;15
GO:0071407;cellular response to organic cyclic compound;8/67;109/2237;0,073394495412844;2,45049979460496;2,72764937208405;0,0144911485017792;0,234583207370682;0,209772900938936;CTNNB1/TIPARP/HSPA1A/JAK2/KLF4/NR1D1/ZFP36/TGM2;8
GO:0007006;mitochondrial membrane organization;3/67;18/2237;0,166666666666667;5,56467661691542;3,41594642726079;0,0151866702338268;0,237295900142103;0,21219869022878;HK2/HSPA1A/BCL2L1;3
GO:0071482;cellular response to light stimulus;3/67;18/2237;0,166666666666667;5,56467661691542;3,41594642726079;0,0151866702338268;0,237295900142103;0,21219869022878;SDE2/ATF4/TIMP1;3
GO:0072539;T-helper 17 cell differentiation;3/67;18/2237;0,166666666666667;5,56467661691542;3,41594642726079;0,0151866702338268;0,237295900142103;0,21219869022878;IRF4/STAT3/JUNB;3
GO:0010952;positive regulation of peptidase activity;4/67;33/2237;0,121212121212121;4,04703753957485;3,09793580165105;0,0156412341485745;0,237295900142103;0,21219869022878;NLRP3/JAK2/FAS/STAT3;4
GO:0030218;erythrocyte differentiation;4/67;33/2237;0,121212121212121;4,04703753957485;3,09793580165105;0,0156412341485745;0,237295900142103;0,21219869022878;HSPA1A/JAK2/STAT3/ZFP36;4
GO:0033044;regulation of chromosome organization;4/67;33/2237;0,121212121212121;4,04703753957485;3,09793580165105;0,0156412341485745;0,237295900142103;0,21219869022878;INO80D/CTNNB1/DUSP1/NEK6;4
GO:1990845;adaptive thermogenesis;4/67;33/2237;0,121212121212121;4,04703753957485;3,09793580165105;0,0156412341485745;0,237295900142103;0,21219869022878;IRF4/JAK2/NR1D1/ATF4;4
GO:0002819;regulation of adaptive immune response;6/67;69/2237;0,0869565217391304;2,90330953926022;2,821290228751;0,0156610282564746;0,237295900142103;0,21219869022878;NLRP3/ARID5A/IRF1/JAK2/JUNB/PVR;6
GO:0030162;regulation of proteolysis;8/67;112/2237;0,0714285714285714;2,38486140724947;2,64167442024221;0,0168860539449709;0,252486687291491;0,225782848803428;NLRP3/HSPA1A/JAK2/KLF4/FAS/UBB/STAT3/TIMP1;8
GO:0001817;regulation of cytokine production;13/67;231/2237;0,0562770562770563;1,87898171480261;2,4783566286262;0,016930205536441;0,252486687291491;0,225782848803428;GBP5/NLRP3/ARID5A/IRF1/IRF4/HSPA1A/JAK2/KLF4/PNP/ADORA2B/STAT3/ZFP36/ATF4;13
GO:0034101;erythrocyte homeostasis;4/67;34/2237;0,117647058823529;3,928007023705;3,02237089324963;0,017334557485768;0,252551168292651;0,225840510077739;HSPA1A/JAK2/STAT3/ZFP36;4
GO:0043281;regulation of cysteine-type endopeptidase activity involved in apoptotic process;4/67;34/2237;0,117647058823529;3,928007023705;3,02237089324963;0,017334557485768;0,252551168292651;0,225840510077739;NLRP3/JAK2/KLF4/FAS;4
GO:0046637;regulation of alpha-beta T cell differentiation;4/67;34/2237;0,117647058823529;3,928007023705;3,02237089324963;0,017334557485768;0,252551168292651;0,225840510077739;NLRP3/IRF4/PNP/JUNB;4
GO:0072526;pyridine-containing compound catabolic process;3/67;19/2237;0,157894736842105;5,27179890023566;3,28511262451655;0,017653515943008;0,255234803023337;0,22824031460265;HK2/PNP/STAT3;3
GO:0051276;chromosome organization;6/67;71/2237;0,0845070422535211;2,82152617195712;2,74017814311881;0,0178553898802172;0,255340526961955;0,22833485682309;INO80D/CTNNB1/DUSP1/HSPA1A/NEK6/H3-3B;6
GO:0014070;response to organic cyclic compound;11/67;183/2237;0,0601092896174863;2,00693255036294;2,49729092784933;0,0179304593906758;0,255340526961955;0,22833485682309;ADSS2/CTNNB1/TIPARP/HSPA1A/JAK2/KLF4/NR1D1/STAT3/ZFP36/BCL2L1/TGM2;11
GO:0001816;cytokine production;13/67;234/2237;0,0555555555555556;1,85489220563847;2,42785220471905;0,0187133796839515;0,264501053144808;0,23652653504696;GBP5/NLRP3/ARID5A/IRF1/IRF4/HSPA1A/JAK2/KLF4/PNP/ADORA2B/STAT3/ZFP36/ATF4;13
GO:2000241;regulation of reproductive process;4/67;35/2237;0,114285714285714;3,81577825159915;2,94962801261846;0,0191386399834501;0,268508030582625;0,240109721117904;CTNNB1/DUSP1/BCL2L1/TIMP1;4
GO:0071346;cellular response to type II interferon;5/67;53/2237;0,0943396226415094;3,14981695297099;2,78263686926528;0,0195664262658835;0,272491259908701;0,243671670757017;GBP5/IRF1/JAK2/CDC42EP2/CDC42EP4;5
GO:0097191;extrinsic apoptotic signaling pathway;6/67;73/2237;0,0821917808219178;2,74422408505418;2,66181896500861;0,0202537846035029;0,275049713520408;0,245959533737751;MCL1/TMBIM1/HSPA1A/JAK2/FAS/BCL2L1;6
GO:0001824;blastocyst development;3/67;20/2237;0,15;5,00820895522388;3,16319480938555;0,0203310242306531;0,275049713520408;0,245959533737751;KLF4/NDEL1/JUNB;3
GO:0043525;positive regulation of neuron apoptotic process;3/67;20/2237;0,15;5,00820895522388;3,16319480938555;0,0203310242306531;0,275049713520408;0,245959533737751;MCL1/CTNNB1/ATF4;3
GO:1902850;microtubule cytoskeleton organization involved in mitosis;3/67;20/2237;0,15;5,00820895522388;3,16319480938555;0,0203310242306531;0,275049713520408;0,245959533737751;HSPA1A/NEK6/NDEL1;3
GO:0000226;microtubule cytoskeleton organization;6/67;74/2237;0,0810810810810811;2,70713997579669;2,62361536976751;0,0215320092249581;0,287456629785493;0,257054252945511;GADD45A/CTNNB1/CCNL1/HSPA1A/NEK6/NDEL1;6
GO:1902531;regulation of intracellular signal transduction;19/67;400/2237;0,0475;1,5859328358209;2,27178217798741;0,0215516586217212;0,287456629785493;0,257054252945511;GADD45A/MCL1/NLRP3/RNF149/CTNNB1/DUSP1/HSPA1A/SH2B2/JAK2/NEK6/FAS/ADORA2B/UBB/ARHGAP23/NR1D1/PHLPP1/BCL2L1/TGM2/ATF4;19
GO:0031347;regulation of defense response;13/67;239/2237;0,0543933054393305;1,81608692936989;2,34520636773741;0,0220012058832183;0,291400587012696;0,260581084034585;GBP5/NLRP3/IRF1/IRF4/HSPA1A/JAK2/KLF4/PTGES/ADORA2B/NR1D1/STAT3/ZFP36/PVR;13
GO:0045165;cell fate commitment;5/67;55/2237;0,0909090909090909;3,03527815468114;2,68485710790261;0,0226550210951799;0,295921447960488;0,264623803572737;MCL1/CTNNB1/IRF4/KLF4/STAT3;5
GO:0050728;negative regulation of inflammatory response;5/67;55/2237;0,0909090909090909;3,03527815468114;2,68485710790261;0,0226550210951799;0,295921447960488;0,264623803572737;NLRP3/KLF4/NR1D1/STAT3/ZFP36;5
GO:2001235;positive regulation of apoptotic signaling pathway;4/67;37/2237;0,108108108108108;3,60951996772892;2,81185926369526;0,0230865608897524;0,297155180127448;0,265727052089737;MCL1/JAK2/FAS/UBB;4
GO:0032623;interleukin-2 production;3/67;21/2237;0,142857142857143;4,76972281449893;3,04914179777098;0,023220151351036;0,297155180127448;0,265727052089737;IRF4/PNP/ZFP36;3
GO:0032663;regulation of interleukin-2 production;3/67;21/2237;0,142857142857143;4,76972281449893;3,04914179777098;0,023220151351036;0,297155180127448;0,265727052089737;IRF4/PNP/ZFP36;3
GO:0071496;cellular response to external stimulus;6/67;76/2237;0,0789473684210526;2,63589945011783;2,54905644961941;0,0242512725619085;0,306212734881698;0,273826649488496;GADD45A/NR4A2/IRF1/FAS/ADORA2B/ATF4;6
GO:1901653;cellular response to peptide;6/67;76/2237;0,0789473684210526;2,63589945011783;2,54905644961941;0,0242512725619085;0,306212734881698;0,273826649488496;NR4A2/SH2B2/JAK2/KLF4/NDEL1/STAT3;6
GO:0060284;regulation of cell development;11/67;192/2237;0,0572916666666667;1,91285758706468;2,32407651267965;0,0248512277625305;0,311710101869091;0,278742596513849;NLRP3/CTNNB1/IRF1/IRF4/HSPA1A/PNP/NR1D1/STAT3/JUNB/ZFP36/TGM2;11
GO:0043065;positive regulation of apoptotic process;9/67;144/2237;0,0625;2,08675373134328;2,36848809386017;0,0254554423303753;0,314346095957819;0,281099799030807;GADD45A/MCL1/CTNNB1/APBB2/JAK2/FAS/UBB/TGM2/ATF4;9
GO:0031324;negative regulation of cellular metabolic process;22/67;493/2237;0,0446247464503043;1,48993369864673;2,16436730839044;0,0255078535150094;0,314346095957819;0,281099799030807;GADD45A/TENT5C/MCL1/NLRP3/HK2/ARID5A/NR4A2/CTNNB1/TIPARP/APBB2/IRF1/DUSP1/HSPA1A/PLAGL1/TFEC/KLF4/ARID5B/NR1D1/STAT3/ZFP36/ATF4/TIMP1;22
GO:0048608;reproductive structure development;5/67;57/2237;0,087719298245614;2,92877716679759;2,59140129351928;0,0260458454775217;0,314346095957819;0,281099799030807;CTNNB1/TIPARP/ARID5B/UBB/BCL2L1;5
GO:0048593;camera-type eye morphogenesis;3/67;22/2237;0,136363636363636;4,55291723202171;2,94206998617644;0,026321173411276;0,314346095957819;0,281099799030807;CTNNB1/STAT3/ATF4;3
GO:0051648;vesicle localization;3/67;22/2237;0,136363636363636;4,55291723202171;2,94206998617644;0,026321173411276;0,314346095957819;0,281099799030807;CTNNB1/SAR1A/NDEL1;3
GO:0051650;establishment of vesicle localization;3/67;22/2237;0,136363636363636;4,55291723202171;2,94206998617644;0,026321173411276;0,314346095957819;0,281099799030807;CTNNB1/SAR1A/NDEL1;3
GO:0120034;positive regulation of plasma membrane bounded cell projection assembly;3/67;22/2237;0,136363636363636;4,55291723202171;2,94206998617644;0,026321173411276;0,314346095957819;0,281099799030807;CDC42EP2/NDEL1/CDC42EP4;3
GO:0009725;response to hormone;10/67;169/2237;0,0591715976331361;1,97562483440784;2,31736458620529;0,0263891389954029;0,314346095957819;0,281099799030807;ARID5A/NR4A2/HSPA1A/SH2B2/JAK2/NDEL1/NR1D1/STAT3/ZFP36/TIMP1;10
GO:0002287;alpha-beta T cell activation involved in immune response;4/67;39/2237;0,102564102564103;3,42441637964026;2,68329921126672;0,0274979770848462;0,314641492280587;0,281363953248188;NLRP3/IRF4/STAT3/JUNB;4
GO:0002293;alpha-beta T cell differentiation involved in immune response;4/67;39/2237;0,102564102564103;3,42441637964026;2,68329921126672;0,0274979770848462;0,314641492280587;0,281363953248188;NLRP3/IRF4/STAT3/JUNB;4
GO:0002294;CD4-positive, alpha-beta T cell differentiation involved in immune response;4/67;39/2237;0,102564102564103;3,42441637964026;2,68329921126672;0,0274979770848462;0,314641492280587;0,281363953248188;NLRP3/IRF4/STAT3/JUNB;4
GO:0032611;interleukin-1 beta production;4/67;39/2237;0,102564102564103;3,42441637964026;2,68329921126672;0,0274979770848462;0,314641492280587;0,281363953248188;GBP5/NLRP3/JAK2/STAT3;4
GO:0032651;regulation of interleukin-1 beta production;4/67;39/2237;0,102564102564103;3,42441637964026;2,68329921126672;0,0274979770848462;0,314641492280587;0,281363953248188;GBP5/NLRP3/JAK2/STAT3;4
GO:0042093;T-helper cell differentiation;4/67;39/2237;0,102564102564103;3,42441637964026;2,68329921126672;0,0274979770848462;0,314641492280587;0,281363953248188;NLRP3/IRF4/STAT3/JUNB;4
GO:0051656;establishment of organelle localization;5/67;58/2237;0,0862068965517241;2,87828100874936;2,5461816451099;0,0278574462568976;0,314641492280587;0,281363953248188;CTNNB1/SAR1A/NDEL1/ADORA2B/UBB;5
GO:0061458;reproductive system development;5/67;58/2237;0,0862068965517241;2,87828100874936;2,5461816451099;0,0278574462568976;0,314641492280587;0,281363953248188;CTNNB1/TIPARP/ARID5B/UBB/BCL2L1;5
GO:0030097;hemopoiesis;13/67;248/2237;0,0524193548387097;1,75018054886856;2,20098803777054;0,029000781215666;0,314641492280587;0,281363953248188;NLRP3/CTNNB1/TIPARP/IRF1/IRF4/HSPA1A/JAK2/KLF4/PNP/STAT3/JUNB/ZFP36/ATF4;13
GO:0043280;positive regulation of cysteine-type endopeptidase activity involved in apoptotic process;3/67;23/2237;0,130434782608696;4,35496430889033;2,84123036956969;0,0296337369763929;0,314641492280587;0,281363953248188;NLRP3/JAK2/FAS;3
GO:0034599;cellular response to oxidative stress;5/67;59/2237;0,0847457627118644;2,82949658487225;2,50191243279027;0,0297478752108558;0,314641492280587;0,281363953248188;NR4A2/HSPA1A/KLF4/OSER1/ATF4;5
GO:0002221;pattern recognition receptor signaling pathway;6/67;80/2237;0,075;2,50410447761194;2,40680751634294;0,0303655959300397;0,314641492280587;0,281363953248188;GBP5/NLRP3/IRF1/IRF4/HSPA1A/NR1D1;6
GO:0010243;response to organonitrogen compound;11/67;198/2237;0,0555555555555556;1,85489220563847;2,21349616437424;0,0304514458230952;0,314641492280587;0,281363953248188;ADSS2/NR4A2/CTNNB1/SH2B2/JAK2/KLF4/NDEL1/STAT3/BCL2L1/TGM2/TIMP1;11
GO:0002460;adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains;7/67;102/2237;0,0686274509803922;2,29133743049459;2,34522394554021;0,0305157845477004;0,314641492280587;0,281363953248188;NLRP3/ARID5A/IRF4/JAK2/STAT3/JUNB/PVR;7
GO:0007017;microtubule-based process;7/67;103/2237;0,0679611650485437;2,26909143602376;2,31663574072103;0,0319779393434465;0,314641492280587;0,281363953248188;GADD45A/CTNNB1/CCNL1/HSPA1A/NEK6/NDEL1/UBB;7
GO:0048872;homeostasis of number of cells;6/67;81/2237;0,0740740740740741;2,47318960751797;2,37257643034634;0,0320396638585765;0,314641492280587;0,281363953248188;HSPA1A/SH2B2/JAK2/FAS/STAT3/ZFP36;6
GO:0032612;interleukin-1 production;4/67;41/2237;0,0975609756097561;3,25737167819439;2,5628445599833;0,0323827412001682;0,314641492280587;0,281363953248188;GBP5/NLRP3/JAK2/STAT3;4
GO:0032652;regulation of interleukin-1 production;4/67;41/2237;0,0975609756097561;3,25737167819439;2,5628445599833;0,0323827412001682;0,314641492280587;0,281363953248188;GBP5/NLRP3/JAK2/STAT3;4
GO:0001570;vasculogenesis;3/67;24/2237;0,125;4,17350746268657;2,74598317446777;0,0331569070261849;0,314641492280587;0,281363953248188;CTNNB1/TIPARP/JUNB;3
GO:0002711;positive regulation of T cell mediated immunity;3/67;24/2237;0,125;4,17350746268657;2,74598317446777;0,0331569070261849;0,314641492280587;0,281363953248188;NLRP3/ARID5A/PVR;3
GO:0032273;positive regulation of protein polymerization;3/67;24/2237;0,125;4,17350746268657;2,74598317446777;0,0331569070261849;0,314641492280587;0,281363953248188;HSPA1A/CDC42EP2/CDC42EP4;3
GO:0048592;eye morphogenesis;3/67;24/2237;0,125;4,17350746268657;2,74598317446777;0,0331569070261849;0,314641492280587;0,281363953248188;CTNNB1/STAT3/ATF4;3
GO:0070059;intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress;3/67;24/2237;0,125;4,17350746268657;2,74598317446777;0,0331569070261849;0,314641492280587;0,281363953248188;HSPA1A/BCL2L1/ATF4;3
GO:1990830;cellular response to leukemia inhibitory factor;3/67;24/2237;0,125;4,17350746268657;2,74598317446777;0,0331569070261849;0,314641492280587;0,281363953248188;HK2/KLF4/ARID5B;3
GO:0030217;T cell differentiation;7/67;104/2237;0,0673076923076923;2,24727324913892;2,28837020154997;0,0334868835447279;0,314641492280587;0,281363953248188;NLRP3/CTNNB1/IRF1/IRF4/PNP/STAT3/JUNB;7
GO:0009150;purine ribonucleotide metabolic process;5/67;61/2237;0,0819672131147541;2,73672620504037;2,41607417532012;0,0337688591331421;0,314641492280587;0,281363953248188;ADSS2/HK2/HSPA1A/PNP/STAT3;5
GO:0045580;regulation of T cell differentiation;5/67;61/2237;0,0819672131147541;2,73672620504037;2,41607417532012;0,0337688591331421;0,314641492280587;0,281363953248188;NLRP3/IRF1/IRF4/PNP/JUNB;5
GO:0061448;connective tissue development;5/67;61/2237;0,0819672131147541;2,73672620504037;2,41607417532012;0,0337688591331421;0,314641492280587;0,281363953248188;ARID5A/CTNNB1/ARID5B/UBB/TIMP1;5
GO:0071375;cellular response to peptide hormone stimulus;5/67;61/2237;0,0819672131147541;2,73672620504037;2,41607417532012;0,0337688591331421;0,314641492280587;0,281363953248188;NR4A2/SH2B2/JAK2/NDEL1/STAT3;5
GO:0001774;microglial cell activation;2/67;10/2237;0,2;6,67761194029851;3,16117858409844;0,0340557053418798;0,314641492280587;0,281363953248188;JAK2/NR1D1;2
GO:0002295;T-helper cell lineage commitment;2/67;10/2237;0,2;6,67761194029851;3,16117858409844;0,0340557053418798;0,314641492280587;0,281363953248188;IRF4/STAT3;2
GO:0009126;purine nucleoside monophosphate metabolic process;2/67;10/2237;0,2;6,67761194029851;3,16117858409844;0,0340557053418798;0,314641492280587;0,281363953248188;ADSS2/PNP;2
GO:0009167;purine ribonucleoside monophosphate metabolic process;2/67;10/2237;0,2;6,67761194029851;3,16117858409844;0,0340557053418798;0,314641492280587;0,281363953248188;ADSS2/PNP;2
GO:0009299;mRNA transcription;2/67;10/2237;0,2;6,67761194029851;3,16117858409844;0,0340557053418798;0,314641492280587;0,281363953248188;STAT3/ATF4;2
GO:0010171;body morphogenesis;2/67;10/2237;0,2;6,67761194029851;3,16117858409844;0,0340557053418798;0,314641492280587;0,281363953248188;TIPARP/ARID5B;2
GO:0010633;negative regulation of epithelial cell migration;2/67;10/2237;0,2;6,67761194029851;3,16117858409844;0,0340557053418798;0,314641492280587;0,281363953248188;GADD45A/KLF4;2
GO:0014075;response to amine;2/67;10/2237;0,2;6,67761194029851;3,16117858409844;0,0340557053418798;0,314641492280587;0,281363953248188;NR4A2/JAK2;2
GO:0031103;axon regeneration;2/67;10/2237;0,2;6,67761194029851;3,16117858409844;0,0340557053418798;0,314641492280587;0,281363953248188;JAK2/KLF4;2
GO:0031109;microtubule polymerization or depolymerization;2/67;10/2237;0,2;6,67761194029851;3,16117858409844;0,0340557053418798;0,314641492280587;0,281363953248188;HSPA1A/NDEL1;2
GO:0032753;positive regulation of interleukin-4 production;2/67;10/2237;0,2;6,67761194029851;3,16117858409844;0,0340557053418798;0,314641492280587;0,281363953248188;NLRP3/IRF4;2
GO:0035195;miRNA-mediated post-transcriptional gene silencing;2/67;10/2237;0,2;6,67761194029851;3,16117858409844;0,0340557053418798;0,314641492280587;0,281363953248188;STAT3/ZFP36;2
GO:0035743;CD4-positive, alpha-beta T cell cytokine production;2/67;10/2237;0,2;6,67761194029851;3,16117858409844;0,0340557053418798;0,314641492280587;0,281363953248188;NLRP3/ARID5A;2
GO:0050795;regulation of behavior;2/67;10/2237;0,2;6,67761194029851;3,16117858409844;0,0340557053418798;0,314641492280587;0,281363953248188;NR1D1/STAT3;2
GO:0051225;spindle assembly;2/67;10/2237;0,2;6,67761194029851;3,16117858409844;0,0340557053418798;0,314641492280587;0,281363953248188;HSPA1A/NEK6;2
GO:0060333;type II interferon-mediated signaling pathway;2/67;10/2237;0,2;6,67761194029851;3,16117858409844;0,0340557053418798;0,314641492280587;0,281363953248188;IRF1/JAK2;2
GO:0072540;T-helper 17 cell lineage commitment;2/67;10/2237;0,2;6,67761194029851;3,16117858409844;0,0340557053418798;0,314641492280587;0,281363953248188;IRF4/STAT3;2
GO:0002292;T cell differentiation involved in immune response;4/67;42/2237;0,0952380952380952;3,17981520966596;2,50536205481349;0,0350048703030641;0,316940156911132;0,283419503401329;NLRP3/IRF4/STAT3/JUNB;4
GO:0002824;positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains;4/67;42/2237;0,0952380952380952;3,17981520966596;2,50536205481349;0,0350048703030641;0,316940156911132;0,283419503401329;NLRP3/ARID5A/JAK2/PVR;4
GO:0071383;cellular response to steroid hormone stimulus;4/67;42/2237;0,0952380952380952;3,17981520966596;2,50536205481349;0,0350048703030641;0,316940156911132;0,283419503401329;HSPA1A/JAK2/NR1D1/ZFP36;4
GO:0034341;response to type II interferon;5/67;62/2237;0,0806451612903226;2,69258545979779;2,37443482818984;0,0359010383597229;0,316940156911132;0,283419503401329;GBP5/IRF1/JAK2/CDC42EP2/CDC42EP4;5
GO:0080134;regulation of response to stress;16/67;338/2237;0,0473372781065089;1,58049986752627;2,03489229224606;0,0367753267865685;0,316940156911132;0,283419503401329;GBP5/NLRP3/INO80D/IRF1/IRF4/HSPA1A/JAK2/KLF4/PTGES/FAS/ADORA2B/NR1D1/STAT3/ZFP36/PVR/BCL2L1;16
GO:0021953;central nervous system neuron differentiation;3/67;25/2237;0,12;4,0065671641791;2,65577811101235;0,036889212380662;0,316940156911132;0,283419503401329;NR4A2/NDEL1/UBB;3
GO:0045622;regulation of T-helper cell differentiation;3/67;25/2237;0,12;4,0065671641791;2,65577811101235;0,036889212380662;0,316940156911132;0,283419503401329;NLRP3/IRF4/JUNB;3
GO:0001501;skeletal system development;6/67;84/2237;0,0714285714285714;2,38486140724947;2,27283220673998;0,0374224082520076;0,316940156911132;0,283419503401329;ARID5A/CTNNB1/TIPARP/ARID5B/TGM2/TIMP1;6
GO:0002758;innate immune response-activating signaling pathway;6/67;84/2237;0,0714285714285714;2,38486140724947;2,27283220673998;0,0374224082520076;0,316940156911132;0,283419503401329;GBP5/NLRP3/IRF1/IRF4/HSPA1A/NR1D1;6
GO:1901565;organonitrogen compound catabolic process;13/67;257/2237;0,0505836575875486;1,68889017945293;2,0621839111492;0,0375369363257169;0,316940156911132;0,283419503401329;HK2/RNF149/CTNNB1/TIPARP/FEM1C/HSPA1A/AZIN1/UBC/PNP/UBB/NR1D1/STAT3/TIMP1;13
GO:0002821;positive regulation of adaptive immune response;4/67;43/2237;0,0930232558139535;3,10586601874349;2,44957131028478;0,0377476531824486;0,316940156911132;0,283419503401329;NLRP3/ARID5A/JAK2/PVR;4
GO:0008406;gonad development;4/67;43/2237;0,0930232558139535;3,10586601874349;2,44957131028478;0,0377476531824486;0,316940156911132;0,283419503401329;TIPARP/ARID5B/UBB/BCL2L1;4
GO:0009259;ribonucleotide metabolic process;5/67;63/2237;0,0793650793650794;2,64984600805496;2,33360501364026;0,0381152933875268;0,316940156911132;0,283419503401329;ADSS2/HK2/HSPA1A/PNP/STAT3;5
GO:0019693;ribose phosphate metabolic process;5/67;63/2237;0,0793650793650794;2,64984600805496;2,33360501364026;0,0381152933875268;0,316940156911132;0,283419503401329;ADSS2/HK2/HSPA1A/PNP/STAT3;5
GO:0010558;negative regulation of macromolecule biosynthetic process;18/67;396/2237;0,0454545454545455;1,51763907734057;1,99476246304813;0,038259240614836;0,316940156911132;0,283419503401329;GADD45A/TENT5C/NLRP3/ARID5A/NR4A2/CTNNB1/TIPARP/APBB2/IRF1/HSPA1A/PLAGL1/TFEC/KLF4/ARID5B/NR1D1/STAT3/ZFP36/ATF4;18
GO:0034660;ncRNA metabolic process;6/67;85/2237;0,0705882352941176;2,356804214223;2,24052063057033;0,039338909771854;0,316940156911132;0,283419503401329;SDE2/ELL2/SRFBP1/KLF4/STAT3/ELL;6
GO:0002822;regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains;5/67;64/2237;0,078125;2,6084421641791;2,29355419774923;0,0404122381505931;0,316940156911132;0,283419503401329;NLRP3/ARID5A/JAK2/JUNB/PVR;5
GO:0007005;mitochondrion organization;5/67;64/2237;0,078125;2,6084421641791;2,29355419774923;0,0404122381505931;0,316940156911132;0,283419503401329;MCL1/HK2/HSPA1A/GGCT/BCL2L1;5
GO:0045862;positive regulation of proteolysis;5/67;64/2237;0,078125;2,6084421641791;2,29355419774923;0,0404122381505931;0,316940156911132;0,283419503401329;NLRP3/HSPA1A/JAK2/FAS/STAT3;5
GO:0007059;chromosome segregation;4/67;44/2237;0,0909090909090909;3,03527815468114;2,39537894377345;0,0406114797957878;0,316940156911132;0,283419503401329;DUSP1/HSPA1A/NEK6/NDEL1;4
GO:0045137;development of primary sexual characteristics;4/67;44/2237;0,0909090909090909;3,03527815468114;2,39537894377345;0,0406114797957878;0,316940156911132;0,283419503401329;TIPARP/ARID5B/UBB/BCL2L1;4
GO:2000116;regulation of cysteine-type endopeptidase activity;4/67;44/2237;0,0909090909090909;3,03527815468114;2,39537894377345;0,0406114797957878;0,316940156911132;0,283419503401329;NLRP3/JAK2/KLF4/FAS;4
GO:0030041;actin filament polymerization;3/67;26/2237;0,115384615384615;3,85246842709529;2,5701388285459;0,0408286887061478;0,316940156911132;0,283419503401329;JAK2/CDC42EP2/CDC42EP4;3
GO:0032200;telomere organization;3/67;26/2237;0,115384615384615;3,85246842709529;2,5701388285459;0,0408286887061478;0,316940156911132;0,283419503401329;INO80D/CTNNB1/H3-3B;3
GO:0071260;cellular response to mechanical stimulus;3/67;26/2237;0,115384615384615;3,85246842709529;2,5701388285459;0,0408286887061478;0,316940156911132;0,283419503401329;GADD45A/IRF1/FAS;3
GO:1990823;response to leukemia inhibitory factor;3/67;26/2237;0,115384615384615;3,85246842709529;2,5701388285459;0,0408286887061478;0,316940156911132;0,283419503401329;HK2/KLF4/ARID5B;3
GO:0007091;metaphase/anaphase transition of mitotic cell cycle;2/67;11/2237;0,181818181818182;6,07055630936228;2,96164367949811;0,0408307277118882;0,316940156911132;0,283419503401329;DUSP1/NEK6;2
GO:0022029;telencephalon cell migration;2/67;11/2237;0,181818181818182;6,07055630936228;2,96164367949811;0,0408307277118882;0,316940156911132;0,283419503401329;CTNNB1/NDEL1;2
GO:0030071;regulation of mitotic metaphase/anaphase transition;2/67;11/2237;0,181818181818182;6,07055630936228;2,96164367949811;0,0408307277118882;0,316940156911132;0,283419503401329;DUSP1/NEK6;2
GO:0031102;neuron projection regeneration;2/67;11/2237;0,181818181818182;6,07055630936228;2,96164367949811;0,0408307277118882;0,316940156911132;0,283419503401329;JAK2/KLF4;2
GO:0032206;positive regulation of telomere maintenance;2/67;11/2237;0,181818181818182;6,07055630936228;2,96164367949811;0,0408307277118882;0,316940156911132;0,283419503401329;INO80D/CTNNB1;2
GO:0034198;cellular response to amino acid starvation;2/67;11/2237;0,181818181818182;6,07055630936228;2,96164367949811;0,0408307277118882;0,316940156911132;0,283419503401329;FAS/ATF4;2
GO:0043373;CD4-positive, alpha-beta T cell lineage commitment;2/67;11/2237;0,181818181818182;6,07055630936228;2,96164367949811;0,0408307277118882;0,316940156911132;0,283419503401329;IRF4/STAT3;2
GO:0044784;metaphase/anaphase transition of cell cycle;2/67;11/2237;0,181818181818182;6,07055630936228;2,96164367949811;0,0408307277118882;0,316940156911132;0,283419503401329;DUSP1/NEK6;2
GO:0060416;response to growth hormone;2/67;11/2237;0,181818181818182;6,07055630936228;2,96164367949811;0,0408307277118882;0,316940156911132;0,283419503401329;JAK2/STAT3;2
GO:1902099;regulation of metaphase/anaphase transition of cell cycle;2/67;11/2237;0,181818181818182;6,07055630936228;2,96164367949811;0,0408307277118882;0,316940156911132;0,283419503401329;DUSP1/NEK6;2
GO:1902235;regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway;2/67;11/2237;0,181818181818182;6,07055630936228;2,96164367949811;0,0408307277118882;0,316940156911132;0,283419503401329;HSPA1A/BCL2L1;2
GO:1990928;response to amino acid starvation;2/67;11/2237;0,181818181818182;6,07055630936228;2,96164367949811;0,0408307277118882;0,316940156911132;0,283419503401329;FAS/ATF4;2
GO:2000737;negative regulation of stem cell differentiation;2/67;11/2237;0,181818181818182;6,07055630936228;2,96164367949811;0,0408307277118882;0,316940156911132;0,283419503401329;STAT3/ZFP36;2
GO:0051345;positive regulation of hydrolase activity;7/67;109/2237;0,0642201834862385;2,14418732027934;2,15163203560222;0,0417519158970323;0,322767872281548;0,28863086005725;NLRP3/HSPA1A/JAK2/FAS/NDEL1/STAT3/TGM2;7
GO:0010605;negative regulation of macromolecule metabolic process;21/67;488/2237;0,0430327868852459;1,4367812576462;1,9170014207435;0,0425559068038723;0,327645884091603;0,292992956985154;GADD45A/TENT5C/NLRP3/ARID5A/NR4A2/CTNNB1/TIPARP/APBB2/IRF1/DUSP1/HSPA1A/PLAGL1/TFEC/AZIN1/KLF4/ARID5B/NR1D1/STAT3/ZFP36/ATF4/TIMP1;21
GO:0050727;regulation of inflammatory response;8/67;134/2237;0,0597014925373134;1,99331699710403;2,08335876360349;0,0438537545997662;0,329841718972102;0,294956553007343;NLRP3/JAK2/KLF4/PTGES/ADORA2B/NR1D1/STAT3/ZFP36;8
GO:0000819;sister chromatid segregation;3/67;27/2237;0,111111111111111;3,70978441127695;2,48865055553995;0,0449729192097147;0,329841718972102;0,294956553007343;DUSP1/HSPA1A/NEK6;3
GO:0006839;mitochondrial transport;3/67;27/2237;0,111111111111111;3,70978441127695;2,48865055553995;0,0449729192097147;0,329841718972102;0,294956553007343;HK2/HSPA1A/BCL2L1;3
GO:0008584;male gonad development;3/67;27/2237;0,111111111111111;3,70978441127695;2,48865055553995;0,0449729192097147;0,329841718972102;0,294956553007343;ARID5B/UBB/BCL2L1;3
GO:0032637;interleukin-8 production;3/67;27/2237;0,111111111111111;3,70978441127695;2,48865055553995;0,0449729192097147;0,329841718972102;0,294956553007343;HSPA1A/KLF4/STAT3;3
GO:0032677;regulation of interleukin-8 production;3/67;27/2237;0,111111111111111;3,70978441127695;2,48865055553995;0,0449729192097147;0,329841718972102;0,294956553007343;HSPA1A/KLF4/STAT3;3
GO:0048008;platelet-derived growth factor receptor signaling pathway;3/67;27/2237;0,111111111111111;3,70978441127695;2,48865055553995;0,0449729192097147;0,329841718972102;0,294956553007343;TIPARP/JAK2/ARID5B;3
GO:1901605;alpha-amino acid metabolic process;3/67;27/2237;0,111111111111111;3,70978441127695;2,48865055553995;0,0449729192097147;0,329841718972102;0,294956553007343;ADSS2/AZIN1/ATF4;3
GO:0019752;carboxylic acid metabolic process;7/67;111/2237;0,0630630630630631;2,10555331450854;2,09895430670931;0,0454029420536783;0,329841718972102;0,294956553007343;ADSS2/HK2/AZIN1/PTGES/NR1D1/STAT3/ATF4;7
GO:0045089;positive regulation of innate immune response;7/67;111/2237;0,0630630630630631;2,10555331450854;2,09895430670931;0,0454029420536783;0,329841718972102;0,294956553007343;GBP5/NLRP3/IRF1/IRF4/HSPA1A/NR1D1/PVR;7
GO:0002262;myeloid cell homeostasis;4/67;46/2237;0,0869565217391304;2,90330953926022;2,29145105569325;0,0467029453909959;0,329841718972102;0,294956553007343;HSPA1A/JAK2/STAT3/ZFP36;4
GO:1901652;response to peptide;7/67;112/2237;0,0625;2,08675373134328;2,07302298855612;0,0473040679275921;0,329841718972102;0,294956553007343;NR4A2/SH2B2/JAK2/KLF4/NDEL1/STAT3/TIMP1;7
GO:0050790;regulation of catalytic activity;14/67;293/2237;0,0477815699658703;1,59533391065152;1,92039132252809;0,0473688817673711;0,329841718972102;0,294956553007343;GADD45A/NLRP3/TMBIM1/DUSP1/HSPA1A/JAK2/KLF4/FAS/NDEL1/ADORA2B/STAT3/ZFP36/TGM2/TIMP1;14
GO:0043434;response to peptide hormone;6/67;89/2237;0,0674157303370786;2,2508804293141;2,11561723637071;0,0476303058347855;0,329841718972102;0,294956553007343;NR4A2/SH2B2/JAK2/NDEL1/STAT3/TIMP1;6
GO:0009314;response to radiation;5/67;67/2237;0,0746268656716418;2,49164624638004;2,17779405559741;0,0478041585251348;0,329841718972102;0,294956553007343;GADD45A/SDE2/BCL2L1/ATF4/TIMP1;5
GO:0042176;regulation of protein catabolic process;5/67;67/2237;0,0746268656716418;2,49164624638004;2,17779405559741;0,0478041585251348;0,329841718972102;0,294956553007343;TIPARP/HSPA1A/AZIN1/UBB/TIMP1;5
GO:0002269;leukocyte activation involved in inflammatory response;2/67;12/2237;0,166666666666667;5,56467661691542;2,78534544399734;0,0480656359220169;0,329841718972102;0,294956553007343;JAK2/NR1D1;2
GO:0002363;alpha-beta T cell lineage commitment;2/67;12/2237;0,166666666666667;5,56467661691542;2,78534544399734;0,0480656359220169;0,329841718972102;0,294956553007343;IRF4/STAT3;2
GO:0009161;ribonucleoside monophosphate metabolic process;2/67;12/2237;0,166666666666667;5,56467661691542;2,78534544399734;0,0480656359220169;0,329841718972102;0,294956553007343;ADSS2/PNP;2
GO:0021885;forebrain cell migration;2/67;12/2237;0,166666666666667;5,56467661691542;2,78534544399734;0,0480656359220169;0,329841718972102;0,294956553007343;CTNNB1/NDEL1;2
GO:0032633;interleukin-4 production;2/67;12/2237;0,166666666666667;5,56467661691542;2,78534544399734;0,0480656359220169;0,329841718972102;0,294956553007343;NLRP3/IRF4;2
GO:0032673;regulation of interleukin-4 production;2/67;12/2237;0,166666666666667;5,56467661691542;2,78534544399734;0,0480656359220169;0,329841718972102;0,294956553007343;NLRP3/IRF4;2
GO:0033045;regulation of sister chromatid segregation;2/67;12/2237;0,166666666666667;5,56467661691542;2,78534544399734;0,0480656359220169;0,329841718972102;0,294956553007343;DUSP1/NEK6;2
GO:0035194;regulatory ncRNA-mediated post-transcriptional gene silencing;2/67;12/2237;0,166666666666667;5,56467661691542;2,78534544399734;0,0480656359220169;0,329841718972102;0,294956553007343;STAT3/ZFP36;2
GO:0045429;positive regulation of nitric oxide biosynthetic process;2/67;12/2237;0,166666666666667;5,56467661691542;2,78534544399734;0,0480656359220169;0,329841718972102;0,294956553007343;JAK2/KLF4;2
GO:0071354;cellular response to interleukin-6;2/67;12/2237;0,166666666666667;5,56467661691542;2,78534544399734;0,0480656359220169;0,329841718972102;0,294956553007343;JAK2/STAT3;2
GO:0072384;organelle transport along microtubule;2/67;12/2237;0,166666666666667;5,56467661691542;2,78534544399734;0,0480656359220169;0,329841718972102;0,294956553007343;NDEL1/UBB;2
GO:1903573;negative regulation of response to endoplasmic reticulum stress;2/67;12/2237;0,166666666666667;5,56467661691542;2,78534544399734;0,0480656359220169;0,329841718972102;0,294956553007343;HSPA1A/BCL2L1;2
GO:1904407;positive regulation of nitric oxide metabolic process;2/67;12/2237;0,166666666666667;5,56467661691542;2,78534544399734;0,0480656359220169;0,329841718972102;0,294956553007343;JAK2/KLF4;2
GO:2000573;positive regulation of DNA biosynthetic process;2/67;12/2237;0,166666666666667;5,56467661691542;2,78534544399734;0,0480656359220169;0,329841718972102;0,294956553007343;CTNNB1/KLF4;2
GO:0043436;oxoacid metabolic process;7/67;113/2237;0,0619469026548673;2,06828688416325;2,04735567188353;0,0492560874264546;0,331242285458768;0,296208990887099;ADSS2/HK2/AZIN1/PTGES/NR1D1/STAT3/ATF4;7
GO:0006195;purine nucleotide catabolic process;3/67;28/2237;0,107142857142857;3,5772921108742;2,41095017976857;0,0493190731253287;0,331242285458768;0,296208990887099;HK2/PNP/STAT3;3
GO:0009154;purine ribonucleotide catabolic process;3/67;28/2237;0,107142857142857;3,5772921108742;2,41095017976857;0,0493190731253287;0,331242285458768;0,296208990887099;HK2/PNP/STAT3;3
GO:0032755;positive regulation of interleukin-6 production;3/67;28/2237;0,107142857142857;3,5772921108742;2,41095017976857;0,0493190731253287;0,331242285458768;0,296208990887099;ARID5A/ADORA2B/STAT3;3
GO:0046034;ATP metabolic process;3/67;28/2237;0,107142857142857;3,5772921108742;2,41095017976857;0,0493190731253287;0,331242285458768;0,296208990887099;HK2/HSPA1A/STAT3;3
GO:0046546;development of primary male sexual characteristics;3/67;28/2237;0,107142857142857;3,5772921108742;2,41095017976857;0,0493190731253287;0,331242285458768;0,296208990887099;ARID5B/UBB/BCL2L1;3
GO:0002286;T cell activation involved in immune response;4/67;47/2237;0,0851063829787234;2,84153699587171;2,24156198993762;0,049930499035608;0,33181882516997;0,296724553825645;NLRP3/IRF4/STAT3/JUNB;4
GO:0043367;CD4-positive, alpha-beta T cell differentiation;4/67;47/2237;0,0851063829787234;2,84153699587171;2,24156198993762;0,049930499035608;0,33181882516997;0,296724553825645;NLRP3/IRF4/STAT3/JUNB;4
GO:0045930;negative regulation of mitotic cell cycle;4/67;47/2237;0,0851063829787234;2,84153699587171;2,24156198993762;0,049930499035608;0,33181882516997;0,296724553825645;SDE2/CTNNB1/DUSP1/KLF4;4
GO:0031327;negative regulation of cellular biosynthetic process;18/67;409/2237;0,0440097799511002;1,46940116045688;1,84485038529813;0,0507197338304494;0,335129441459711;0,299685028238024;GADD45A/TENT5C/NLRP3/ARID5A/NR4A2/CTNNB1/TIPARP/APBB2/IRF1/HSPA1A/PLAGL1/TFEC/KLF4/ARID5B/NR1D1/STAT3/ZFP36/ATF4;18
GO:0002250;adaptive immune response;8/67;138/2237;0,0579710144927536;1,93553969284015;1,99314537548135;0,0507825499994389;0,335129441459711;0,299685028238024;NLRP3/ARID5A/IRF1/IRF4/JAK2/STAT3/JUNB/PVR;8
GO:0006082;organic acid metabolic process;7/67;114/2237;0,0614035087719298;2,05014401675831;2,02194680166657;0,0512593321056823;0,337101302111674;0,30144833829694;ADSS2/HK2/AZIN1/PTGES/NR1D1/STAT3/ATF4;7
GO:0009890;negative regulation of biosynthetic process;18/67;410/2237;0,0439024390243902;1,46581725518748;1,83350315119652;0,0517881945125135;0,339400831857095;0,303504662067508;GADD45A/TENT5C/NLRP3/ARID5A/NR4A2/CTNNB1/TIPARP/APBB2/IRF1/HSPA1A/PLAGL1/TFEC/KLF4/ARID5B/NR1D1/STAT3/ZFP36/ATF4;18
GO:0002218;activation of innate immune response;6/67;91/2237;0,0659340659340659;2,20141052976874;2,05560992254975;0,0521571819987185;0,339469768747673;0,303566307961433;GBP5/NLRP3/IRF1/IRF4/HSPA1A/NR1D1;6
GO:0006979;response to oxidative stress;6/67;91/2237;0,0659340659340659;2,20141052976874;2,05560992254975;0,0521571819987185;0,339469768747673;0,303566307961433;NR4A2/HSPA1A/JAK2/KLF4/OSER1/ATF4;6
GO:0030099;myeloid cell differentiation;7/67;115/2237;0,0608695652173913;2,03231667748215;1,99679098842366;0,0533141073632236;0,343236654975779;0,306934795673889;CTNNB1/IRF4/HSPA1A/JAK2/STAT3/JUNB/ZFP36;7
GO:0045595;regulation of cell differentiation;15/67;326/2237;0,0460122699386503;1,53626041571285;1,84033815833911;0,053598969186781;0,343236654975779;0,306934795673889;TENT5C/NLRP3/CTNNB1/IRF1/IRF4/HSPA1A/JAK2/KLF4/PNP/NR1D1/STAT3/JUNB/ZFP36/TGM2/ATF4;15
GO:0008154;actin polymerization or depolymerization;3/67;29/2237;0,103448275862069;3,45393721049923;2,33671821842442;0,0538639420909549;0,343236654975779;0,306934795673889;JAK2/CDC42EP2/CDC42EP4;3
GO:0043370;regulation of CD4-positive, alpha-beta T cell differentiation;3/67;29/2237;0,103448275862069;3,45393721049923;2,33671821842442;0,0538639420909549;0,343236654975779;0,306934795673889;NLRP3/IRF4/JUNB;3
GO:0072523;purine-containing compound catabolic process;3/67;29/2237;0,103448275862069;3,45393721049923;2,33671821842442;0,0538639420909549;0,343236654975779;0,306934795673889;HK2/PNP/STAT3;3
GO:2001056;positive regulation of cysteine-type endopeptidase activity;3/67;29/2237;0,103448275862069;3,45393721049923;2,33671821842442;0,0538639420909549;0,343236654975779;0,306934795673889;NLRP3/JAK2/FAS;3
GO:0030163;protein catabolic process;10/67;191/2237;0,0523560209424084;1,74806595295772;1,89909719332968;0,054641325403807;0,343236654975779;0,306934795673889;RNF149/CTNNB1/TIPARP/FEM1C/HSPA1A/AZIN1/UBC/UBB/NR1D1/TIMP1;10
GO:0002347;response to tumor cell;2/67;13/2237;0,153846153846154;5,13662456946039;2,62780918228835;0,0557276919304558;0,343236654975779;0,306934795673889;KLF4/PVR;2
GO:0002534;cytokine production involved in inflammatory response;2/67;13/2237;0,153846153846154;5,13662456946039;2,62780918228835;0,0557276919304558;0,343236654975779;0,306934795673889;GBP5/STAT3;2
GO:0002726;positive regulation of T cell cytokine production;2/67;13/2237;0,153846153846154;5,13662456946039;2,62780918228835;0,0557276919304558;0,343236654975779;0,306934795673889;NLRP3/ARID5A;2
GO:0016441;post-transcriptional gene silencing;2/67;13/2237;0,153846153846154;5,13662456946039;2,62780918228835;0,0557276919304558;0,343236654975779;0,306934795673889;STAT3/ZFP36;2
GO:0032922;circadian regulation of gene expression;2/67;13/2237;0,153846153846154;5,13662456946039;2,62780918228835;0,0557276919304558;0,343236654975779;0,306934795673889;NR1D1/ATF4;2
GO:0051983;regulation of chromosome segregation;2/67;13/2237;0,153846153846154;5,13662456946039;2,62780918228835;0,0557276919304558;0,343236654975779;0,306934795673889;DUSP1/NEK6;2
GO:0060324;face development;2/67;13/2237;0,153846153846154;5,13662456946039;2,62780918228835;0,0557276919304558;0,343236654975779;0,306934795673889;TIPARP/ARID5B;2
GO:0070741;response to interleukin-6;2/67;13/2237;0,153846153846154;5,13662456946039;2,62780918228835;0,0557276919304558;0,343236654975779;0,306934795673889;JAK2/STAT3;2
GO:1900015;regulation of cytokine production involved in inflammatory response;2/67;13/2237;0,153846153846154;5,13662456946039;2,62780918228835;0,0557276919304558;0,343236654975779;0,306934795673889;GBP5/STAT3;2
GO:0045619;regulation of lymphocyte differentiation;5/67;70/2237;0,0714285714285714;2,38486140724947;2,06808941158282;0,0559547810951657;0,343236654975779;0,306934795673889;NLRP3/IRF1/IRF4/PNP/JUNB;5
GO:0051336;regulation of hydrolase activity;9/67;166/2237;0,0542168674698795;1,81019600791225;1,90588866674281;0,0559979547980548;0,343236654975779;0,306934795673889;NLRP3/HSPA1A/JAK2/KLF4/FAS/NDEL1/STAT3/TGM2/TIMP1;9
GO:0065003;protein-containing complex assembly;10/67;192/2237;0,0520833333333333;1,73896144278607;1,88134815034767;0,0562781439555255;0,343841305328275;0,307475496178067;GBP5/NLRP3/HSPA1A/JAK2/SAR1A/FAS/CDC42EP2/NDEL1/CDC42EP4/H3-3B;10
GO:2001236;regulation of extrinsic apoptotic signaling pathway;4/67;49/2237;0,0816326530612245;2,72555589399939;2,14559054493095;0,0567478070016389;0,345595969328309;0,309044581031095;MCL1/TMBIM1/HSPA1A/BCL2L1;4
GO:0043086;negative regulation of catalytic activity;6/67;93/2237;0,0645161290322581;2,15406836783823;1,99711951438383;0,0569416801636125;0,34566519945475;0,309106489147276;GADD45A/TMBIM1/DUSP1/KLF4/ZFP36/TIMP1;6
GO:1901698;response to nitrogen compound;11/67;219/2237;0,0502283105022831;1,67702582975533;1,85314818509795;0,057254043247798;0,346450983742266;0,309809166254269;ADSS2/NR4A2/CTNNB1/SH2B2/JAK2/KLF4/NDEL1/STAT3/BCL2L1/TGM2/TIMP1;11
GO:0002833;positive regulation of response to biotic stimulus;7/67;117/2237;0,0598290598290598;1,99757622145682;1,9472177648366;0,0575793389395684;0,347309770546314;0,310577124886911;GBP5/NLRP3/IRF1/IRF4/HSPA1A/NR1D1/PVR;7
GO:1901700;response to oxygen-containing compound;16/67;358/2237;0,0446927374301676;1,49220378554157;1,78511626411473;0,058159183545198;0,349043797879023;0,312127755675734;GBP5/NLRP3/ARID5A/NR4A2/CTNNB1/SH2B2/JAK2/KLF4/NDEL1/NR1D1/STAT3/ZFP36/BCL2L1/TGM2/OSER1/TIMP1;16
GO:0032271;regulation of protein polymerization;3/67;30/2237;0,1;3,33880597014925;2,2656722663663;0,0586039745118952;0,349043797879023;0,312127755675734;HSPA1A/CDC42EP2/CDC42EP4;3
GO:0046635;positive regulation of alpha-beta T cell activation;3/67;30/2237;0,1;3,33880597014925;2,2656722663663;0,0586039745118952;0,349043797879023;0,312127755675734;NLRP3/JAK2/PNP;3
GO:0072524;pyridine-containing compound metabolic process;3/67;30/2237;0,1;3,33880597014925;2,2656722663663;0,0586039745118952;0,349043797879023;0,312127755675734;HK2/PNP/STAT3;3
GO:0045765;regulation of angiogenesis;5/67;71/2237;0,0704225352112676;2,35127180996426;2,03275996583586;0,0588410986114496;0,349357494577071;0,312408274759355;GADD45A/HK2/CTNNB1/KLF4/STAT3;5
GO:0055086;nucleobase-containing small molecule metabolic process;6/67;94/2237;0,0638297872340425;2,13115274690378;1,96841891582995;0,0594311163403437;0,350906921362404;0,31379382897355;ADSS2/HK2/GLRX/HSPA1A/PNP/STAT3;6
GO:0051248;negative regulation of protein metabolic process;9/67;168/2237;0,0535714285714286;1,7886460554371;1,86723923797438;0,0596240656203188;0,350906921362404;0,31379382897355;GADD45A/CTNNB1/DUSP1/HSPA1A/AZIN1/KLF4/ZFP36/ATF4/TIMP1;9
GO:0002682;regulation of immune system process;18/67;417/2237;0,0431654676258993;1,44121121013637;1,75477850467665;0,0597308823012298;0,350906921362404;0,31379382897355;GBP5/NLRP3/ARID5A/CTNNB1/IRF1/DUSP1/IRF4/HSPA1A/SH2B2/JAK2/PNP/ADORA2B/NR1D1/STAT3/PHLPP1/JUNB/ZFP36/PVR;18
GO:0071495;cellular response to endogenous stimulus;13/67;275/2237;0,0472727272727273;1,57834464043419;1,79906558030527;0,0598431550158693;0,350906921362404;0,31379382897355;ARID5A/NR4A2/CTNNB1/HSPA1A/SH2B2/JAK2/KLF4/NDEL1/NR1D1/STAT3/ZFP36/BCL2L1/TGM2;13
GO:0031334;positive regulation of protein-containing complex assembly;4/67;50/2237;0,08;2,6710447761194;2,0993852025953;0,0603365149215931;0,352707898955239;0,315404329138542;GBP5/HSPA1A/CDC42EP2/CDC42EP4;4
GO:0043254;regulation of protein-containing complex assembly;5/67;72/2237;0,0694444444444444;2,31861525704809;1,9980153864592;0,0618121826362878;0,353644103292463;0,316241517366517;GBP5/HSPA1A/SAR1A/CDC42EP2/CDC42EP4;5
GO:1901342;regulation of vasculature development;5/67;72/2237;0,0694444444444444;2,31861525704809;1,9980153864592;0,0618121826362878;0,353644103292463;0,316241517366517;GADD45A/HK2/CTNNB1/KLF4/STAT3;5
GO:0043009;chordate embryonic development;7/67;119/2237;0,0588235294117647;1,9640035118525;1,89859596205716;0,0620536933995691;0,353644103292463;0,316241517366517;TENT5C/CTNNB1/KLF4/NDEL1/JUNB/ELL/BCL2L1;7
GO:0009261;ribonucleotide catabolic process;3/67;31/2237;0,0967741935483871;3,23110255175734;2,19756161094187;0,0635353080018015;0,353644103292463;0,316241517366517;HK2/PNP/STAT3;3
GO:0032760;positive regulation of tumor necrosis factor production;3/67;31/2237;0,0967741935483871;3,23110255175734;2,19756161094187;0,0635353080018015;0,353644103292463;0,316241517366517;ARID5A/JAK2/STAT3;3
GO:0007052;mitotic spindle organization;2/67;14/2237;0,142857142857143;4,76972281449893;2,48569099213867;0,0637856552843546;0,353644103292463;0,316241517366517;HSPA1A/NEK6;2
GO:0009123;nucleoside monophosphate metabolic process;2/67;14/2237;0,142857142857143;4,76972281449893;2,48569099213867;0,0637856552843546;0,353644103292463;0,316241517366517;ADSS2/PNP;2
GO:0032418;lysosome localization;2/67;14/2237;0,142857142857143;4,76972281449893;2,48569099213867;0,0637856552843546;0,353644103292463;0,316241517366517;NDEL1/ADORA2B;2
GO:0032733;positive regulation of interleukin-10 production;2/67;14/2237;0,142857142857143;4,76972281449893;2,48569099213867;0,0637856552843546;0,353644103292463;0,316241517366517;IRF4/STAT3;2
GO:0032740;positive regulation of interleukin-17 production;2/67;14/2237;0,142857142857143;4,76972281449893;2,48569099213867;0,0637856552843546;0,353644103292463;0,316241517366517;ARID5A/JAK2;2
GO:0032743;positive regulation of interleukin-2 production;2/67;14/2237;0,142857142857143;4,76972281449893;2,48569099213867;0,0637856552843546;0,353644103292463;0,316241517366517;IRF4/PNP;2
GO:0043369;CD4-positive or CD8-positive, alpha-beta T cell lineage commitment;2/67;14/2237;0,142857142857143;4,76972281449893;2,48569099213867;0,0637856552843546;0,353644103292463;0,316241517366517;IRF4/STAT3;2
GO:0046640;regulation of alpha-beta T cell proliferation;2/67;14/2237;0,142857142857143;4,76972281449893;2,48569099213867;0,0637856552843546;0,353644103292463;0,316241517366517;IRF1/JAK2;2
GO:0048255;mRNA stabilization;2/67;14/2237;0,142857142857143;4,76972281449893;2,48569099213867;0,0637856552843546;0,353644103292463;0,316241517366517;TENT5C/ZFP36;2
GO:0060612;adipose tissue development;2/67;14/2237;0,142857142857143;4,76972281449893;2,48569099213867;0,0637856552843546;0,353644103292463;0,316241517366517;ARID5B/UBB;2
GO:0061900;glial cell activation;2/67;14/2237;0,142857142857143;4,76972281449893;2,48569099213867;0,0637856552843546;0,353644103292463;0,316241517366517;JAK2/NR1D1;2
GO:1990849;vacuolar localization;2/67;14/2237;0,142857142857143;4,76972281449893;2,48569099213867;0,0637856552843546;0,353644103292463;0,316241517366517;NDEL1/ADORA2B;2
GO:0032640;tumor necrosis factor production;4/67;51/2237;0,0784313725490196;2,61867134913667;2,05429175430842;0,0640443122646858;0,353644103292463;0,316241517366517;ARID5A/JAK2/STAT3/ZFP36;4
GO:0032680;regulation of tumor necrosis factor production;4/67;51/2237;0,0784313725490196;2,61867134913667;2,05429175430842;0,0640443122646858;0,353644103292463;0,316241517366517;ARID5A/JAK2/STAT3/ZFP36;4
GO:0006163;purine nucleotide metabolic process;5/67;73/2237;0,0684931506849315;2,28685340421182;1,96383642782372;0,0648679471975221;0,357150848814264;0,319377377725866;ADSS2/HK2/HSPA1A/PNP/STAT3;5
GO:0034655;nucleobase-containing compound catabolic process;6/67;97/2237;0,0618556701030928;2,06524080627789;1,88438747584698;0,0672899161889209;0,367282712570075;0,328437661604652;TENT5C/HK2/HSPA1A/PNP/STAT3/ZFP36;6
GO:0071219;cellular response to molecule of bacterial origin;6/67;97/2237;0,0618556701030928;2,06524080627789;1,88438747584698;0,0672899161889209;0,367282712570075;0,328437661604652;GBP5/NLRP3/ARID5A/JAK2/NR1D1/ZFP36;6
GO:0071222;cellular response to lipopolysaccharide;6/67;97/2237;0,0618556701030928;2,06524080627789;1,88438747584698;0,0672899161889209;0,367282712570075;0,328437661604652;GBP5/NLRP3/ARID5A/JAK2/NR1D1/ZFP36;6
GO:0035710;CD4-positive, alpha-beta T cell activation;4/67;52/2237;0,0769230769230769;2,5683122847302;2,01025860373504;0,0678703104894558;0,368021692755924;0,329098484768677;NLRP3/IRF4/STAT3/JUNB;4
GO:0030336;negative regulation of cell migration;5/67;74/2237;0,0675675675675676;2,25594997983058;1,93020473860377;0,0680082325578528;0,368021692755924;0,329098484768677;GADD45A/DUSP1/KLF4/STAT3/TIMP1;5
GO:2000146;negative regulation of cell motility;5/67;74/2237;0,0675675675675676;2,25594997983058;1,93020473860377;0,0680082325578528;0,368021692755924;0,329098484768677;GADD45A/DUSP1/KLF4/STAT3/TIMP1;5
GO:0002709;regulation of T cell mediated immunity;3/67;32/2237;0,09375;3,13013059701493;2,13216277527965;0,0686537999891207;0,368357782377888;0,329399028425511;NLRP3/ARID5A/PVR;3
GO:0009166;nucleotide catabolic process;3/67;32/2237;0,09375;3,13013059701493;2,13216277527965;0,0686537999891207;0,368357782377888;0,329399028425511;HK2/PNP/STAT3;3
GO:1903557;positive regulation of tumor necrosis factor superfamily cytokine production;3/67;32/2237;0,09375;3,13013059701493;2,13216277527965;0,0686537999891207;0,368357782377888;0,329399028425511;ARID5A/JAK2/STAT3;3
GO:0009792;embryo development ending in birth or egg hatching;7/67;122/2237;0,0573770491803279;1,91570834352826;1,82736513598799;0,0691604486415031;0,368985604864808;0,329960450301493;TENT5C/CTNNB1/KLF4/NDEL1/JUNB/ELL/BCL2L1;7
GO:0050863;regulation of T cell activation;7/67;122/2237;0,0573770491803279;1,91570834352826;1,82736513598799;0,0691604486415031;0,368985604864808;0,329960450301493;NLRP3/CTNNB1/IRF1/IRF4/JAK2/PNP/JUNB;7
GO:1902105;regulation of leukocyte differentiation;6/67;98/2237;0,0612244897959184;2,04416692049954;1,85703893836551;0,0700399133051587;0,371644616923388;0,332338236330646;NLRP3/CTNNB1/IRF1/IRF4/PNP/JUNB;6
GO:0009790;embryo development;10/67;200/2237;0,05;1,66940298507463;1,74281208214061;0,0705624769386322;0,371644616923388;0,332338236330646;TENT5C/INO80D/CTNNB1/DUSP1/KLF4/NDEL1/JUNB/ELL/BCL2L1/ATF4;10
GO:0009968;negative regulation of signal transduction;13/67;282/2237;0,0460992907801418;1,53916587276384;1,7014414253857;0,0705815201778315;0,371644616923388;0,332338236330646;MCL1/NLRP3/RNF149/NR4A2/TMBIM1/CTNNB1/DUSP1/IRF4/HSPA1A/NR1D1/PHLPP1/BCL2L1/ATF4;13
GO:0072521;purine-containing compound metabolic process;5/67;75/2237;0,0666666666666667;2,22587064676617;1,89710280857939;0,0712328064044418;0,371644616923388;0,332338236330646;ADSS2/HK2/HSPA1A/PNP/STAT3;5
GO:0031668;cellular response to extracellular stimulus;4/67;53/2237;0,0754716981132075;2,5198535623768;1,96723751420287;0,0718134847117882;0,371644616923388;0,332338236330646;NR4A2/FAS/ADORA2B/ATF4;4
GO:0071706;tumor necrosis factor superfamily cytokine production;4/67;53/2237;0,0754716981132075;2,5198535623768;1,96723751420287;0,0718134847117882;0,371644616923388;0,332338236330646;ARID5A/JAK2/STAT3/ZFP36;4
GO:1903555;regulation of tumor necrosis factor superfamily cytokine production;4/67;53/2237;0,0754716981132075;2,5198535623768;1,96723751420287;0,0718134847117882;0,371644616923388;0,332338236330646;ARID5A/JAK2/STAT3/ZFP36;4
GO:0009057;macromolecule catabolic process;12/67;255/2237;0,0470588235294118;1,571202809482;1,70236246100744;0,0718489811783309;0,371644616923388;0,332338236330646;TENT5C/RNF149/CTNNB1/TIPARP/FEM1C/HSPA1A/AZIN1/UBC/UBB/NR1D1/ZFP36/TIMP1;12
GO:0002360;T cell lineage commitment;2/67;15/2237;0,133333333333333;4,45174129353234;2,35643396734604;0,072209724935484;0,371644616923388;0,332338236330646;IRF4/STAT3;2
GO:0034605;cellular response to heat;2/67;15/2237;0,133333333333333;4,45174129353234;2,35643396734604;0,072209724935484;0,371644616923388;0,332338236330646;HSPA1A/TFEC;2
GO:0071385;cellular response to glucocorticoid stimulus;2/67;15/2237;0,133333333333333;4,45174129353234;2,35643396734604;0,072209724935484;0,371644616923388;0,332338236330646;JAK2/ZFP36;2
GO:1902373;negative regulation of mRNA catabolic process;2/67;15/2237;0,133333333333333;4,45174129353234;2,35643396734604;0,072209724935484;0,371644616923388;0,332338236330646;TENT5C/ZFP36;2
GO:2001252;positive regulation of chromosome organization;2/67;15/2237;0,133333333333333;4,45174129353234;2,35643396734604;0,072209724935484;0,371644616923388;0,332338236330646;INO80D/CTNNB1;2
GO:0001704;formation of primary germ layer;3/67;33/2237;0,0909090909090909;3,03527815468114;2,06927580635739;0,0739550565731752;0,375525139811244;0,33580834210876;CTNNB1/DUSP1/KLF4;3
GO:0009199;ribonucleoside triphosphate metabolic process;3/67;33/2237;0,0909090909090909;3,03527815468114;2,06927580635739;0,0739550565731752;0,375525139811244;0,33580834210876;HK2/HSPA1A/STAT3;3
GO:0009205;purine ribonucleoside triphosphate metabolic process;3/67;33/2237;0,0909090909090909;3,03527815468114;2,06927580635739;0,0739550565731752;0,375525139811244;0,33580834210876;HK2/HSPA1A/STAT3;3
GO:0098813;nuclear chromosome segregation;3/67;33/2237;0,0909090909090909;3,03527815468114;2,06927580635739;0,0739550565731752;0,375525139811244;0,33580834210876;DUSP1/HSPA1A/NEK6;3
GO:1901292;nucleoside phosphate catabolic process;3/67;33/2237;0,0909090909090909;3,03527815468114;2,06927580635739;0,0739550565731752;0,375525139811244;0,33580834210876;HK2/PNP/STAT3;3
GO:0071216;cellular response to biotic stimulus;6/67;100/2237;0,06;2,00328358208955;1,8032871101931;0,0757354755625609;0,382188442830842;0,34176691186285;GBP5/NLRP3/ARID5A/JAK2/NR1D1/ZFP36;6
GO:0009612;response to mechanical stimulus;4/67;54/2237;0,0740740740740741;2,47318960751797;1,92518333040208;0,0758726792525854;0,382188442830842;0,34176691186285;GADD45A/CTNNB1/IRF1/FAS;4
GO:1901988;negative regulation of cell cycle phase transition;4/67;54/2237;0,0740740740740741;2,47318960751797;1,92518333040208;0,0758726792525854;0,382188442830842;0,34176691186285;SDE2/APBB2/DUSP1/KLF4;4
GO:0048585;negative regulation of response to stimulus;16/67;371/2237;0,0431266846361186;1,43991632135817;1,62983876912371;0,0760888909086186;0,382260900214652;0,34183170591084;MCL1/NLRP3/RNF149/NR4A2/TMBIM1/CTNNB1/DUSP1/IRF4/HSPA1A/KLF4/NR1D1/STAT3/PHLPP1/ZFP36/BCL2L1/ATF4;16
GO:0032101;regulation of response to external stimulus;14/67;314/2237;0,0445859872611465;1,48863960452514;1,64061727372042;0,0768049995918902;0,384837749277884;0,344136018778478;GBP5/NLRP3/IRF1/DUSP1/IRF4/HSPA1A/JAK2/KLF4/PTGES/ADORA2B/NR1D1/STAT3/ZFP36/PVR;14
GO:1901987;regulation of cell cycle phase transition;5/67;77/2237;0,0649350649350649;2,16805582477224;1,83242209808676;0,0779335351695635;0,388797009430754;0,347676534304498;SDE2/APBB2/DUSP1/KLF4/NEK6;5
GO:0016071;mRNA metabolic process;6/67;101/2237;0,0594059405940594;1,98344909117777;1,77686887533596;0,0786808837016877;0,388797009430754;0,347676534304498;TENT5C/SDE2/HSPA1A/STAT3/ZFP36/ATF4;6
GO:0009144;purine nucleoside triphosphate metabolic process;3/67;34/2237;0,0882352941176471;2,94600526777875;2,0087211648839;0,0794344597106663;0,388797009430754;0,347676534304498;HK2/HSPA1A/STAT3;3
GO:0009411;response to UV;3/67;34/2237;0,0882352941176471;2,94600526777875;2,0087211648839;0,0794344597106663;0,388797009430754;0,347676534304498;SDE2/ATF4/TIMP1;3
GO:1904019;epithelial cell apoptotic process;3/67;34/2237;0,0882352941176471;2,94600526777875;2,0087211648839;0,0794344597106663;0,388797009430754;0,347676534304498;JAK2/ZFP36/BCL2L1;3
GO:2000514;regulation of CD4-positive, alpha-beta T cell activation;3/67;34/2237;0,0882352941176471;2,94600526777875;2,0087211648839;0,0794344597106663;0,388797009430754;0,347676534304498;NLRP3/IRF4/JUNB;3
GO:0001706;endoderm formation;2/67;16/2237;0,125;4,17350746268657;2,23804425503836;0,0809714831186618;0,388797009430754;0,347676534304498;CTNNB1/DUSP1;2
GO:0030838;positive regulation of actin filament polymerization;2/67;16/2237;0,125;4,17350746268657;2,23804425503836;0,0809714831186618;0,388797009430754;0,347676534304498;CDC42EP2/CDC42EP4;2
GO:0030901;midbrain development;2/67;16/2237;0,125;4,17350746268657;2,23804425503836;0,0809714831186618;0,388797009430754;0,347676534304498;NR4A2/CTNNB1;2
GO:0035019;somatic stem cell population maintenance;2/67;16/2237;0,125;4,17350746268657;2,23804425503836;0,0809714831186618;0,388797009430754;0,347676534304498;KLF4/STAT3;2
GO:0043279;response to alkaloid;2/67;16/2237;0,125;4,17350746268657;2,23804425503836;0,0809714831186618;0,388797009430754;0,347676534304498;BCL2L1/TGM2;2
GO:0046633;alpha-beta T cell proliferation;2/67;16/2237;0,125;4,17350746268657;2,23804425503836;0,0809714831186618;0,388797009430754;0,347676534304498;IRF1/JAK2;2
GO:0071384;cellular response to corticosteroid stimulus;2/67;16/2237;0,125;4,17350746268657;2,23804425503836;0,0809714831186618;0,388797009430754;0,347676534304498;JAK2/ZFP36;2
GO:0071479;cellular response to ionizing radiation;2/67;16/2237;0,125;4,17350746268657;2,23804425503836;0,0809714831186618;0,388797009430754;0,347676534304498;GADD45A/BCL2L1;2
GO:0097009;energy homeostasis;2/67;16/2237;0,125;4,17350746268657;2,23804425503836;0,0809714831186618;0,388797009430754;0,347676534304498;UBB/STAT3;2
GO:1903312;negative regulation of mRNA metabolic process;2/67;16/2237;0,125;4,17350746268657;2,23804425503836;0,0809714831186618;0,388797009430754;0,347676534304498;TENT5C/ZFP36;2
GO:0141124;intracellular signaling cassette;18/67;433/2237;0,0415704387990762;1,3879562924408;1,57925374662724;0,0810849095697719;0,388797009430754;0,347676534304498;GADD45A/NLRP3/RNF149/CTNNB1/DUSP1/SH2B2/JAK2/NEK6/FAS/CDC42EP2/ADORA2B/ARHGAP23/NR1D1/STAT3/CDC42EP4/PHLPP1/ZFP36/TGM2;18
GO:0006338;chromatin remodeling;5/67;78/2237;0,0641025641025641;2,14026023727516;1,80081207568153;0,0814088744763771;0,389364667318834;0,34818415479131;INO80D/IRF4/JAK2/H3-3B/TGM2;5
GO:0030098;lymphocyte differentiation;7/67;127/2237;0,0551181102362205;1,84028675520038;1,71289832628625;0,0820653997660703;0,390711412722353;0,349388463886104;NLRP3/CTNNB1/IRF1/IRF4/PNP/STAT3/JUNB;7
GO:0009894;regulation of catabolic process;9/67;179/2237;0,0502793296089385;1,67872925873426;1,66319754593741;0,082294001891887;0,390711412722353;0,349388463886104;TENT5C/MCL1/TIPARP/HSPA1A/AZIN1/UBB/STAT3/ZFP36/TIMP1;9
GO:1901575;organic substance catabolic process;15/67;346/2237;0,0433526011560694;1,44745923561384;1,59033711814452;0,0823093208427766;0,390711412722353;0,349388463886104;TENT5C/HK2/RNF149/CTNNB1/TIPARP/FEM1C/HSPA1A/AZIN1/UBC/PNP/UBB/NR1D1/STAT3/ZFP36/TIMP1;15
GO:0050778;positive regulation of immune response;10/67;207/2237;0,0483091787439614;1,61294974403346;1,62631795150626;0,0848367564857971;0,398726414287192;0,356555772015835;GBP5/NLRP3/ARID5A/IRF1/IRF4/HSPA1A/SH2B2/JAK2/NR1D1/PVR;10
GO:0009117;nucleotide metabolic process;5/67;79/2237;0,0632911392405063;2,1131683355375;1,76966924627856;0,0849668739822686;0,398726414287192;0,356555772015835;ADSS2/HK2/HSPA1A/PNP/STAT3;5
GO:0061564;axon development;5/67;79/2237;0,0632911392405063;2,1131683355375;1,76966924627856;0,0849668739822686;0,398726414287192;0,356555772015835;NR4A2/APBB2/JAK2/KLF4/NDEL1;5
GO:0033157;regulation of intracellular protein transport;3/67;35/2237;0,0857142857142857;2,86183368869936;1,95033710481481;0,0850871928100928;0,398726414287192;0,356555772015835;JAK2/SAR1A/NDEL1;3
GO:0042594;response to starvation;3/67;35/2237;0,0857142857142857;2,86183368869936;1,95033710481481;0,0850871928100928;0,398726414287192;0,356555772015835;FAS/ZFP36/ATF4;3
GO:0031349;positive regulation of defense response;8/67;154/2237;0,051948051948052;1,73444465981779;1,65927449215781;0,0854714488915524;0,398726414287192;0,356555772015835;GBP5/NLRP3/IRF1/IRF4/HSPA1A/ADORA2B/NR1D1/PVR;8
GO:0044092;negative regulation of molecular function;8/67;154/2237;0,051948051948052;1,73444465981779;1,65927449215781;0,0854714488915524;0,398726414287192;0,356555772015835;GADD45A/NLRP3/TMBIM1/DUSP1/JAK2/KLF4/ZFP36/TIMP1;8
GO:0043085;positive regulation of catalytic activity;9/67;181/2237;0,0497237569060773;1,66017976416261;1,62754638393288;0,0869191000655637;0,402224139808221;0,359683566359933;NLRP3/HSPA1A/JAK2/KLF4/FAS/NDEL1/ADORA2B/STAT3/TGM2;9
GO:0006753;nucleoside phosphate metabolic process;5/67;80/2237;0,0625;2,08675373134328;1,73897963069928;0,0886069591857505;0,402224139808221;0,359683566359933;ADSS2/HK2/HSPA1A/PNP/STAT3;5
GO:0031348;negative regulation of defense response;5/67;80/2237;0,0625;2,08675373134328;1,73897963069928;0,0886069591857505;0,402224139808221;0,359683566359933;NLRP3/KLF4/NR1D1/STAT3/ZFP36;5
GO:0000280;nuclear division;4/67;57/2237;0,0701754385964912;2,34302173343807;1,80441178855015;0,0887329835575127;0,402224139808221;0,359683566359933;DUSP1/HSPA1A/NDEL1/UBB;4
GO:0043010;camera-type eye development;4/67;57/2237;0,0701754385964912;2,34302173343807;1,80441178855015;0,0887329835575127;0,402224139808221;0,359683566359933;CTNNB1/KLF4/STAT3/ATF4;4
GO:0002067;glandular epithelial cell differentiation;2/67;17/2237;0,117647058823529;3,928007023705;2,12894048921808;0,0900438412242269;0,402224139808221;0,359683566359933;CTNNB1/KLF4;2
GO:0002088;lens development in camera-type eye;2/67;17/2237;0,117647058823529;3,928007023705;2,12894048921808;0,0900438412242269;0,402224139808221;0,359683566359933;CTNNB1/ATF4;2
GO:0002369;T cell cytokine production;2/67;17/2237;0,117647058823529;3,928007023705;2,12894048921808;0,0900438412242269;0,402224139808221;0,359683566359933;NLRP3/ARID5A;2
GO:0002724;regulation of T cell cytokine production;2/67;17/2237;0,117647058823529;3,928007023705;2,12894048921808;0,0900438412242269;0,402224139808221;0,359683566359933;NLRP3/ARID5A;2
GO:0006576;biogenic amine metabolic process;2/67;17/2237;0,117647058823529;3,928007023705;2,12894048921808;0,0900438412242269;0,402224139808221;0,359683566359933;NR4A2/AZIN1;2
GO:0032204;regulation of telomere maintenance;2/67;17/2237;0,117647058823529;3,928007023705;2,12894048921808;0,0900438412242269;0,402224139808221;0,359683566359933;INO80D/CTNNB1;2
GO:0032620;interleukin-17 production;2/67;17/2237;0,117647058823529;3,928007023705;2,12894048921808;0,0900438412242269;0,402224139808221;0,359683566359933;ARID5A/JAK2;2
GO:0032660;regulation of interleukin-17 production;2/67;17/2237;0,117647058823529;3,928007023705;2,12894048921808;0,0900438412242269;0,402224139808221;0,359683566359933;ARID5A/JAK2;2
GO:0043489;RNA stabilization;2/67;17/2237;0,117647058823529;3,928007023705;2,12894048921808;0,0900438412242269;0,402224139808221;0,359683566359933;TENT5C/ZFP36;2
GO:0051881;regulation of mitochondrial membrane potential;2/67;17/2237;0,117647058823529;3,928007023705;2,12894048921808;0,0900438412242269;0,402224139808221;0,359683566359933;UBB/BCL2L1;2
GO:0070269;pyroptosis;2/67;17/2237;0,117647058823529;3,928007023705;2,12894048921808;0,0900438412242269;0,402224139808221;0,359683566359933;GBP5/NLRP3;2
GO:1902041;regulation of extrinsic apoptotic signaling pathway via death domain receptors;2/67;17/2237;0,117647058823529;3,928007023705;2,12894048921808;0,0900438412242269;0,402224139808221;0,359683566359933;TMBIM1/BCL2L1;2
GO:1903076;regulation of protein localization to plasma membrane;2/67;17/2237;0,117647058823529;3,928007023705;2,12894048921808;0,0900438412242269;0,402224139808221;0,359683566359933;TMBIM1/BCL2L1;2
GO:0009141;nucleoside triphosphate metabolic process;3/67;36/2237;0,0833333333333333;2,78233830845771;1,89397745379885;0,0909082648084151;0,405130008346208;0,362282100499665;HK2/HSPA1A/STAT3;3
GO:0045786;negative regulation of cell cycle;5/67;81/2237;0,0617283950617284;2,0609913395983;1,70872984189296;0,0923284917730646;0,409531998637434;0,366218521540394;SDE2/CTNNB1/APBB2/DUSP1/KLF4;5
GO:0051640;organelle localization;5/67;81/2237;0,0617283950617284;2,0609913395983;1,70872984189296;0,0923284917730646;0,409531998637434;0,366218521540394;CTNNB1/SAR1A/NDEL1/ADORA2B/UBB;5
GO:1901990;regulation of mitotic cell cycle phase transition;4/67;58/2237;0,0689655172413793;2,30262480699949;1,76582702939393;0,0932422826168175;0,412105071225807;0,368519457345814;SDE2/DUSP1/KLF4/NEK6;4
GO:0045088;regulation of innate immune response;7/67;131/2237;0,0534351145038168;1,78409479320952;1,62486943130067;0,0933437568932793;0,412105071225807;0,368519457345814;GBP5/NLRP3/IRF1/IRF4/HSPA1A/NR1D1/PVR;7
GO:0070661;leukocyte proliferation;6/67;106/2237;0,0566037735849057;1,8898901717826;1,64907744649819;0,0943773354122317;0,414833145192017;0,370959001063722;CTNNB1/IRF1/JAK2/PNP/JUNB/BCL2L1;6
GO:0009719;response to endogenous stimulus;14/67;324/2237;0,0432098765432099;1,44269393771881;1,5137774409602;0,0943997283937482;0,414833145192017;0,370959001063722;ARID5A/NR4A2/CTNNB1/HSPA1A/SH2B2/JAK2/KLF4/NDEL1/NR1D1/STAT3/ZFP36/BCL2L1/TGM2/TIMP1;14
GO:0032944;regulation of mononuclear cell proliferation;5/67;82/2237;0,0609756097560976;2,0358572988715;1,67890705276583;0,0961307712966213;0,416516527678457;0,372464343375;CTNNB1/IRF1/JAK2/PNP/BCL2L1;5
GO:0040013;negative regulation of locomotion;5/67;82/2237;0,0609756097560976;2,0358572988715;1,67890705276583;0,0961307712966213;0,416516527678457;0,372464343375;GADD45A/DUSP1/KLF4/STAT3/TIMP1;5
GO:0051093;negative regulation of developmental process;9/67;185/2237;0,0486486486486487;1,62428398547802;1,55748120431439;0,0966373765659779;0,416516527678457;0,372464343375;GADD45A/TENT5C/CTNNB1/IRF1/KLF4/NR1D1/STAT3/ZFP36/BCL2L1;9
GO:0002708;positive regulation of lymphocyte mediated immunity;3/67;37/2237;0,0810810810810811;2,70713997579669;1,83950972390762;0,0968925328012383;0,416516527678457;0,372464343375;NLRP3/ARID5A/PVR;3
GO:0019827;stem cell population maintenance;3/67;37/2237;0,0810810810810811;2,70713997579669;1,83950972390762;0,0968925328012383;0,416516527678457;0,372464343375;CTNNB1/KLF4/STAT3;3
GO:0048705;skeletal system morphogenesis;3/67;37/2237;0,0810810810810811;2,70713997579669;1,83950972390762;0,0968925328012383;0,416516527678457;0,372464343375;CTNNB1/TIPARP/ARID5B;3
GO:0044270;cellular nitrogen compound catabolic process;6/67;107/2237;0,0560747663551402;1,87222764681267;1,62433412920181;0,0977086714839613;0,416516527678457;0,372464343375;TENT5C/HK2/HSPA1A/PNP/STAT3/ZFP36;6
GO:0046700;heterocycle catabolic process;6/67;107/2237;0,0560747663551402;1,87222764681267;1,62433412920181;0,0977086714839613;0,416516527678457;0,372464343375;TENT5C/HK2/HSPA1A/PNP/STAT3/ZFP36;6
GO:0044281;small molecule metabolic process;11/67;241/2237;0,045643153526971;1,5239363349229;1,51269093594083;0,0990114876622472;0,416516527678457;0,372464343375;ADSS2/HK2/GLRX/HSPA1A/CA13/AZIN1/PTGES/PNP/NR1D1/STAT3/ATF4;11
GO:0006096;glycolytic process;2/67;18/2237;0,111111111111111;3,70978441127695;2,02784975918043;0,0994009875980268;0,416516527678457;0,372464343375;HK2/STAT3;2
GO:0009308;amine metabolic process;2/67;18/2237;0,111111111111111;3,70978441127695;2,02784975918043;0,0994009875980268;0,416516527678457;0,372464343375;NR4A2/AZIN1;2
GO:0019364;pyridine nucleotide catabolic process;2/67;18/2237;0,111111111111111;3,70978441127695;2,02784975918043;0,0994009875980268;0,416516527678457;0,372464343375;HK2/STAT3;2
GO:0021987;cerebral cortex development;2/67;18/2237;0,111111111111111;3,70978441127695;2,02784975918043;0,0994009875980268;0,416516527678457;0,372464343375;CTNNB1/NDEL1;2
GO:0031047;regulatory ncRNA-mediated gene silencing;2/67;18/2237;0,111111111111111;3,70978441127695;2,02784975918043;0,0994009875980268;0,416516527678457;0,372464343375;STAT3/ZFP36;2
GO:0043368;positive T cell selection;2/67;18/2237;0,111111111111111;3,70978441127695;2,02784975918043;0,0994009875980268;0,416516527678457;0,372464343375;IRF4/STAT3;2
GO:0045428;regulation of nitric oxide biosynthetic process;2/67;18/2237;0,111111111111111;3,70978441127695;2,02784975918043;0,0994009875980268;0,416516527678457;0,372464343375;JAK2/KLF4;2
GO:0048678;response to axon injury;2/67;18/2237;0,111111111111111;3,70978441127695;2,02784975918043;0,0994009875980268;0,416516527678457;0,372464343375;JAK2/KLF4;2
GO:0060021;roof of mouth development;2/67;18/2237;0,111111111111111;3,70978441127695;2,02784975918043;0,0994009875980268;0,416516527678457;0,372464343375;TIPARP/ARID5B;2
GO:0170039;proteinogenic amino acid metabolic process;2/67;18/2237;0,111111111111111;3,70978441127695;2,02784975918043;0,0994009875980268;0,416516527678457;0,372464343375;ADSS2/ATF4;2
GO:2000278;regulation of DNA biosynthetic process;2/67;18/2237;0,111111111111111;3,70978441127695;2,02784975918043;0,0994009875980268;0,416516527678457;0,372464343375;CTNNB1/KLF4;2
GO:2000736;regulation of stem cell differentiation;2/67;18/2237;0,111111111111111;3,70978441127695;2,02784975918043;0,0994009875980268;0,416516527678457;0,372464343375;STAT3/ZFP36;2
GO:0002697;regulation of immune effector process;6/67;108/2237;0,0555555555555556;1,85489220563847;1,59984842664428;0,101103227194022;0,420577081725136;0,37609543961304;NLRP3/ARID5A/IRF4/ADORA2B/JUNB/PVR;6
GO:0019439;aromatic compound catabolic process;6/67;108/2237;0,0555555555555556;1,85489220563847;1,59984842664428;0,101103227194022;0,420577081725136;0,37609543961304;TENT5C/HK2/HSPA1A/PNP/STAT3/ZFP36;6
GO:0010648;negative regulation of cell communication;13/67;299/2237;0,0434782608695652;1,45165476963011;1,47403821436231;0,101831831468147;0,420577081725136;0,37609543961304;MCL1/NLRP3/RNF149/NR4A2/TMBIM1/CTNNB1/DUSP1/IRF4/HSPA1A/NR1D1/PHLPP1/BCL2L1/ATF4;13
GO:0010948;negative regulation of cell cycle process;4/67;60/2237;0,0666666666666667;2,22587064676617;1,69096450246659;0,10258448594326;0,420577081725136;0,37609543961304;SDE2/APBB2/DUSP1/KLF4;4
GO:0045637;regulation of myeloid cell differentiation;4/67;60/2237;0,0666666666666667;2,22587064676617;1,69096450246659;0,10258448594326;0,420577081725136;0,37609543961304;CTNNB1/HSPA1A/STAT3/ZFP36;4
GO:0048285;organelle fission;4/67;60/2237;0,0666666666666667;2,22587064676617;1,69096450246659;0,10258448594326;0,420577081725136;0,37609543961304;DUSP1/HSPA1A/NDEL1/UBB;4
GO:0006520;amino acid metabolic process;3/67;38/2237;0,0789473684210526;2,63589945011783;1,78681349600027;0,103034723294859;0,420577081725136;0,37609543961304;ADSS2/AZIN1/ATF4;3
GO:0007623;circadian rhythm;3/67;38/2237;0,0789473684210526;2,63589945011783;1,78681349600027;0,103034723294859;0,420577081725136;0,37609543961304;NR1D1/PHLPP1/ATF4;3
GO:0090596;sensory organ morphogenesis;3/67;38/2237;0,0789473684210526;2,63589945011783;1,78681349600027;0,103034723294859;0,420577081725136;0,37609543961304;CTNNB1/STAT3/ATF4;3
GO:0098727;maintenance of cell number;3/67;38/2237;0,0789473684210526;2,63589945011783;1,78681349600027;0,103034723294859;0,420577081725136;0,37609543961304;CTNNB1/KLF4/STAT3;3
GO:0140014;mitotic nuclear division;3/67;38/2237;0,0789473684210526;2,63589945011783;1,78681349600027;0,103034723294859;0,420577081725136;0,37609543961304;DUSP1/HSPA1A/NDEL1;3
GO:1901991;negative regulation of mitotic cell cycle phase transition;3/67;38/2237;0,0789473684210526;2,63589945011783;1,78681349600027;0,103034723294859;0,420577081725136;0,37609543961304;SDE2/DUSP1/KLF4;3
GO:0023057;negative regulation of signaling;13/67;300/2237;0,0433333333333333;1,44681592039801;1,46105945813239;0,103903566821808;0,42078556509578;0,376281873083483;MCL1/NLRP3/RNF149/NR4A2/TMBIM1/CTNNB1/DUSP1/IRF4/HSPA1A/NR1D1/PHLPP1/BCL2L1/ATF4;13
GO:0043933;protein-containing complex organization;13/67;300/2237;0,0433333333333333;1,44681592039801;1,46105945813239;0,103903566821808;0,42078556509578;0,376281873083483;GBP5/NLRP3/INO80D/IRF4/HSPA1A/JAK2/SAR1A/FAS/CDC42EP2/NDEL1/CDC42EP4/H3-3B/TGM2;13
GO:0002263;cell activation involved in immune response;5/67;84/2237;0,0595238095238095;1,98738450604122;1,62049378661202;0,103974469094417;0,42078556509578;0,376281873083483;NLRP3/IRF4/ADORA2B/STAT3/JUNB;5
GO:0002366;leukocyte activation involved in immune response;5/67;84/2237;0,0595238095238095;1,98738450604122;1,62049378661202;0,103974469094417;0,42078556509578;0,376281873083483;NLRP3/IRF4/ADORA2B/STAT3/JUNB;5
GO:0000003;reproduction;9/67;189/2237;0,0476190476190476;1,58990760483298;1,48899539600457;0,106978587639254;0,426069922559554;0,381007339186529;CTNNB1/TIPARP/DUSP1/ARID5B/UBB/STAT3/JUNB/BCL2L1/TIMP1;9
GO:0000902;cell morphogenesis;8/67;162/2237;0,0493827160493827;1,64879307167864;1,50625358741631;0,107102463263581;0,426069922559554;0,381007339186529;NR4A2/CTNNB1/APBB2/CDC42EP2/NDEL1/UBB/CDC42EP4/ATF4;8
GO:0002285;lymphocyte activation involved in immune response;4/67;61/2237;0,0655737704918033;2,1893809640323;1,65462617163019;0,107413652736952;0,426069922559554;0,381007339186529;NLRP3/IRF4/STAT3/JUNB;4
GO:0051091;positive regulation of DNA-binding transcription factor activity;4/67;61/2237;0,0655737704918033;2,1893809640323;1,65462617163019;0,107413652736952;0,426069922559554;0,381007339186529;NLRP3/HSPA1A/ARID5B/STAT3;4
GO:0071356;cellular response to tumor necrosis factor;5/67;85/2237;0,0588235294117647;1,9640035118525;1,59188019436148;0,108014191552077;0,426069922559554;0,381007339186529;HSPA1A/JAK2/FAS/NR1D1/ZFP36;5
GO:0080135;regulation of cellular response to stress;5/67;85/2237;0,0588235294117647;1,9640035118525;1,59188019436148;0,108014191552077;0,426069922559554;0,381007339186529;INO80D/HSPA1A/KLF4/FAS/BCL2L1;5
GO:0002532;production of molecular mediator involved in inflammatory response;2/67;19/2237;0,105263157894737;3,51453260015711;1,93373400350818;0,1090183372045;0,426069922559554;0,381007339186529;GBP5/STAT3;2
GO:0009137;purine nucleoside diphosphate catabolic process;2/67;19/2237;0,105263157894737;3,51453260015711;1,93373400350818;0,1090183372045;0,426069922559554;0,381007339186529;HK2/STAT3;2
GO:0009181;purine ribonucleoside diphosphate catabolic process;2/67;19/2237;0,105263157894737;3,51453260015711;1,93373400350818;0,1090183372045;0,426069922559554;0,381007339186529;HK2/STAT3;2
GO:0010507;negative regulation of autophagy;2/67;19/2237;0,105263157894737;3,51453260015711;1,93373400350818;0,1090183372045;0,426069922559554;0,381007339186529;MCL1/STAT3;2
GO:0010970;transport along microtubule;2/67;19/2237;0,105263157894737;3,51453260015711;1,93373400350818;0,1090183372045;0,426069922559554;0,381007339186529;NDEL1/UBB;2
GO:0046032;ADP catabolic process;2/67;19/2237;0,105263157894737;3,51453260015711;1,93373400350818;0,1090183372045;0,426069922559554;0,381007339186529;HK2/STAT3;2
GO:0080164;regulation of nitric oxide metabolic process;2/67;19/2237;0,105263157894737;3,51453260015711;1,93373400350818;0,1090183372045;0,426069922559554;0,381007339186529;JAK2/KLF4;2
GO:1902369;negative regulation of RNA catabolic process;2/67;19/2237;0,105263157894737;3,51453260015711;1,93373400350818;0,1090183372045;0,426069922559554;0,381007339186529;TENT5C/ZFP36;2
GO:1904375;regulation of protein localization to cell periphery;2/67;19/2237;0,105263157894737;3,51453260015711;1,93373400350818;0,1090183372045;0,426069922559554;0,381007339186529;TMBIM1/BCL2L1;2
GO:0033500;carbohydrate homeostasis;3/67;39/2237;0,0769230769230769;2,5683122847302;1,73577903200805;0,109329452145693;0,426069922559554;0,381007339186529;HK2/NR1D1/STAT3;3
GO:0042593;glucose homeostasis;3/67;39/2237;0,0769230769230769;2,5683122847302;1,73577903200805;0,109329452145693;0,426069922559554;0,381007339186529;HK2/NR1D1/STAT3;3
GO:0046434;organophosphate catabolic process;3/67;39/2237;0,0769230769230769;2,5683122847302;1,73577903200805;0,109329452145693;0,426069922559554;0,381007339186529;HK2/PNP/STAT3;3
GO:0002757;immune response-activating signaling pathway;7/67;137/2237;0,0510948905109489;1,70595925482079;1,49821350067006;0,111833948019225;0,433156436704321;0,387344359838411;GBP5/NLRP3/IRF1/IRF4/HSPA1A/SH2B2/NR1D1;7
GO:0048514;blood vessel morphogenesis;7/67;137/2237;0,0510948905109489;1,70595925482079;1,49821350067006;0,111833948019225;0,433156436704321;0,387344359838411;GADD45A/HK2/CTNNB1/TIPARP/KLF4/STAT3/JUNB;7
GO:0051603;proteolysis involved in protein catabolic process;7/67;137/2237;0,0510948905109489;1,70595925482079;1,49821350067006;0,111833948019225;0,433156436704321;0,387344359838411;RNF149/CTNNB1/FEM1C/HSPA1A/UBC/UBB/NR1D1;7
GO:0033043;regulation of organelle organization;9/67;192/2237;0,046875;1,56506529850746;1,4386197880157;0,115140692845364;0,442327078533151;0,395545083843628;INO80D/CTNNB1/DUSP1/HSPA1A/NEK6/SAR1A/CDC42EP2/CDC42EP4/BCL2L1;9
GO:0032879;regulation of localization;15/67;364/2237;0,0412087912087912;1,37588158110546;1,37681719796531;0,115669905691568;0,442327078533151;0,395545083843628;HK2/TMBIM1/CTNNB1/HSPA1A/AZIN1/JAK2/PTGES/SAR1A/NDEL1/ADORA2B/NR1D1/ZFP36/BCL2L1/TGM2/ATF4;15
GO:0033209;tumor necrosis factor-mediated signaling pathway;3/67;40/2237;0,075;2,50410447761194;1,68630607802408;0,115771243249886;0,442327078533151;0,395545083843628;HSPA1A/JAK2/FAS;3
GO:0042129;regulation of T cell proliferation;4/67;63/2237;0,0634920634920635;2,11987680644397;1,58399639567454;0,117378117433658;0,442327078533151;0,395545083843628;CTNNB1/IRF1/JAK2/PNP;4
GO:0050776;regulation of immune response;11/67;249/2237;0,0441767068273092;1,47497452496553;1,39670675840043;0,117901597299786;0,442327078533151;0,395545083843628;GBP5/NLRP3/ARID5A/IRF1/IRF4/HSPA1A/SH2B2/JAK2/NR1D1/JUNB/PVR;11
GO:0002673;regulation of acute inflammatory response;2/67;20/2237;0,1;3,33880597014925;1,84573683347874;0,118872483090483;0,442327078533151;0,395545083843628;NLRP3/PTGES;2
GO:0006364;rRNA processing;2/67;20/2237;0,1;3,33880597014925;1,84573683347874;0,118872483090483;0,442327078533151;0,395545083843628;SDE2/SRFBP1;2
GO:0006809;nitric oxide biosynthetic process;2/67;20/2237;0,1;3,33880597014925;1,84573683347874;0,118872483090483;0,442327078533151;0,395545083843628;JAK2/KLF4;2
GO:0009134;nucleoside diphosphate catabolic process;2/67;20/2237;0,1;3,33880597014925;1,84573683347874;0,118872483090483;0,442327078533151;0,395545083843628;HK2/STAT3;2
GO:0009191;ribonucleoside diphosphate catabolic process;2/67;20/2237;0,1;3,33880597014925;1,84573683347874;0,118872483090483;0,442327078533151;0,395545083843628;HK2/STAT3;2
GO:0009408;response to heat;2/67;20/2237;0,1;3,33880597014925;1,84573683347874;0,118872483090483;0,442327078533151;0,395545083843628;HSPA1A/TFEC;2
GO:0010660;regulation of muscle cell apoptotic process;2/67;20/2237;0,1;3,33880597014925;1,84573683347874;0,118872483090483;0,442327078533151;0,395545083843628;JAK2/ATF4;2
GO:0042177;negative regulation of protein catabolic process;2/67;20/2237;0,1;3,33880597014925;1,84573683347874;0,118872483090483;0,442327078533151;0,395545083843628;AZIN1/TIMP1;2
GO:0062208;positive regulation of pattern recognition receptor signaling pathway;2/67;20/2237;0,1;3,33880597014925;1,84573683347874;0,118872483090483;0,442327078533151;0,395545083843628;GBP5/HSPA1A;2
GO:0071901;negative regulation of protein serine/threonine kinase activity;2/67;20/2237;0,1;3,33880597014925;1,84573683347874;0,118872483090483;0,442327078533151;0,395545083843628;GADD45A/DUSP1;2
GO:0120162;positive regulation of cold-induced thermogenesis;2/67;20/2237;0,1;3,33880597014925;1,84573683347874;0,118872483090483;0,442327078533151;0,395545083843628;IRF4/JAK2;2
GO:0150076;neuroinflammatory response;2/67;20/2237;0,1;3,33880597014925;1,84573683347874;0,118872483090483;0,442327078533151;0,395545083843628;JAK2/NR1D1;2
GO:1902895;positive regulation of miRNA transcription;2/67;20/2237;0,1;3,33880597014925;1,84573683347874;0,118872483090483;0,442327078533151;0,395545083843628;KLF4/STAT3;2
GO:1905897;regulation of response to endoplasmic reticulum stress;2/67;20/2237;0,1;3,33880597014925;1,84573683347874;0,118872483090483;0,442327078533151;0,395545083843628;HSPA1A/BCL2L1;2
GO:2001244;positive regulation of intrinsic apoptotic signaling pathway;2/67;20/2237;0,1;3,33880597014925;1,84573683347874;0,118872483090483;0,442327078533151;0,395545083843628;MCL1/UBB;2
GO:0051090;regulation of DNA-binding transcription factor activity;5/67;88/2237;0,0568181818181818;1,89704884667571;1,50828236941588;0,120593523678054;0,447851242835755;0,400484994010298;NLRP3/HSPA1A/KLF4/ARID5B/STAT3;5
GO:0007169;transmembrane receptor protein tyrosine kinase signaling pathway;7/67;140/2237;0,05;1,66940298507463;1,43712942411203;0,121772840431484;0,449979631467924;0,402388277125487;CTNNB1/TIPARP/SH2B2/JAK2/ARID5B/NDEL1/STAT3;7
GO:0042110;T cell activation;8/67;167/2237;0,0479041916167665;1,59942800965234;1,41466474109838;0,122060261007986;0,449979631467924;0,402388277125487;NLRP3/CTNNB1/IRF1/IRF4/JAK2/PNP/STAT3/JUNB;8
GO:0002705;positive regulation of leukocyte mediated immunity;3/67;41/2237;0,0731707317073171;2,4430287586458;1,6383028278945;0,122354546043284;0,449979631467924;0,402388277125487;NLRP3/ARID5A/PVR;3
GO:0009913;epidermal cell differentiation;3/67;41/2237;0,0731707317073171;2,4430287586458;1,6383028278945;0,122354546043284;0,449979631467924;0,402388277125487;CTNNB1/KLF4/ZFP36;3
GO:0051216;cartilage development;3/67;41/2237;0,0731707317073171;2,4430287586458;1,6383028278945;0,122354546043284;0,449979631467924;0,402388277125487;ARID5A/CTNNB1/TIMP1;3
GO:1901361;organic cyclic compound catabolic process;6/67;114/2237;0,0526315789473684;1,75726630007855;1,45804018212684;0,12277224803618;0,450640770892489;0,402979492228097;TENT5C/HK2/HSPA1A/PNP/STAT3/ZFP36;6
GO:0007346;regulation of mitotic cell cycle;5/67;89/2237;0,0561797752808989;1,87573369109509;1,4811306084365;0,124936572359201;0,455379357725339;0,407216910231796;SDE2/CTNNB1/DUSP1/KLF4/NEK6;5
GO:0070663;regulation of leukocyte proliferation;5/67;89/2237;0,0561797752808989;1,87573369109509;1,4811306084365;0,124936572359201;0,455379357725339;0,407216910231796;CTNNB1/IRF1/JAK2/PNP/BCL2L1;5
GO:0019637;organophosphate metabolic process;7/67;141/2237;0,049645390070922;1,65756324759183;1,4170816779863;0,125186419690129;0,455379357725339;0,407216910231796;ADSS2/HK2/SGMS2/HSPA1A/PNP/STAT3/PGS1;7
GO:1903131;mononuclear cell differentiation;7/67;141/2237;0,049645390070922;1,65756324759183;1,4170816779863;0,125186419690129;0,455379357725339;0,407216910231796;NLRP3/CTNNB1/IRF1/IRF4/PNP/STAT3/JUNB;7
GO:0019941;modification-dependent protein catabolic process;6/67;115/2237;0,0521739130434783;1,74198572355613;1,43520921307746;0,126595631926434;0,455379357725339;0,407216910231796;RNF149/CTNNB1/FEM1C/HSPA1A/UBC/UBB;6
GO:0001654;eye development;4/67;65/2237;0,0615384615384615;2,05464982778416;1,51592769732557;0,127736505165355;0,455379357725339;0,407216910231796;CTNNB1/KLF4/STAT3/ATF4;4
GO:0002703;regulation of leukocyte mediated immunity;4/67;65/2237;0,0615384615384615;2,05464982778416;1,51592769732557;0,127736505165355;0,455379357725339;0,407216910231796;NLRP3/ARID5A/ADORA2B/PVR;4
GO:0071396;cellular response to lipid;8/67;169/2237;0,0473372781065089;1,58049986752627;1,37883927085429;0,128346718754234;0,455379357725339;0,407216910231796;GBP5/NLRP3/ARID5A/HSPA1A/JAK2/KLF4/NR1D1/ZFP36;8
GO:0000070;mitotic sister chromatid segregation;2/67;21/2237;0,0952380952380952;3,17981520966596;1,7631443992767;0,128941149589372;0,455379357725339;0,407216910231796;DUSP1/HSPA1A;2
GO:0006090;pyruvate metabolic process;2/67;21/2237;0,0952380952380952;3,17981520966596;1,7631443992767;0,128941149589372;0,455379357725339;0,407216910231796;HK2/STAT3;2
GO:0006939;smooth muscle contraction;2/67;21/2237;0,0952380952380952;3,17981520966596;1,7631443992767;0,128941149589372;0,455379357725339;0,407216910231796;APBB2/ADORA2B;2
GO:0007051;spindle organization;2/67;21/2237;0,0952380952380952;3,17981520966596;1,7631443992767;0,128941149589372;0,455379357725339;0,407216910231796;HSPA1A/NEK6;2
GO:0017148;negative regulation of translation;2/67;21/2237;0,0952380952380952;3,17981520966596;1,7631443992767;0,128941149589372;0,455379357725339;0,407216910231796;ZFP36/ATF4;2
GO:0034620;cellular response to unfolded protein;2/67;21/2237;0,0952380952380952;3,17981520966596;1,7631443992767;0,128941149589372;0,455379357725339;0,407216910231796;HSPA1A/ATF4;2
GO:0043401;steroid hormone mediated signaling pathway;2/67;21/2237;0,0952380952380952;3,17981520966596;1,7631443992767;0,128941149589372;0,455379357725339;0,407216910231796;JAK2/NR1D1;2
GO:0045058;T cell selection;2/67;21/2237;0,0952380952380952;3,17981520966596;1,7631443992767;0,128941149589372;0,455379357725339;0,407216910231796;IRF4/STAT3;2
GO:0046031;ADP metabolic process;2/67;21/2237;0,0952380952380952;3,17981520966596;1,7631443992767;0,128941149589372;0,455379357725339;0,407216910231796;HK2/STAT3;2
GO:0140467;integrated stress response signaling;2/67;21/2237;0,0952380952380952;3,17981520966596;1,7631443992767;0,128941149589372;0,455379357725339;0,407216910231796;JUNB/ATF4;2
GO:0170033;L-amino acid metabolic process;2/67;21/2237;0,0952380952380952;3,17981520966596;1,7631443992767;0,128941149589372;0,455379357725339;0,407216910231796;ADSS2/ATF4;2
GO:0006996;organelle organization;19/67;491/2237;0,0386965376782077;1,29200231024106;1,28661422255094;0,128952462549748;0,455379357725339;0,407216910231796;GADD45A/MCL1/HK2/INO80D/CTNNB1/CCNL1/DUSP1/HSPA1A/GGCT/SH2B2/JAK2/NEK6/SAR1A/CDC42EP2/NDEL1/UBB/CDC42EP4/H3-3B/BCL2L1;19
GO:0010498;proteasomal protein catabolic process;5/67;90/2237;0,0555555555555556;1,85489220563847;1,45432015865705;0,129352742585128;0,455379357725339;0,407216910231796;CTNNB1/FEM1C/HSPA1A/UBB/NR1D1;5
GO:0034612;response to tumor necrosis factor;5/67;90/2237;0,0555555555555556;1,85489220563847;1,45432015865705;0,129352742585128;0,455379357725339;0,407216910231796;HSPA1A/JAK2/FAS/NR1D1/ZFP36;5
GO:0032102;negative regulation of response to external stimulus;6/67;116/2237;0,0517241379310345;1,72696860524961;1,41259527837408;0,130477901366708;0,457639157756565;0,409237706235932;NLRP3/DUSP1/KLF4/NR1D1/STAT3/ZFP36;6
GO:0043632;modification-dependent macromolecule catabolic process;6/67;116/2237;0,0517241379310345;1,72696860524961;1,41259527837408;0,130477901366708;0,457639157756565;0,409237706235932;RNF149/CTNNB1/FEM1C/HSPA1A/UBC/UBB;6
GO:0033993;response to lipid;10/67;226/2237;0,0442477876106195;1,47734777440232;1,329616881035;0,132083287782646;0,460985354159302;0,412229997689277;GBP5/NLRP3/ARID5A/CTNNB1/HSPA1A/JAK2/KLF4/NR1D1/STAT3/ZFP36;10
GO:0002764;immune response-regulating signaling pathway;7/67;143/2237;0,048951048951049;1,63438054482831;1,37744088552725;0,132162115791183;0,460985354159302;0,412229997689277;GBP5/NLRP3/IRF1/IRF4/HSPA1A/SH2B2/NR1D1;7
GO:0016567;protein ubiquitination;7/67;143/2237;0,048951048951049;1,63438054482831;1,37744088552725;0,132162115791183;0,460985354159302;0,412229997689277;SDE2/RNF149/CTNNB1/FEM1C/HSPA1A/UBC/UBB;7
GO:0051240;positive regulation of multicellular organismal process;16/67;402/2237;0,0398009950248756;1,32887799806935;1,27900795733266;0,133004094509499;0,462406413200997;0,413500760762744;GBP5/NLRP3/HK2/ARID5A/TMBIM1/CTNNB1/IRF1/IRF4/HSPA1A/JAK2/KLF4/PNP/ADORA2B/STAT3/TGM2/ATF4;16
GO:0150063;visual system development;4/67;66/2237;0,0606060606060606;2,02351876978743;1,48279564372007;0,133057811612747;0,462406413200997;0,413500760762744;CTNNB1/KLF4/STAT3/ATF4;4
GO:0000278;mitotic cell cycle;7/67;144/2237;0,0486111111111111;1,62303067993367;1,35784281661359;0,135723357034485;0,462545194404213;0,413624864000655;SDE2/CTNNB1/DUSP1/HSPA1A/KLF4/NEK6/NDEL1;7
GO:0002456;T cell mediated immunity;3/67;43/2237;0,0697674418604651;2,32939951405762;1,54637516373672;0,135923209270981;0,462545194404213;0,413624864000655;NLRP3/ARID5A/PVR;3
GO:0051348;negative regulation of transferase activity;3/67;43/2237;0,0697674418604651;2,32939951405762;1,54637516373672;0,135923209270981;0,462545194404213;0,413624864000655;GADD45A/DUSP1/ZFP36;3
GO:0097305;response to alcohol;3/67;43/2237;0,0697674418604651;2,32939951405762;1,54637516373672;0,135923209270981;0,462545194404213;0,413624864000655;CTNNB1/KLF4/BCL2L1;3
GO:0002694;regulation of leukocyte activation;8/67;172/2237;0,0465116279069767;1,55293300937175;1,32592862643946;0,138094778775119;0,462545194404213;0,413624864000655;NLRP3/CTNNB1/IRF1/IRF4/JAK2/PNP/NR1D1/JUNB;8
GO:0008285;negative regulation of cell population proliferation;8/67;172/2237;0,0465116279069767;1,55293300937175;1,32592862643946;0,138094778775119;0,462545194404213;0,413624864000655;CTNNB1/IRF1/DUSP1/HSPA1A/JAK2/KLF4/PTGES/STAT3;8
GO:0048880;sensory system development;4/67;67/2237;0,0597014925373134;1,99331699710403;1,45023651342725;0,138470741967516;0,462545194404213;0,413624864000655;CTNNB1/KLF4/STAT3/ATF4;4
GO:0002224;toll-like receptor signaling pathway;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;IRF1/IRF4;2
GO:0002260;lymphocyte homeostasis;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;SH2B2/FAS;2
GO:0007492;endoderm development;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;CTNNB1/DUSP1;2
GO:0021761;limbic system development;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;CTNNB1/UBB;2
GO:0030833;regulation of actin filament polymerization;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;CDC42EP2/CDC42EP4;2
GO:0032088;negative regulation of NF-kappaB transcription factor activity;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;NLRP3/KLF4;2
GO:0032613;interleukin-10 production;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;IRF4/STAT3;2
GO:0032653;regulation of interleukin-10 production;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;IRF4/STAT3;2
GO:0032757;positive regulation of interleukin-8 production;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;HSPA1A/STAT3;2
GO:0035967;cellular response to topologically incorrect protein;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;HSPA1A/ATF4;2
GO:0042752;regulation of circadian rhythm;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;NR1D1/PHLPP1;2
GO:0044344;cellular response to fibroblast growth factor stimulus;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;CTNNB1/ZFP36;2
GO:0045995;regulation of embryonic development;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;INO80D/CTNNB1;2
GO:0046209;nitric oxide metabolic process;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;JAK2/KLF4;2
GO:0099111;microtubule-based transport;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;NDEL1/UBB;2
GO:1902807;negative regulation of cell cycle G1/S phase transition;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;SDE2/KLF4;2
GO:2000134;negative regulation of G1/S transition of mitotic cell cycle;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;SDE2/KLF4;2
GO:2001057;reactive nitrogen species metabolic process;2/67;22/2237;0,0909090909090909;3,03527815468114;1,6853561119972;0,139203147207181;0,462545194404213;0,413624864000655;JAK2/KLF4;2
GO:0009653;anatomical structure morphogenesis;18/67;466/2237;0,0386266094420601;1,28966754211774;1,23460191442252;0,140262245145743;0,465248147646299;0,416041943846438;GADD45A/HK2/NR4A2/TMBIM1/CTNNB1/TIPARP/APBB2/DUSP1/KLF4/ARID5B/CDC42EP2/NDEL1/UBB/STAT3/CDC42EP4/JUNB/TGM2/ATF4;18
GO:0006952;defense response;18/67;467/2237;0,0385438972162741;1,28690594138515;1,2244887039208;0,142382947162056;0,467867032169113;0,418383846362532;GBP5/NLRP3/ARID5A/IRF1/IRF4/HSPA1A/JAK2/KLF4/PTGES/CDC42EP2/ADORA2B/NR1D1/STAT3/CDC42EP4/ZFP36/PVR/BCL2L1/TIMP1;18
GO:0032635;interleukin-6 production;3/67;44/2237;0,0681818181818182;2,27645861601085;1,50230182756991;0,142897238256971;0,467867032169113;0,418383846362532;ARID5A/ADORA2B/STAT3;3
GO:0032675;regulation of interleukin-6 production;3/67;44/2237;0,0681818181818182;2,27645861601085;1,50230182756991;0,142897238256971;0,467867032169113;0,418383846362532;ARID5A/ADORA2B/STAT3;3
GO:0048660;regulation of smooth muscle cell proliferation;3/67;44/2237;0,0681818181818182;2,27645861601085;1,50230182756991;0,142897238256971;0,467867032169113;0,418383846362532;CTNNB1/JAK2/KLF4;3
GO:0120032;regulation of plasma membrane bounded cell projection assembly;3/67;44/2237;0,0681818181818182;2,27645861601085;1,50230182756991;0,142897238256971;0,467867032169113;0,418383846362532;CDC42EP2/NDEL1/CDC42EP4;3
GO:1901654;response to ketone;3/67;44/2237;0,0681818181818182;2,27645861601085;1,50230182756991;0,142897238256971;0,467867032169113;0,418383846362532;JAK2/KLF4/BCL2L1;3
GO:1902905;positive regulation of supramolecular fiber organization;3/67;44/2237;0,0681818181818182;2,27645861601085;1,50230182756991;0,142897238256971;0,467867032169113;0,418383846362532;HSPA1A/CDC42EP2/CDC42EP4;3
GO:0006325;chromatin organization;5/67;93/2237;0,0537634408602151;1,79505697319852;1,37584898821548;0,143027989242828;0,467867032169113;0,418383846362532;INO80D/IRF4/JAK2/H3-3B/TGM2;5
GO:0045597;positive regulation of cell differentiation;9/67;202/2237;0,0445544554455446;1,48758681838333;1,27640609163006;0,144810580261029;0,472881446576531;0,422867919491824;NLRP3/CTNNB1/HSPA1A/JAK2/PNP/STAT3/JUNB/ZFP36/TGM2;9
GO:0016049;cell growth;5/67;94/2237;0,0531914893617021;1,77596062241982;1,35031769254084;0,147724442776676;0,473468886622664;0,423393229909335;SERTAD2/CTNNB1/HSPA1A/NDEL1/H3-3B;5
GO:0000165;MAPK cascade;8/67;175/2237;0,0457142857142857;1,52631130063966;1,27397475733593;0,148217190669112;0,473468886622664;0,423393229909335;GADD45A/RNF149/CTNNB1/DUSP1/JAK2/FAS/PHLPP1/ZFP36;8
GO:0048545;response to steroid hormone;4/67;69/2237;0,0579710144927536;1,93553969284015;1,38675761329106;0,149561788762732;0,473468886622664;0,423393229909335;HSPA1A/JAK2/NR1D1/ZFP36;4
GO:0000723;telomere maintenance;2/67;23/2237;0,0869565217391304;2,90330953926022;1,61186241275588;0,149638329133923;0,473468886622664;0,423393229909335;INO80D/CTNNB1;2
GO:0009135;purine nucleoside diphosphate metabolic process;2/67;23/2237;0,0869565217391304;2,90330953926022;1,61186241275588;0,149638329133923;0,473468886622664;0,423393229909335;HK2/STAT3;2
GO:0009179;purine ribonucleoside diphosphate metabolic process;2/67;23/2237;0,0869565217391304;2,90330953926022;1,61186241275588;0,149638329133923;0,473468886622664;0,423393229909335;HK2/STAT3;2
GO:0010657;muscle cell apoptotic process;2/67;23/2237;0,0869565217391304;2,90330953926022;1,61186241275588;0,149638329133923;0,473468886622664;0,423393229909335;JAK2/ATF4;2
GO:0010821;regulation of mitochondrion organization;2/67;23/2237;0,0869565217391304;2,90330953926022;1,61186241275588;0,149638329133923;0,473468886622664;0,423393229909335;HSPA1A/BCL2L1;2
GO:0030705;cytoskeleton-dependent intracellular transport;2/67;23/2237;0,0869565217391304;2,90330953926022;1,61186241275588;0,149638329133923;0,473468886622664;0,423393229909335;NDEL1/UBB;2
GO:0032355;response to estradiol;2/67;23/2237;0,0869565217391304;2,90330953926022;1,61186241275588;0,149638329133923;0,473468886622664;0,423393229909335;CTNNB1/STAT3;2
GO:0034249;negative regulation of amide metabolic process;2/67;23/2237;0,0869565217391304;2,90330953926022;1,61186241275588;0,149638329133923;0,473468886622664;0,423393229909335;ZFP36/ATF4;2
GO:0045685;regulation of glial cell differentiation;2/67;23/2237;0,0869565217391304;2,90330953926022;1,61186241275588;0,149638329133923;0,473468886622664;0,423393229909335;CTNNB1/NR1D1;2
GO:0048708;astrocyte differentiation;2/67;23/2237;0,0869565217391304;2,90330953926022;1,61186241275588;0,149638329133923;0,473468886622664;0,423393229909335;NR1D1/STAT3;2
GO:0070167;regulation of biomineral tissue development;2/67;23/2237;0,0869565217391304;2,90330953926022;1,61186241275588;0,149638329133923;0,473468886622664;0,423393229909335;SGMS2/ATF4;2
GO:0071897;DNA biosynthetic process;2/67;23/2237;0,0869565217391304;2,90330953926022;1,61186241275588;0,149638329133923;0,473468886622664;0,423393229909335;CTNNB1/KLF4;2
GO:0097306;cellular response to alcohol;2/67;23/2237;0,0869565217391304;2,90330953926022;1,61186241275588;0,149638329133923;0,473468886622664;0,423393229909335;CTNNB1/KLF4;2
GO:2000630;positive regulation of miRNA metabolic process;2/67;23/2237;0,0869565217391304;2,90330953926022;1,61186241275588;0,149638329133923;0,473468886622664;0,423393229909335;KLF4/STAT3;2
GO:0034470;ncRNA processing;3/67;45/2237;0,0666666666666667;2,22587064676617;1,45939905966195;0,149990143597465;0,473468886622664;0,423393229909335;SDE2/SRFBP1/STAT3;3
GO:0048659;smooth muscle cell proliferation;3/67;45/2237;0,0666666666666667;2,22587064676617;1,45939905966195;0,149990143597465;0,473468886622664;0,423393229909335;CTNNB1/JAK2/KLF4;3
GO:0060491;regulation of cell projection assembly;3/67;45/2237;0,0666666666666667;2,22587064676617;1,45939905966195;0,149990143597465;0,473468886622664;0,423393229909335;CDC42EP2/NDEL1/CDC42EP4;3
GO:1903047;mitotic cell cycle process;6/67;122/2237;0,0491803278688525;1,64203572302422;1,28123075934068;0,154967260505976;0,488366042260098;0,436714812425108;SDE2/DUSP1/HSPA1A/KLF4/NEK6/NDEL1;6
GO:0015833;peptide transport;3/67;46/2237;0,0652173913043478;2,17748215444517;1,41760584403526;0,157196227193265;0,492647692244423;0,440543620753224;JAK2/NR1D1/SLC13A3;3
GO:0031647;regulation of protein stability;3/67;46/2237;0,0652173913043478;2,17748215444517;1,41760584403526;0,157196227193265;0,492647692244423;0,440543620753224;RNF149/HSPA1A/NR1D1;3
GO:0043408;regulation of MAPK cascade;7/67;150/2237;0,0466666666666667;1,55810945273632;1,24321779338397;0,158087280628737;0,492647692244423;0,440543620753224;GADD45A/RNF149/CTNNB1/DUSP1/JAK2/FAS/PHLPP1;7
GO:0045087;innate immune response;11/67;264/2237;0,0416666666666667;1,39116915422886;1,18890309020091;0,158593804987598;0,492647692244423;0,440543620753224;GBP5/NLRP3/ARID5A/IRF1/IRF4/HSPA1A/JAK2/CDC42EP2/NR1D1/CDC42EP4/PVR;11
GO:0001678;intracellular glucose homeostasis;2/67;24/2237;0,0833333333333333;2,78233830845771;1,54222766569168;0,160227549325536;0,492647692244423;0,440543620753224;HK2/NR1D1;2
GO:0002062;chondrocyte differentiation;2/67;24/2237;0,0833333333333333;2,78233830845771;1,54222766569168;0,160227549325536;0,492647692244423;0,440543620753224;ARID5A/CTNNB1;2
GO:0007292;female gamete generation;2/67;24/2237;0,0833333333333333;2,78233830845771;1,54222766569168;0,160227549325536;0,492647692244423;0,440543620753224;CTNNB1/UBB;2
GO:0008064;regulation of actin polymerization or depolymerization;2/67;24/2237;0,0833333333333333;2,78233830845771;1,54222766569168;0,160227549325536;0,492647692244423;0,440543620753224;CDC42EP2/CDC42EP4;2
GO:0009185;ribonucleoside diphosphate metabolic process;2/67;24/2237;0,0833333333333333;2,78233830845771;1,54222766569168;0,160227549325536;0,492647692244423;0,440543620753224;HK2/STAT3;2
GO:0016072;rRNA metabolic process;2/67;24/2237;0,0833333333333333;2,78233830845771;1,54222766569168;0,160227549325536;0,492647692244423;0,440543620753224;SDE2/SRFBP1;2
GO:0030832;regulation of actin filament length;2/67;24/2237;0,0833333333333333;2,78233830845771;1,54222766569168;0,160227549325536;0,492647692244423;0,440543620753224;CDC42EP2/CDC42EP4;2
GO:0046638;positive regulation of alpha-beta T cell differentiation;2/67;24/2237;0,0833333333333333;2,78233830845771;1,54222766569168;0,160227549325536;0,492647692244423;0,440543620753224;NLRP3/PNP;2
GO:0051260;protein homooligomerization;2/67;24/2237;0,0833333333333333;2,78233830845771;1,54222766569168;0,160227549325536;0,492647692244423;0,440543620753224;GBP5/NLRP3;2
GO:0071774;response to fibroblast growth factor;2/67;24/2237;0,0833333333333333;2,78233830845771;1,54222766569168;0,160227549325536;0,492647692244423;0,440543620753224;CTNNB1/ZFP36;2
GO:0090316;positive regulation of intracellular protein transport;2/67;24/2237;0,0833333333333333;2,78233830845771;1,54222766569168;0,160227549325536;0,492647692244423;0,440543620753224;JAK2/SAR1A;2
GO:0042098;T cell proliferation;4/67;71/2237;0,0563380281690141;1,88101744797141;1,32534178855291;0,160989796989219;0,493348475840587;0,441170287126941;CTNNB1/IRF1/JAK2/PNP;4
GO:0007010;cytoskeleton organization;10/67;236/2237;0,0423728813559322;1,41474829243612;1,18347884134273;0,161827477483113;0,493348475840587;0,441170287126941;GADD45A/CTNNB1/CCNL1/HSPA1A/SH2B2/JAK2/NEK6/CDC42EP2/NDEL1/CDC42EP4;10
GO:0051249;regulation of lymphocyte activation;7/67;151/2237;0,0463576158940397;1,54779084708906;1,22458666827871;0,161975596985615;0,493348475840587;0,441170287126941;NLRP3/CTNNB1/IRF1/IRF4/JAK2/PNP/JUNB;7
GO:0009991;response to extracellular stimulus;5/67;97/2237;0,0515463917525773;1,72103400523157;1,27549324163209;0,16220917149132;0,493348475840587;0,441170287126941;NR4A2/FAS/ADORA2B/ZFP36/ATF4;5
GO:0032943;mononuclear cell proliferation;5/67;97/2237;0,0515463917525773;1,72103400523157;1,27549324163209;0,16220917149132;0,493348475840587;0,441170287126941;CTNNB1/IRF1/JAK2/PNP/BCL2L1;5
GO:0044770;cell cycle phase transition;5/67;97/2237;0,0515463917525773;1,72103400523157;1,27549324163209;0,16220917149132;0,493348475840587;0,441170287126941;SDE2/APBB2/DUSP1/KLF4/NEK6;5
GO:0035239;tube morphogenesis;8/67;179/2237;0,0446927374301676;1,49220378554157;1,20612470683889;0,162278828114406;0,493348475840587;0,441170287126941;GADD45A/HK2/CTNNB1/TIPARP/KLF4/STAT3/JUNB/TGM2;8
GO:0003006;developmental process involved in reproduction;6/67;124/2237;0,0483870967741935;1,61555127587867;1,2389927466282;0,163566674548309;0,49646679742708;0,443958804568539;CTNNB1/TIPARP/ARID5B/UBB/JUNB/BCL2L1;6
GO:0008380;RNA splicing;3/67;47/2237;0,0638297872340425;2,13115274690378;1,37686563341228;0,164509799567651;0,496940287689203;0,444382216913204;SDE2/CCNL1/HSPA1A;3
GO:0048771;tissue remodeling;3/67;47/2237;0,0638297872340425;2,13115274690378;1,37686563341228;0,164509799567651;0,496940287689203;0,444382216913204;TMBIM1/CTNNB1/TIMP1;3
GO:0051092;positive regulation of NF-kappaB transcription factor activity;3/67;47/2237;0,0638297872340425;2,13115274690378;1,37686563341228;0,164509799567651;0,496940287689203;0,444382216913204;NLRP3/HSPA1A/STAT3;3
GO:0022603;regulation of anatomical structure morphogenesis;8/67;180/2237;0,0444444444444444;1,48391376451078;1,18940707130791;0,165892398924152;0,498730481844991;0,445983074133602;GADD45A/HK2/TMBIM1/CTNNB1/KLF4/CDC42EP2/STAT3/CDC42EP4;8
GO:0043687;post-translational protein modification;8/67;180/2237;0,0444444444444444;1,48391376451078;1,18940707130791;0,165892398924152;0,498730481844991;0,445983074133602;SDE2/RNF149/CTNNB1/FEM1C/HSPA1A/JAK2/UBC/UBB;8
GO:0060341;regulation of cellular localization;8/67;180/2237;0,0444444444444444;1,48391376451078;1,18940707130791;0,165892398924152;0,498730481844991;0,445983074133602;TMBIM1/CTNNB1/JAK2/SAR1A/NDEL1/NR1D1/ZFP36/BCL2L1;8
GO:0002274;myeloid leukocyte activation;4/67;72/2237;0,0555555555555556;1,85489220563847;1,29536479386225;0,166823774304098;0,499943399575888;0,447067709619076;IRF4/JAK2/ADORA2B/NR1D1;4
GO:0002699;positive regulation of immune effector process;4/67;72/2237;0,0555555555555556;1,85489220563847;1,29536479386225;0,166823774304098;0,499943399575888;0,447067709619076;NLRP3/ARID5A/ADORA2B/PVR;4
GO:0010638;positive regulation of organelle organization;5/67;98/2237;0,0510204081632653;1,70347243374962;1,25111768615961;0,167164507952941;0,500173109104061;0,447273124297468;INO80D/CTNNB1/HSPA1A/CDC42EP2/CDC42EP4;5
GO:0002253;activation of immune response;7/67;153/2237;0,0457516339869281;1,52755828699639;1,1877108983456;0,169884881136199;0,5032573261721;0,450031144228816;GBP5/NLRP3/IRF1/IRF4/HSPA1A/SH2B2/NR1D1;7
GO:0006006;glucose metabolic process;2/67;25/2237;0,08;2,6710447761194;1,47607683334463;0,170952622103351;0,5032573261721;0,450031144228816;HK2/ATF4;2
GO:0008286;insulin receptor signaling pathway;2/67;25/2237;0,08;2,6710447761194;1,47607683334463;0,170952622103351;0,5032573261721;0,450031144228816;SH2B2/NDEL1;2
GO:0008630;intrinsic apoptotic signaling pathway in response to DNA damage;2/67;25/2237;0,08;2,6710447761194;1,47607683334463;0,170952622103351;0,5032573261721;0,450031144228816;MCL1/BCL2L1;2
GO:0009132;nucleoside diphosphate metabolic process;2/67;25/2237;0,08;2,6710447761194;1,47607683334463;0,170952622103351;0,5032573261721;0,450031144228816;HK2/STAT3;2
GO:0035148;tube formation;2/67;25/2237;0,08;2,6710447761194;1,47607683334463;0,170952622103351;0,5032573261721;0,450031144228816;CTNNB1/TGM2;2
GO:0045638;negative regulation of myeloid cell differentiation;2/67;25/2237;0,08;2,6710447761194;1,47607683334463;0,170952622103351;0,5032573261721;0,450031144228816;CTNNB1/ZFP36;2
GO:1901655;cellular response to ketone;2/67;25/2237;0,08;2,6710447761194;1,47607683334463;0,170952622103351;0,5032573261721;0,450031144228816;JAK2/KLF4;2
GO:1903321;negative regulation of protein modification by small protein conjugation or removal;2/67;25/2237;0,08;2,6710447761194;1,47607683334463;0,170952622103351;0,5032573261721;0,450031144228816;CTNNB1/HSPA1A;2
GO:1904035;regulation of epithelial cell apoptotic process;2/67;25/2237;0,08;2,6710447761194;1,47607683334463;0,170952622103351;0,5032573261721;0,450031144228816;JAK2/ZFP36;2
GO:0007369;gastrulation;3/67;48/2237;0,0625;2,08675373134328;1,33712593329103;0,171925190524458;0,5032573261721;0,450031144228816;CTNNB1/DUSP1/KLF4;3
GO:0051054;positive regulation of DNA metabolic process;3/67;48/2237;0,0625;2,08675373134328;1,33712593329103;0,171925190524458;0,5032573261721;0,450031144228816;INO80D/CTNNB1/KLF4;3
GO:0051495;positive regulation of cytoskeleton organization;3/67;48/2237;0,0625;2,08675373134328;1,33712593329103;0,171925190524458;0,5032573261721;0,450031144228816;HSPA1A/CDC42EP2/CDC42EP4;3
GO:0006396;RNA processing;5/67;99/2237;0,0505050505050505;1,68626564148952;1,22701377117971;0,172180964814953;0,5032573261721;0,450031144228816;SDE2/CCNL1/SRFBP1/HSPA1A/STAT3;5
GO:0048812;neuron projection morphogenesis;5/67;99/2237;0,0505050505050505;1,68626564148952;1,22701377117971;0,172180964814953;0,5032573261721;0,450031144228816;NR4A2/CTNNB1/APBB2/NDEL1/UBB;5
GO:0090407;organophosphate biosynthetic process;4/67;73/2237;0,0547945205479452;1,82948272336945;1,26585389063884;0,172734257034914;0,504096583704355;0,450781639070921;ADSS2/SGMS2/PNP/PGS1;4
GO:0140546;defense response to symbiont;12/67;299/2237;0,040133779264214;1,3399890181201;1,10960148961336;0,174832251748082;0,509434284324412;0,455554806579213;GBP5/NLRP3/ARID5A/IRF1/IRF4/HSPA1A/JAK2/CDC42EP2/NR1D1/CDC42EP4/PVR/BCL2L1;12
GO:0030900;forebrain development;4/67;74/2237;0,0540540540540541;1,80475998386446;1,23679410744003;0,178718601290746;0,516225128063375;0,461627427918619;NR4A2/CTNNB1/NDEL1/UBB;4
GO:0032787;monocarboxylic acid metabolic process;4/67;74/2237;0,0540540540540541;1,80475998386446;1,23679410744003;0,178718601290746;0,516225128063375;0,461627427918619;HK2/PTGES/NR1D1/STAT3;4
GO:0002706;regulation of lymphocyte mediated immunity;3/67;49/2237;0,0612244897959184;2,04416692049954;1,29833793257251;0,179436759015077;0,516225128063375;0,461627427918619;NLRP3/ARID5A/PVR;3
GO:0006402;mRNA catabolic process;3/67;49/2237;0,0612244897959184;2,04416692049954;1,29833793257251;0,179436759015077;0,516225128063375;0,461627427918619;TENT5C/HSPA1A/ZFP36;3
GO:0009416;response to light stimulus;3/67;49/2237;0,0612244897959184;2,04416692049954;1,29833793257251;0,179436759015077;0,516225128063375;0,461627427918619;SDE2/ATF4/TIMP1;3
GO:0051246;regulation of protein metabolic process;16/67;422/2237;0,037914691943128;1,26589799816085;1,06531100279096;0,180533659384623;0,516225128063375;0,461627427918619;GADD45A/NLRP3/ARID5A/CTNNB1/TIPARP/DUSP1/HSPA1A/AZIN1/JAK2/KLF4/FAS/UBB/STAT3/ZFP36/ATF4/TIMP1;16
GO:0007093;mitotic cell cycle checkpoint signaling;2/67;26/2237;0,0769230769230769;2,5683122847302;1,41308498281091;0,181796283219784;0,516225128063375;0,461627427918619;SDE2/DUSP1;2
GO:0010951;negative regulation of endopeptidase activity;2/67;26/2237;0,0769230769230769;2,5683122847302;1,41308498281091;0,181796283219784;0,516225128063375;0,461627427918619;KLF4/TIMP1;2
GO:0043484;regulation of RNA splicing;2/67;26/2237;0,0769230769230769;2,5683122847302;1,41308498281091;0,181796283219784;0,516225128063375;0,461627427918619;CCNL1/HSPA1A;2
GO:0043535;regulation of blood vessel endothelial cell migration;2/67;26/2237;0,0769230769230769;2,5683122847302;1,41308498281091;0,181796283219784;0,516225128063375;0,461627427918619;GADD45A/KLF4;2
GO:0051606;detection of stimulus;2/67;26/2237;0,0769230769230769;2,5683122847302;1,41308498281091;0,181796283219784;0,516225128063375;0,461627427918619;NLRP3/CTNNB1;2
GO:0061614;miRNA transcription;2/67;26/2237;0,0769230769230769;2,5683122847302;1,41308498281091;0,181796283219784;0,516225128063375;0,461627427918619;KLF4/STAT3;2
GO:0098586;cellular response to virus;2/67;26/2237;0,0769230769230769;2,5683122847302;1,41308498281091;0,181796283219784;0,516225128063375;0,461627427918619;NLRP3/JAK2;2
GO:0098742;cell-cell adhesion via plasma-membrane adhesion molecules;2/67;26/2237;0,0769230769230769;2,5683122847302;1,41308498281091;0,181796283219784;0,516225128063375;0,461627427918619;KLF4/PVR;2
GO:0140747;regulation of ncRNA transcription;2/67;26/2237;0,0769230769230769;2,5683122847302;1,41308498281091;0,181796283219784;0,516225128063375;0,461627427918619;KLF4/STAT3;2
GO:1901874;negative regulation of post-translational protein modification;2/67;26/2237;0,0769230769230769;2,5683122847302;1,41308498281091;0,181796283219784;0,516225128063375;0,461627427918619;CTNNB1/HSPA1A;2
GO:1902893;regulation of miRNA transcription;2/67;26/2237;0,0769230769230769;2,5683122847302;1,41308498281091;0,181796283219784;0,516225128063375;0,461627427918619;KLF4/STAT3;2
GO:0048732;gland development;5/67;101/2237;0,0495049504950495;1,65287424264815;1,17959529545218;0,182391218170354;0,517139172477022;0,462444799930822;HK2/CTNNB1/JAK2/ARID5B/TGM2;5
GO:0009056;catabolic process;16/67;423/2237;0,0378250591016548;1,26290533149854;1,05485889573852;0,183124818085807;0,518443057480596;0,463610781685254;TENT5C/MCL1/HK2/RNF149/CTNNB1/TIPARP/FEM1C/HSPA1A/AZIN1/UBC/PNP/UBB/NR1D1/STAT3/ZFP36/TIMP1;16
GO:0051049;regulation of transport;12/67;302/2237;0,0397350993377483;1,32667786893348;1,07232426787888;0,183774263788541;0,51950515763507;0,464560550566791;HK2/CTNNB1/HSPA1A/AZIN1/JAK2/PTGES/SAR1A/NDEL1/ADORA2B/NR1D1/TGM2/ATF4;12
GO:0051241;negative regulation of multicellular organismal process;10/67;243/2237;0,0411522633744856;1,37399422639887;1,08479803938651;0,184522057779906;0,52084169513434;0,46575573137951;GADD45A/NLRP3/CTNNB1/IRF1/KLF4/ADORA2B/NR1D1/ZFP36/ATF4/TIMP1;10
GO:0032446;protein modification by small protein conjugation;7/67;157/2237;0,0445859872611465;1,48863960452514;1,11545038222642;0,186215766927841;0,524817304994272;0,469310867412763;SDE2/RNF149/CTNNB1/FEM1C/HSPA1A/UBC/UBB;7
GO:0010639;negative regulation of organelle organization;3/67;50/2237;0,06;2,00328358208955;1,26045617469146;0,187038902255086;0,524817304994272;0,469310867412763;DUSP1/HSPA1A/BCL2L1;3
GO:0048863;stem cell differentiation;3/67;50/2237;0,06;2,00328358208955;1,26045617469146;0,187038902255086;0,524817304994272;0,469310867412763;CTNNB1/STAT3/ZFP36;3
GO:1901136;carbohydrate derivative catabolic process;3/67;50/2237;0,06;2,00328358208955;1,26045617469146;0,187038902255086;0,524817304994272;0,469310867412763;HK2/PNP/STAT3;3
GO:0040007;growth;8/67;186/2237;0,043010752688172;1,43604557855882;1,09106082649187;0,188362734100251;0,527750027198041;0,47193341508456;SERTAD2/CTNNB1/HSPA1A/ARID5B/NDEL1/STAT3/H3-3B/BCL2L1;8
GO:0002831;regulation of response to biotic stimulus;7/67;158/2237;0,0443037974683544;1,47921783487625;1,09768493920688;0,190401215891202;0,52884220459999;0,472910080143047;GBP5/NLRP3/IRF1/IRF4/HSPA1A/NR1D1/PVR;7
GO:0060322;head development;6/67;130/2237;0,0461538461538462;1,54098737083812;1,11652890106389;0,190573306311222;0,52884220459999;0,472910080143047;NR4A2/CTNNB1/TIPARP/ARID5B/NDEL1/UBB;6
GO:0044283;small molecule biosynthetic process;4/67;76/2237;0,0526315789473684;1,75726630007855;1,17997138892346;0,190898182025546;0,52884220459999;0,472910080143047;PTGES/PNP/NR1D1/ATF4;4
GO:0022414;reproductive process;8/67;187/2237;0,0427807486631016;1,42836619043818;1,07498521915094;0,192234574026515;0,52884220459999;0,472910080143047;CTNNB1/TIPARP/DUSP1/ARID5B/UBB/JUNB/BCL2L1/TIMP1;8
GO:0050865;regulation of cell activation;8/67;187/2237;0,0427807486631016;1,42836619043818;1,07498521915094;0,192234574026515;0,52884220459999;0,472910080143047;NLRP3/CTNNB1/IRF1/IRF4/JAK2/PNP/NR1D1/JUNB;8
GO:0035295;tube development;9/67;216/2237;0,0416666666666667;1,39116915422886;1,06255581868296;0,192347614017255;0,52884220459999;0,472910080143047;GADD45A/HK2/CTNNB1/TIPARP/KLF4/UBB/STAT3/JUNB/TGM2;9
GO:0008625;extrinsic apoptotic signaling pathway via death domain receptors;2/67;27/2237;0,0740740740740741;2,47318960751797;1,35296893727335;0,19274215234059;0,52884220459999;0,472910080143047;TMBIM1/BCL2L1;2
GO:0009755;hormone-mediated signaling pathway;2/67;27/2237;0,0740740740740741;2,47318960751797;1,35296893727335;0,19274215234059;0,52884220459999;0,472910080143047;JAK2/NR1D1;2
GO:0061136;regulation of proteasomal protein catabolic process;2/67;27/2237;0,0740740740740741;2,47318960751797;1,35296893727335;0,19274215234059;0,52884220459999;0,472910080143047;HSPA1A/UBB;2
GO:0070301;cellular response to hydrogen peroxide;2/67;27/2237;0,0740740740740741;2,47318960751797;1,35296893727335;0,19274215234059;0,52884220459999;0,472910080143047;KLF4/OSER1;2
GO:0072522;purine-containing compound biosynthetic process;2/67;27/2237;0,0740740740740741;2,47318960751797;1,35296893727335;0,19274215234059;0,52884220459999;0,472910080143047;ADSS2/PNP;2
GO:0050673;epithelial cell proliferation;5/67;103/2237;0,0485436893203883;1,62077959715983;1,13318880032529;0,192827639154983;0,52884220459999;0,472910080143047;CTNNB1/NR1D1/STAT3/ZFP36/BCL2L1;5
GO:0071824;protein-DNA complex organization;5/67;103/2237;0,0485436893203883;1,62077959715983;1,13318880032529;0,192827639154983;0,52884220459999;0,472910080143047;INO80D/IRF4/JAK2/H3-3B/TGM2;5
GO:0002684;positive regulation of immune system process;12/67;305/2237;0,039344262295082;1,31362857841938;1,03539347130939;0,192940846556807;0,52884220459999;0,472910080143047;GBP5/NLRP3/ARID5A/IRF1/IRF4/HSPA1A/SH2B2/JAK2/PNP/ADORA2B/NR1D1/PVR;12
GO:0051094;positive regulation of developmental process;12/67;305/2237;0,039344262295082;1,31362857841938;1,03539347130939;0,192940846556807;0,52884220459999;0,472910080143047;NLRP3/HK2/CTNNB1/HSPA1A/JAK2/KLF4/PNP/STAT3/JUNB/ZFP36/TGM2/ATF4;12
GO:0001649;osteoblast differentiation;3/67;51/2237;0,0588235294117647;1,9640035118525;1,22343826409183;0,194726064129486;0,532964111938218;0,476596040742841;CTNNB1/JUNB/ATF4;3
GO:0048858;cell projection morphogenesis;5/67;104/2237;0,0480769230769231;1,60519517795637;1,11035060866831;0,198126721808174;0,540708949718562;0,483521758515626;NR4A2/CTNNB1/APBB2/NDEL1/UBB;5
GO:0120039;plasma membrane bounded cell projection morphogenesis;5/67;104/2237;0,0480769230769231;1,60519517795637;1,11035060866831;0,198126721808174;0,540708949718562;0,483521758515626;NR4A2/CTNNB1/APBB2/NDEL1/UBB;5
GO:0001568;blood vessel development;7/67;160/2237;0,04375;1,4607276119403;1,06250117230363;0,198890334336978;0,541233179934247;0,483990544386263;GADD45A/HK2/CTNNB1/TIPARP/KLF4/STAT3/JUNB;7
GO:0031175;neuron projection development;7/67;160/2237;0,04375;1,4607276119403;1,06250117230363;0,198890334336978;0,541233179934247;0,483990544386263;NR4A2/CTNNB1/APBB2/JAK2/KLF4/NDEL1/UBB;7
GO:0022008;neurogenesis;11/67;278/2237;0,039568345323741;1,32111027595834;1,0050850606596;0,202409859692557;0,542825985823186;0,485414889784642;NR4A2/CTNNB1/APBB2/JAK2/KLF4/NDEL1/UBB/NR1D1/STAT3/TGM2/ATF4;11
GO:0002753;cytoplasmic pattern recognition receptor signaling pathway;3/67;52/2237;0,0576923076923077;1,92623421354765;1,18724460363341;0,202492742923774;0,542825985823186;0,485414889784642;GBP5/NLRP3/HSPA1A;3
GO:0022412;cellular process involved in reproduction in multicellular organism;3/67;52/2237;0,0576923076923077;1,92623421354765;1,18724460363341;0,202492742923774;0,542825985823186;0,485414889784642;CTNNB1/UBB/BCL2L1;3
GO:0032386;regulation of intracellular transport;3/67;52/2237;0,0576923076923077;1,92623421354765;1,18724460363341;0,202492742923774;0,542825985823186;0,485414889784642;JAK2/SAR1A/NDEL1;3
GO:0042886;amide transport;3/67;52/2237;0,0576923076923077;1,92623421354765;1,18724460363341;0,202492742923774;0,542825985823186;0,485414889784642;JAK2/NR1D1/SLC13A3;3
GO:0045766;positive regulation of angiogenesis;3/67;52/2237;0,0576923076923077;1,92623421354765;1,18724460363341;0,202492742923774;0,542825985823186;0,485414889784642;HK2/KLF4/STAT3;3
GO:0044772;mitotic cell cycle phase transition;4/67;78/2237;0,0512820512820513;1,71220818982013;1,12478982139397;0,203340952781455;0,542825985823186;0,485414889784642;SDE2/DUSP1/KLF4/NEK6;4
GO:0044089;positive regulation of cellular component biogenesis;5/67;105/2237;0,0476190476190476;1,58990760483298;1,08774846307475;0,203477577964644;0,542825985823186;0,485414889784642;GBP5/HSPA1A/CDC42EP2/NDEL1/CDC42EP4;5
GO:0007266;Rho protein signal transduction;2/67;28/2237;0,0714285714285714;2,38486140724947;1,29548057229343;0,20377469689561;0,542825985823186;0,485414889784642;CDC42EP2/CDC42EP4;2
GO:0010466;negative regulation of peptidase activity;2/67;28/2237;0,0714285714285714;2,38486140724947;1,29548057229343;0,20377469689561;0,542825985823186;0,485414889784642;KLF4/TIMP1;2
GO:0016052;carbohydrate catabolic process;2/67;28/2237;0,0714285714285714;2,38486140724947;1,29548057229343;0,20377469689561;0,542825985823186;0,485414889784642;HK2/STAT3;2
GO:0046425;regulation of receptor signaling pathway via JAK-STAT;2/67;28/2237;0,0714285714285714;2,38486140724947;1,29548057229343;0,20377469689561;0,542825985823186;0,485414889784642;GADD45A/JAK2;2
GO:0072330;monocarboxylic acid biosynthetic process;2/67;28/2237;0,0714285714285714;2,38486140724947;1,29548057229343;0,20377469689561;0,542825985823186;0,485414889784642;PTGES/NR1D1;2
GO:0098773;skin epidermis development;2/67;28/2237;0,0714285714285714;2,38486140724947;1,29548057229343;0,20377469689561;0,542825985823186;0,485414889784642;CTNNB1/KLF4;2
GO:1903050;regulation of proteolysis involved in protein catabolic process;2/67;28/2237;0,0714285714285714;2,38486140724947;1,29548057229343;0,20377469689561;0,542825985823186;0,485414889784642;HSPA1A/UBB;2
GO:0048513;animal organ development;18/67;493/2237;0,0365111561866126;1,21903666252914;0,967632545029033;0,204094640044452;0,54291467450027;0,485494198449916;HK2/ARID5A/NR4A2/CTNNB1/TIPARP/SGMS2/JAK2/KLF4/ARID5B/NDEL1/UBB/STAT3/JUNB/ZFP36/BCL2L1/TGM2/ATF4/TIMP1;18
GO:0032496;response to lipopolysaccharide;6/67;133/2237;0,0451127819548872;1,50622825721019;1,05753018000563;0,204707257734107;0,543780569633099;0,486268513610657;GBP5/NLRP3/ARID5A/JAK2/NR1D1/ZFP36;6
GO:0065009;regulation of molecular function;15/67;401/2237;0,0374064837905237;1,24892991402092;0,966621322722612;0,206975862631658;0,549036812078937;0,490968838234318;GADD45A/NLRP3/TMBIM1/DUSP1/HSPA1A/JAK2/KLF4/ARID5B/FAS/NDEL1/ADORA2B/STAT3/ZFP36/TGM2/TIMP1;15
GO:0010001;glial cell differentiation;3/67;53/2237;0,0566037735849057;1,8898901717826;1,15183815914046;0,210333498416493;0,555608990238268;0,496845920798851;CTNNB1/NR1D1/STAT3;3
GO:0048511;rhythmic process;3/67;53/2237;0,0566037735849057;1,8898901717826;1,15183815914046;0,210333498416493;0,555608990238268;0,496845920798851;NR1D1/PHLPP1/ATF4;3
GO:1904018;positive regulation of vasculature development;3/67;53/2237;0,0566037735849057;1,8898901717826;1,15183815914046;0,210333498416493;0,555608990238268;0,496845920798851;HK2/KLF4/STAT3;3
GO:0006955;immune response;17/67;465/2237;0,0365591397849462;1,220638741775;0,939117263051647;0,212637254099822;0,557508492595014;0,498544525418428;GBP5/NLRP3/ARID5A/IRF1/IRF4/HSPA1A/SH2B2/JAK2/FAS/CDC42EP2/PNP/ADORA2B/NR1D1/STAT3/CDC42EP4/JUNB/PVR;17
GO:0002237;response to molecule of bacterial origin;6/67;135/2237;0,0444444444444444;1,48391376451078;1,01897126683407;0,214344178551292;0,557508492595014;0,498544525418428;GBP5/NLRP3/ARID5A/JAK2/NR1D1/ZFP36;6
GO:0030182;neuron differentiation;9/67;222/2237;0,0405405405405405;1,35356998789835;0,975119383989712;0,214658123152654;0,557508492595014;0,498544525418428;NR4A2/CTNNB1/APBB2/JAK2/KLF4/NDEL1/UBB/STAT3/ATF4;9
GO:0009165;nucleotide biosynthetic process;2/67;29/2237;0,0689655172413793;2,30262480699949;1,24040138650004;0,21487919725151;0,557508492595014;0,498544525418428;ADSS2/PNP;2
GO:0009266;response to temperature stimulus;2/67;29/2237;0,0689655172413793;2,30262480699949;1,24040138650004;0,21487919725151;0,557508492595014;0,498544525418428;HSPA1A/TFEC;2
GO:0010212;response to ionizing radiation;2/67;29/2237;0,0689655172413793;2,30262480699949;1,24040138650004;0,21487919725151;0,557508492595014;0,498544525418428;GADD45A/BCL2L1;2
GO:0019362;pyridine nucleotide metabolic process;2/67;29/2237;0,0689655172413793;2,30262480699949;1,24040138650004;0,21487919725151;0,557508492595014;0,498544525418428;HK2/STAT3;2
GO:0042254;ribosome biogenesis;2/67;29/2237;0,0689655172413793;2,30262480699949;1,24040138650004;0,21487919725151;0,557508492595014;0,498544525418428;SDE2/SRFBP1;2
GO:0046496;nicotinamide nucleotide metabolic process;2/67;29/2237;0,0689655172413793;2,30262480699949;1,24040138650004;0,21487919725151;0,557508492595014;0,498544525418428;HK2/STAT3;2
GO:0050796;regulation of insulin secretion;2/67;29/2237;0,0689655172413793;2,30262480699949;1,24040138650004;0,21487919725151;0,557508492595014;0,498544525418428;JAK2/NR1D1;2
GO:1901293;nucleoside phosphate biosynthetic process;2/67;29/2237;0,0689655172413793;2,30262480699949;1,24040138650004;0,21487919725151;0,557508492595014;0,498544525418428;ADSS2/PNP;2
GO:1905475;regulation of protein localization to membrane;2/67;29/2237;0,0689655172413793;2,30262480699949;1,24040138650004;0,21487919725151;0,557508492595014;0,498544525418428;TMBIM1/BCL2L1;2
GO:2000377;regulation of reactive oxygen species metabolic process;2/67;29/2237;0,0689655172413793;2,30262480699949;1,24040138650004;0,21487919725151;0,557508492595014;0,498544525418428;GADD45A/HK2;2
GO:0050670;regulation of lymphocyte proliferation;4/67;80/2237;0,05;1,66940298507463;1,07115174505563;0,216025146341885;0,558950026411585;0,499833597785939;CTNNB1/IRF1/JAK2/PNP;4
GO:0070482;response to oxygen levels;4/67;80/2237;0,05;1,66940298507463;1,07115174505563;0,216025146341885;0,558950026411585;0,499833597785939;HK2/NR4A2/FAS/ATF4;4
GO:0032880;regulation of protein localization;7/67;164/2237;0,0426829268292683;1,42510010921005;0,993474955707818;0,216320152777028;0,558950026411585;0,499833597785939;TMBIM1/CTNNB1/JAK2/SAR1A/NDEL1/NR1D1/BCL2L1;7
GO:0042127;regulation of cell population proliferation;14/67;374/2237;0,0374331550802139;1,24982041663341;0,930038090879022;0,218063642154756;0,560857751896455;0,501539555828042;CTNNB1/IRF1/DUSP1/HSPA1A/JAK2/KLF4/PTGES/PNP/NR1D1/STAT3/JUNB/ZFP36/BCL2L1/TIMP1;14
GO:0007259;receptor signaling pathway via JAK-STAT;3/67;54/2237;0,0555555555555556;1,85489220563847;1,11718424782995;0,218242958367311;0,560857751896455;0,501539555828042;GADD45A/JAK2/STAT3;3
GO:0034976;response to endoplasmic reticulum stress;3/67;54/2237;0,0555555555555556;1,85489220563847;1,11718424782995;0,218242958367311;0,560857751896455;0,501539555828042;HSPA1A/BCL2L1/ATF4;3
GO:0042391;regulation of membrane potential;3/67;54/2237;0,0555555555555556;1,85489220563847;1,11718424782995;0,218242958367311;0,560857751896455;0,501539555828042;GLRX/UBB/BCL2L1;3
GO:0051128;regulation of cellular component organization;16/67;436/2237;0,036697247706422;1,22524989730248;0,92086172863924;0,218558367378332;0,560907246361192;0,501583815592263;GBP5/SERTAD2/INO80D/CTNNB1/CCNL1/DUSP1/HSPA1A/KLF4/NEK6/SAR1A/CDC42EP2/NDEL1/CDC42EP4/H3-3B/BCL2L1/TGM2;16
GO:0001944;vasculature development;7/67;165/2237;0,0424242424242424;1,4164631388512;0,976488422725603;0,220767100018451;0,565809049303039;0,505967187422103;GADD45A/HK2/CTNNB1/TIPARP/KLF4/STAT3/JUNB;7
GO:0010629;negative regulation of gene expression;9/67;224/2237;0,0401785714285714;1,34148454157783;0,946491252266617;0,222328207654245;0,56598780908379;0,506127040969164;TENT5C/NLRP3/CTNNB1/TIPARP/HSPA1A/KLF4/STAT3/ZFP36/ATF4;9
GO:0007162;negative regulation of cell adhesion;4/67;81/2237;0,0493827160493827;1,64879307167864;1,04488325343958;0,222450946579227;0,56598780908379;0,506127040969164;IRF1/DUSP1/JAK2/KLF4;4
GO:0044093;positive regulation of molecular function;10/67;254/2237;0,0393700787401575;1,31449053942884;0,935204355272019;0,223031219330979;0,56598780908379;0,506127040969164;NLRP3/HSPA1A/JAK2/KLF4/ARID5B/FAS/NDEL1/ADORA2B/STAT3/TGM2;10
GO:0009888;tissue development;14/67;376/2237;0,0372340425531915;1,24317243569387;0,908193762385476;0,224163136231356;0,56598780908379;0,506127040969164;ARID5A/CTNNB1/TIPARP/SGMS2/DUSP1/JAK2/KLF4/ARID5B/UBB/JUNB/ZFP36/TGM2/ATF4/TIMP1;14
GO:0019953;sexual reproduction;5/67;109/2237;0,0458715596330275;1,5315623716281;0,999597362638562;0,225365969108925;0,56598780908379;0,506127040969164;CTNNB1/DUSP1/UBB/STAT3/BCL2L1;5
GO:0002065;columnar/cuboidal epithelial cell differentiation;2/67;30/2237;0,0666666666666667;2,22587064676617;1,18753806941641;0,226041713161483;0,56598780908379;0,506127040969164;CTNNB1/KLF4;2
GO:0006260;DNA replication;2/67;30/2237;0,0666666666666667;2,22587064676617;1,18753806941641;0,226041713161483;0,56598780908379;0,506127040969164;SDE2/INO80D;2
GO:0007498;mesoderm development;2/67;30/2237;0,0666666666666667;2,22587064676617;1,18753806941641;0,226041713161483;0,56598780908379;0,506127040969164;JAK2/KLF4;2
GO:0009267;cellular response to starvation;2/67;30/2237;0,0666666666666667;2,22587064676617;1,18753806941641;0,226041713161483;0,56598780908379;0,506127040969164;FAS/ATF4;2
GO:0014013;regulation of gliogenesis;2/67;30/2237;0,0666666666666667;2,22587064676617;1,18753806941641;0,226041713161483;0,56598780908379;0,506127040969164;CTNNB1/NR1D1;2
GO:0021543;pallium development;2/67;30/2237;0,0666666666666667;2,22587064676617;1,18753806941641;0,226041713161483;0,56598780908379;0,506127040969164;CTNNB1/NDEL1;2
GO:0032729;positive regulation of type II interferon production;2/67;30/2237;0,0666666666666667;2,22587064676617;1,18753806941641;0,226041713161483;0,56598780908379;0,506127040969164;ARID5A/JAK2;2
GO:0032886;regulation of microtubule-based process;2/67;30/2237;0,0666666666666667;2,22587064676617;1,18753806941641;0,226041713161483;0,56598780908379;0,506127040969164;CCNL1/HSPA1A;2
GO:0039531;regulation of cytoplasmic pattern recognition receptor signaling pathway;2/67;30/2237;0,0666666666666667;2,22587064676617;1,18753806941641;0,226041713161483;0,56598780908379;0,506127040969164;GBP5/HSPA1A;2
GO:0043534;blood vessel endothelial cell migration;2/67;30/2237;0,0666666666666667;2,22587064676617;1,18753806941641;0,226041713161483;0,56598780908379;0,506127040969164;GADD45A/KLF4;2
GO:0050768;negative regulation of neurogenesis;2/67;30/2237;0,0666666666666667;2,22587064676617;1,18753806941641;0,226041713161483;0,56598780908379;0,506127040969164;CTNNB1/NR1D1;2
GO:0031396;regulation of protein ubiquitination;3/67;55/2237;0,0545454545454545;1,82116689280868;1,08325034780177;0,226215824433172;0,56598780908379;0,506127040969164;CTNNB1/HSPA1A/UBB;3
GO:0032946;positive regulation of mononuclear cell proliferation;3/67;55/2237;0,0545454545454545;1,82116689280868;1,08325034780177;0,226215824433172;0,56598780908379;0,506127040969164;JAK2/PNP/BCL2L1;3
GO:0007264;small GTPase-mediated signal transduction;5/67;110/2237;0,0454545454545455;1,51763907734057;0,978099610797147;0,230951001406028;0,577072818816645;0,516039662911122;SH2B2/CDC42EP2/ARHGAP23/CDC42EP4/TGM2;5
GO:0097696;receptor signaling pathway via STAT;3/67;56/2237;0,0535714285714286;1,7886460554371;1,05000592615073;0,234246877543632;0,582594774260041;0,520977597834939;GADD45A/JAK2/STAT3;3
GO:0010035;response to inorganic substance;5/67;111/2237;0,045045045045045;1,50396665322038;0,956808652584105;0,236577847997856;0,582594774260041;0,520977597834939;ADSS2/KLF4/JUNB/OSER1/ATF4;5
GO:0032103;positive regulation of response to external stimulus;8/67;198/2237;0,0404040404040404;1,34901251319162;0,903666981840465;0,236993549622875;0,582594774260041;0,520977597834939;GBP5/NLRP3/IRF1/IRF4/HSPA1A/ADORA2B/NR1D1/PVR;8
GO:0006986;response to unfolded protein;2/67;31/2237;0,0645161290322581;2,15406836783823;1,13671885658775;0,237249051448357;0,582594774260041;0,520977597834939;HSPA1A/ATF4;2
GO:0019318;hexose metabolic process;2/67;31/2237;0,0645161290322581;2,15406836783823;1,13671885658775;0,237249051448357;0,582594774260041;0,520977597834939;HK2/ATF4;2
GO:0035264;multicellular organism growth;2/67;31/2237;0,0645161290322581;2,15406836783823;1,13671885658775;0,237249051448357;0,582594774260041;0,520977597834939;ARID5B/STAT3;2
GO:0042116;macrophage activation;2/67;31/2237;0,0645161290322581;2,15406836783823;1,13671885658775;0,237249051448357;0,582594774260041;0,520977597834939;JAK2/NR1D1;2
GO:0043488;regulation of mRNA stability;2/67;31/2237;0,0645161290322581;2,15406836783823;1,13671885658775;0,237249051448357;0,582594774260041;0,520977597834939;TENT5C/ZFP36;2
GO:0051321;meiotic cell cycle;2/67;31/2237;0,0645161290322581;2,15406836783823;1,13671885658775;0,237249051448357;0,582594774260041;0,520977597834939;DUSP1/UBB;2
GO:0051384;response to glucocorticoid;2/67;31/2237;0,0645161290322581;2,15406836783823;1,13671885658775;0,237249051448357;0,582594774260041;0,520977597834939;JAK2/ZFP36;2
GO:0051961;negative regulation of nervous system development;2/67;31/2237;0,0645161290322581;2,15406836783823;1,13671885658775;0,237249051448357;0,582594774260041;0,520977597834939;CTNNB1/NR1D1;2
GO:1904892;regulation of receptor signaling pathway via STAT;2/67;31/2237;0,0645161290322581;2,15406836783823;1,13671885658775;0,237249051448357;0,582594774260041;0,520977597834939;GADD45A/JAK2;2
GO:2000628;regulation of miRNA metabolic process;2/67;31/2237;0,0645161290322581;2,15406836783823;1,13671885658775;0,237249051448357;0,582594774260041;0,520977597834939;KLF4/STAT3;2
GO:0006954;inflammatory response;10/67;258/2237;0,0387596899224806;1,29411084114312;0,882351083098443;0,237817591867252;0,582594774260041;0,520977597834939;GBP5/NLRP3/JAK2/KLF4/PTGES/ADORA2B/NR1D1/STAT3/ZFP36/TIMP1;10
GO:0045321;leukocyte activation;10/67;258/2237;0,0387596899224806;1,29411084114312;0,882351083098443;0,237817591867252;0,582594774260041;0,520977597834939;NLRP3/CTNNB1/IRF1/IRF4/JAK2/PNP/ADORA2B/NR1D1/STAT3/JUNB;10
GO:0048699;generation of neurons;9/67;230/2237;0,0391304347826087;1,3064892926671;0,862082784877473;0,245983249488516;0,582594774260041;0,520977597834939;NR4A2/CTNNB1/APBB2/JAK2/KLF4/NDEL1/UBB/STAT3/ATF4;9
GO:0002720;positive regulation of cytokine production involved in immune response;2/67;32/2237;0,0625;2,08675373134328;1,08779051158345;0,248488734878973;0,582594774260041;0,520977597834939;NLRP3/ARID5A;2
GO:0030073;insulin secretion;2/67;32/2237;0,0625;2,08675373134328;1,08779051158345;0,248488734878973;0,582594774260041;0,520977597834939;JAK2/NR1D1;2
GO:0035966;response to topologically incorrect protein;2/67;32/2237;0,0625;2,08675373134328;1,08779051158345;0,248488734878973;0,582594774260041;0,520977597834939;HSPA1A/ATF4;2
GO:0045667;regulation of osteoblast differentiation;2/67;32/2237;0,0625;2,08675373134328;1,08779051158345;0,248488734878973;0,582594774260041;0,520977597834939;CTNNB1/ATF4;2
GO:0071248;cellular response to metal ion;2/67;32/2237;0,0625;2,08675373134328;1,08779051158345;0,248488734878973;0,582594774260041;0,520977597834939;JUNB/ATF4;2
GO:0007423;sensory organ development;4/67;85/2237;0,0470588235294118;1,571202809482;0,94323975815262;0,248648464451024;0,582594774260041;0,520977597834939;CTNNB1/KLF4/STAT3/ATF4;4
GO:0045596;negative regulation of cell differentiation;6/67;142/2237;0,0422535211267606;1,41076308597856;0,888560494467744;0,24928257496761;0,582594774260041;0,520977597834939;TENT5C/CTNNB1/IRF1/NR1D1/STAT3/ZFP36;6
GO:0007167;enzyme-linked receptor protein signaling pathway;8/67;201/2237;0,0398009950248756;1,32887799806935;0,858593104117303;0,249825970534484;0,582594774260041;0,520977597834939;CTNNB1/TIPARP/HSPA1A/SH2B2/JAK2/ARID5B/NDEL1/STAT3;8
GO:0006401;RNA catabolic process;3/67;58/2237;0,0517241379310345;1,72696860524961;0,985472413677964;0,250463093682261;0,582594774260041;0,520977597834939;TENT5C/HSPA1A/ZFP36;3
GO:0070647;protein modification by small protein conjugation or removal;7/67;172/2237;0,0406976744186047;1,35881638320028;0,860438617439922;0,252805641929384;0,582594774260041;0,520977597834939;SDE2/RNF149/CTNNB1/FEM1C/HSPA1A/UBC/UBB;7
GO:0065008;regulation of biological quality;16/67;448/2237;0,0357142857142857;1,19243070362473;0,800113574541045;0,253950178850858;0,582594774260041;0,520977597834939;TENT5C/HK2/RNF149/CTNNB1/TIPARP/GLRX/HSPA1A/JAK2/CDC42EP2/ADORA2B/UBB/NR1D1/CDC42EP4/ZFP36/BCL2L1/ATF4;16
GO:0002252;immune effector process;7/67;173/2237;0,0404624277456647;1,35096195323958;0,844251182381441;0,257502298670742;0,582594774260041;0,520977597834939;NLRP3/ARID5A/IRF4/ADORA2B/STAT3/JUNB/PVR;7
GO:0008283;cell population proliferation;15/67;418/2237;0,0358851674641148;1,19813611368992;0,789185079378185;0,258208787965225;0,582594774260041;0,520977597834939;CTNNB1/IRF1/DUSP1/HSPA1A/JAK2/KLF4/PTGES/PNP/NDEL1/NR1D1/STAT3/JUNB/ZFP36/BCL2L1/TIMP1;15
GO:0002791;regulation of peptide secretion;2/67;33/2237;0,0606060606060606;2,02351876978743;1,04061581106373;0,259748972189025;0,582594774260041;0,520977597834939;JAK2/NR1D1;2
GO:0010586;miRNA metabolic process;2/67;33/2237;0,0606060606060606;2,02351876978743;1,04061581106373;0,259748972189025;0,582594774260041;0,520977597834939;KLF4/STAT3;2
GO:0016051;carbohydrate biosynthetic process;2/67;33/2237;0,0606060606060606;2,02351876978743;1,04061581106373;0,259748972189025;0,582594774260041;0,520977597834939;NR1D1/ATF4;2
GO:0045639;positive regulation of myeloid cell differentiation;2/67;33/2237;0,0606060606060606;2,02351876978743;1,04061581106373;0,259748972189025;0,582594774260041;0,520977597834939;HSPA1A/STAT3;2
GO:0051259;protein complex oligomerization;2/67;33/2237;0,0606060606060606;2,02351876978743;1,04061581106373;0,259748972189025;0,582594774260041;0,520977597834939;GBP5/NLRP3;2
GO:0090087;regulation of peptide transport;2/67;33/2237;0,0606060606060606;2,02351876978743;1,04061581106373;0,259748972189025;0,582594774260041;0,520977597834939;JAK2/NR1D1;2
GO:0090276;regulation of peptide hormone secretion;2/67;33/2237;0,0606060606060606;2,02351876978743;1,04061581106373;0,259748972189025;0,582594774260041;0,520977597834939;JAK2/NR1D1;2
GO:1902106;negative regulation of leukocyte differentiation;2/67;33/2237;0,0606060606060606;2,02351876978743;1,04061581106373;0,259748972189025;0,582594774260041;0,520977597834939;CTNNB1/IRF1;2
GO:1990138;neuron projection extension;2/67;33/2237;0,0606060606060606;2,02351876978743;1,04061581106373;0,259748972189025;0,582594774260041;0,520977597834939;CTNNB1/NDEL1;2
GO:1901566;organonitrogen compound biosynthetic process;9/67;234/2237;0,0384615384615385;1,2841561423651;0,806989597256088;0,262248677796891;0,582594774260041;0,520977597834939;ADSS2/NR4A2/CTNNB1/SGMS2/AZIN1/KLF4/PNP/ZFP36/ATF4;9
GO:0001658;branching involved in ureteric bud morphogenesis;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0001825;blastocyst formation;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;JUNB;1
GO:0001916;positive regulation of T cell mediated cytotoxicity;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;PVR;1
GO:0002279;mast cell activation involved in immune response;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;ADORA2B;1
GO:0002544;chronic inflammatory response;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;ADORA2B;1
GO:0002643;regulation of tolerance induction;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;PHLPP1;1
GO:0006360;transcription by RNA polymerase I;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;ATF4;1
GO:0006636;unsaturated fatty acid biosynthetic process;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;PTGES;1
GO:0007431;salivary gland development;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;TGM2;1
GO:0007435;salivary gland morphogenesis;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;TGM2;1
GO:0008344;adult locomotory behavior;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;NR4A2;1
GO:0009994;oocyte differentiation;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0010464;regulation of mesenchymal cell proliferation;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0010662;regulation of striated muscle cell apoptotic process;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;JAK2;1
GO:0015844;monoamine transport;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;TGM2;1
GO:0031648;protein destabilization;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;NR1D1;1
GO:0032309;icosanoid secretion;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;PTGES;1
GO:0033687;osteoblast proliferation;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;JUNB;1
GO:0034112;positive regulation of homotypic cell-cell adhesion;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;JAK2;1
GO:0035458;cellular response to interferon-beta;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;IRF1;1
GO:0035773;insulin secretion involved in cellular response to glucose stimulus;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;NR1D1;1
GO:0036037;CD8-positive, alpha-beta T cell activation;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;IRF1;1
GO:0042274;ribosomal small subunit biogenesis;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;SRFBP1;1
GO:0042551;neuron maturation;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;NR4A2;1
GO:0043300;regulation of leukocyte degranulation;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;ADORA2B;1
GO:0043303;mast cell degranulation;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;ADORA2B;1
GO:0045066;regulatory T cell differentiation;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;IRF1;1
GO:0045103;intermediate filament-based process;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;NDEL1;1
GO:0045104;intermediate filament cytoskeleton organization;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;NDEL1;1
GO:0045601;regulation of endothelial cell differentiation;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0045739;positive regulation of DNA repair;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;INO80D;1
GO:0045747;positive regulation of Notch signaling pathway;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;STAT3;1
GO:0046641;positive regulation of alpha-beta T cell proliferation;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;JAK2;1
GO:0048538;thymus development;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0048599;oocyte development;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0048713;regulation of oligodendrocyte differentiation;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0060135;maternal process involved in female pregnancy;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;JUNB;1
GO:0060218;hematopoietic stem cell differentiation;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;ZFP36;1
GO:0061178;regulation of insulin secretion involved in cellular response to glucose stimulus;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;NR1D1;1
GO:0070306;lens fiber cell differentiation;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;ATF4;1
GO:0070431;nucleotide-binding oligomerization domain containing 2 signaling pathway;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;HSPA1A;1
GO:0070918;regulatory ncRNA processing;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;STAT3;1
GO:0071676;negative regulation of mononuclear cell migration;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;DUSP1;1
GO:0090330;regulation of platelet aggregation;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;JAK2;1
GO:0097396;response to interleukin-17;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;STAT3;1
GO:0097398;cellular response to interleukin-17;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;STAT3;1
GO:1903670;regulation of sprouting angiogenesis;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;KLF4;1
GO:2000191;regulation of fatty acid transport;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;PTGES;1
GO:2000772;regulation of cellular senescence;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;NEK6;1
GO:2001222;regulation of neuron migration;1/67;10/2237;0,1;3,33880597014925;1,30219948508997;0,262661384402615;0,582594774260041;0,520977597834939;STAT3;1
GO:0098542;defense response to other organism;12/67;327/2237;0,036697247706422;1,22524989730248;0,77439979330736;0,266373059303634;0,582594774260041;0,520977597834939;GBP5/NLRP3/ARID5A/IRF1/IRF4/HSPA1A/JAK2/CDC42EP2/NR1D1/CDC42EP4/PVR/BCL2L1;12
GO:0043588;skin development;3/67;60/2237;0,05;1,66940298507463;0,923373676164284;0,266851612659955;0,582594774260041;0,520977597834939;CTNNB1/KLF4/ZFP36;3
GO:0070665;positive regulation of leukocyte proliferation;3/67;60/2237;0,05;1,66940298507463;0,923373676164284;0,266851612659955;0,582594774260041;0,520977597834939;JAK2/PNP/BCL2L1;3
GO:0002521;leukocyte differentiation;7/67;175/2237;0,04;1,3355223880597;0,812156327233763;0,266976639509563;0,582594774260041;0,520977597834939;NLRP3/CTNNB1/IRF1/IRF4/PNP/STAT3/JUNB;7
GO:0001776;leukocyte homeostasis;2/67;34/2237;0,0588235294117647;1,9640035118525;0,995071436518168;0,271018629218922;0,582594774260041;0,520977597834939;SH2B2/FAS;2
GO:0005996;monosaccharide metabolic process;2/67;34/2237;0,0588235294117647;1,9640035118525;0,995071436518168;0,271018629218922;0,582594774260041;0,520977597834939;HK2/ATF4;2
GO:0030282;bone mineralization;2/67;34/2237;0,0588235294117647;1,9640035118525;0,995071436518168;0,271018629218922;0,582594774260041;0,520977597834939;SGMS2/ATF4;2
GO:0030316;osteoclast differentiation;2/67;34/2237;0,0588235294117647;1,9640035118525;0,995071436518168;0,271018629218922;0,582594774260041;0,520977597834939;CTNNB1/JUNB;2
GO:0031960;response to corticosteroid;2/67;34/2237;0,0588235294117647;1,9640035118525;0,995071436518168;0,271018629218922;0,582594774260041;0,520977597834939;JAK2/ZFP36;2
GO:0140888;interferon-mediated signaling pathway;2/67;34/2237;0,0588235294117647;1,9640035118525;0,995071436518168;0,271018629218922;0,582594774260041;0,520977597834939;IRF1/JAK2;2
GO:1903707;negative regulation of hemopoiesis;2/67;34/2237;0,0588235294117647;1,9640035118525;0,995071436518168;0,271018629218922;0,582594774260041;0,520977597834939;CTNNB1/IRF1;2
GO:0009967;positive regulation of signal transduction;13/67;360/2237;0,0361111111111111;1,20567993366501;0,748435659894033;0,273121429857641;0,582594774260041;0,520977597834939;GADD45A/GBP5/MCL1/NLRP3/CTNNB1/HSPA1A/JAK2/NEK6/FAS/ADORA2B/UBB/STAT3/TGM2;13
GO:0001822;kidney development;3/67;61/2237;0,0491803278688525;1,64203572302422;0,893178167940264;0,275098403690455;0,582594774260041;0,520977597834939;CTNNB1/TIPARP/ARID5B;3
GO:0022408;negative regulation of cell-cell adhesion;3/67;61/2237;0,0491803278688525;1,64203572302422;0,893178167940264;0,275098403690455;0,582594774260041;0,520977597834939;IRF1/JAK2/KLF4;3
GO:0051056;regulation of small GTPase mediated signal transduction;3/67;61/2237;0,0491803278688525;1,64203572302422;0,893178167940264;0,275098403690455;0,582594774260041;0,520977597834939;SH2B2/ARHGAP23/TGM2;3
GO:0007268;chemical synaptic transmission;4/67;89/2237;0,0449438202247191;1,50058695287607;0,846643980502288;0,275506947681266;0,582594774260041;0,520977597834939;CTNNB1/JAK2/ADORA2B/ATF4;4
GO:0050678;regulation of epithelial cell proliferation;4/67;89/2237;0,0449438202247191;1,50058695287607;0,846643980502288;0,275506947681266;0,582594774260041;0,520977597834939;CTNNB1/NR1D1/STAT3/ZFP36;4
GO:0098916;anterograde trans-synaptic signaling;4/67;89/2237;0,0449438202247191;1,50058695287607;0,846643980502288;0,275506947681266;0,582594774260041;0,520977597834939;CTNNB1/JAK2/ADORA2B/ATF4;4
GO:1903037;regulation of leukocyte cell-cell adhesion;5/67;118/2237;0,0423728813559322;1,41474829243612;0,813211601909879;0,276993824116973;0,582594774260041;0,520977597834939;NLRP3/IRF1/JAK2/KLF4/PNP;5
GO:0006469;negative regulation of protein kinase activity;2/67;35/2237;0,0571428571428571;1,90788912579957;0,951046197011163;0,282287201122487;0,582594774260041;0,520977597834939;GADD45A/DUSP1;2
GO:0032388;positive regulation of intracellular transport;2/67;35/2237;0,0571428571428571;1,90788912579957;0,951046197011163;0,282287201122487;0,582594774260041;0,520977597834939;JAK2/SAR1A;2
GO:0043409;negative regulation of MAPK cascade;2/67;35/2237;0,0571428571428571;1,90788912579957;0,951046197011163;0,282287201122487;0,582594774260041;0,520977597834939;RNF149/DUSP1;2
GO:0043487;regulation of RNA stability;2/67;35/2237;0,0571428571428571;1,90788912579957;0,951046197011163;0,282287201122487;0,582594774260041;0,520977597834939;TENT5C/ZFP36;2
GO:0045598;regulation of fat cell differentiation;2/67;35/2237;0,0571428571428571;1,90788912579957;0,951046197011163;0,282287201122487;0,582594774260041;0,520977597834939;NR1D1/ZFP36;2
GO:0061013;regulation of mRNA catabolic process;2/67;35/2237;0,0571428571428571;1,90788912579957;0,951046197011163;0,282287201122487;0,582594774260041;0,520977597834939;TENT5C/ZFP36;2
GO:0010608;post-transcriptional regulation of gene expression;4/67;90/2237;0,0444444444444444;1,48391376451078;0,823221381757765;0,282304817685738;0,582594774260041;0,520977597834939;TENT5C/STAT3/ZFP36/ATF4;4
GO:0072001;renal system development;3/67;62/2237;0,0483870967741935;1,61555127587867;0,863522949179549;0,283373972157253;0,582594774260041;0,520977597834939;CTNNB1/TIPARP/ARID5B;3
GO:1903532;positive regulation of secretion by cell;3/67;62/2237;0,0483870967741935;1,61555127587867;0,863522949179549;0,283373972157253;0,582594774260041;0,520977597834939;JAK2/PTGES/ADORA2B;3
GO:0051247;positive regulation of protein metabolic process;10/67;270/2237;0,037037037037037;1,23659480375898;0,728330233682498;0,28431907109255;0,582594774260041;0,520977597834939;NLRP3/ARID5A/CTNNB1/TIPARP/HSPA1A/JAK2/KLF4/FAS/UBB/STAT3;10
GO:0002717;positive regulation of natural killer cell mediated immunity;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;PVR;1
GO:0002827;positive regulation of T-helper 1 type immune response;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;ARID5A;1
GO:0006513;protein monoubiquitination;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;UBB;1
GO:0007156;homophilic cell adhesion via plasma membrane adhesion molecules;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;PVR;1
GO:0009116;nucleoside metabolic process;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;PNP;1
GO:0010463;mesenchymal cell proliferation;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0010559;regulation of glycoprotein biosynthetic process;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0010656;negative regulation of muscle cell apoptotic process;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;JAK2;1
GO:0010659;cardiac muscle cell apoptotic process;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;JAK2;1
GO:0014002;astrocyte development;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;NR1D1;1
GO:0015732;prostaglandin transport;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;PTGES;1
GO:0021872;forebrain generation of neurons;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;UBB;1
GO:0030850;prostate gland development;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0031529;ruffle organization;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;NDEL1;1
GO:0032465;regulation of cytokinesis;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;BCL2L1;1
GO:0032507;maintenance of protein location in cell;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;HK2;1
GO:0032735;positive regulation of interleukin-12 production;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;IRF1;1
GO:0032816;positive regulation of natural killer cell activation;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;JAK2;1
GO:0033559;unsaturated fatty acid metabolic process;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;PTGES;1
GO:0034405;response to fluid shear stress;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;KLF4;1
GO:0042311;vasodilation;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;ADORA2B;1
GO:0042733;embryonic digit morphogenesis;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0043407;negative regulation of MAP kinase activity;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;DUSP1;1
GO:0043616;keratinocyte proliferation;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;ZFP36;1
GO:0045064;T-helper 2 cell differentiation;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;NLRP3;1
GO:0045954;positive regulation of natural killer cell mediated cytotoxicity;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;PVR;1
GO:0046324;regulation of glucose import;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;HK2;1
GO:0046677;response to antibiotic;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;JAK2;1
GO:0048710;regulation of astrocyte differentiation;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;NR1D1;1
GO:0050982;detection of mechanical stimulus;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0051262;protein tetramerization;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;GBP5;1
GO:0051303;establishment of chromosome localization;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;NDEL1;1
GO:0060425;lung morphogenesis;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0060675;ureteric bud morphogenesis;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0061333;renal tubule morphogenesis;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0070169;positive regulation of biomineral tissue development;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;ATF4;1
GO:0071470;cellular response to osmotic stress;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;NLRP3;1
GO:0072078;nephron tubule morphogenesis;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0072171;mesonephric tubule morphogenesis;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0170041;non-proteinogenic amino acid metabolic process;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;AZIN1;1
GO:1904888;cranial skeletal system development;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;CTNNB1;1
GO:1904994;regulation of leukocyte adhesion to vascular endothelial cell;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;KLF4;1
GO:2000179;positive regulation of neural precursor cell proliferation;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;CTNNB1;1
GO:2000273;positive regulation of signaling receptor activity;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;JAK2;1
GO:2000319;regulation of T-helper 17 cell differentiation;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;JUNB;1
GO:2000648;positive regulation of stem cell proliferation;1/67;11/2237;0,0909090909090909;3,03527815468114;1,18877857084484;0,284844450071687;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0099537;trans-synaptic signaling;4/67;91/2237;0,043956043956044;1,46760701984583;0,800074251083867;0,289130746932314;0,582594774260041;0,520977597834939;CTNNB1/JAK2/ADORA2B/ATF4;4
GO:0048666;neuron development;7/67;180/2237;0,0388888888888889;1,29842454394693;0,733494867998142;0,291093228020196;0,582594774260041;0,520977597834939;NR4A2/CTNNB1/APBB2/JAK2/KLF4/NDEL1/UBB;7
GO:0031346;positive regulation of cell projection organization;3/67;63/2237;0,0476190476190476;1,58990760483298;0,834387777708822;0,291673764893433;0,582594774260041;0,520977597834939;CDC42EP2/NDEL1/CDC42EP4;3
GO:0033002;muscle cell proliferation;3/67;63/2237;0,0476190476190476;1,58990760483298;0,834387777708822;0,291673764893433;0,582594774260041;0,520977597834939;CTNNB1/JAK2/KLF4;3
GO:0060070;canonical Wnt signaling pathway;3/67;63/2237;0,0476190476190476;1,58990760483298;0,834387777708822;0,291673764893433;0,582594774260041;0,520977597834939;NR4A2/CTNNB1/KLF4;3
GO:1902903;regulation of supramolecular fiber organization;3/67;63/2237;0,0476190476190476;1,58990760483298;0,834387777708822;0,291673764893433;0,582594774260041;0,520977597834939;HSPA1A/CDC42EP2/CDC42EP4;3
GO:0002526;acute inflammatory response;2/67;36/2237;0,0555555555555556;1,85489220563847;0,908439523082864;0,293544785611551;0,582594774260041;0,520977597834939;NLRP3/PTGES;2
GO:0032642;regulation of chemokine production;2/67;36/2237;0,0555555555555556;1,85489220563847;0,908439523082864;0,293544785611551;0,582594774260041;0,520977597834939;KLF4/ADORA2B;2
GO:0032869;cellular response to insulin stimulus;2/67;36/2237;0,0555555555555556;1,85489220563847;0,908439523082864;0,293544785611551;0,582594774260041;0,520977597834939;SH2B2/NDEL1;2
GO:0043433;negative regulation of DNA-binding transcription factor activity;2/67;36/2237;0,0555555555555556;1,85489220563847;0,908439523082864;0,293544785611551;0,582594774260041;0,520977597834939;NLRP3/KLF4;2
GO:0071241;cellular response to inorganic substance;2/67;36/2237;0,0555555555555556;1,85489220563847;0,908439523082864;0,293544785611551;0,582594774260041;0,520977597834939;JUNB/ATF4;2
GO:2000045;regulation of G1/S transition of mitotic cell cycle;2/67;36/2237;0,0555555555555556;1,85489220563847;0,908439523082864;0,293544785611551;0,582594774260041;0,520977597834939;SDE2/KLF4;2
GO:0001525;angiogenesis;5/67;121/2237;0,0413223140495868;1,37967188849143;0,754374031697288;0,29477201320531;0,582594774260041;0,520977597834939;GADD45A/HK2/CTNNB1/KLF4/STAT3;5
GO:0120036;plasma membrane bounded cell projection organization;9/67;242/2237;0,0371900826446281;1,24170469964228;0,699463025064977;0,295808873816588;0,582594774260041;0,520977597834939;NR4A2/CTNNB1/APBB2/JAK2/KLF4/CDC42EP2/NDEL1/UBB/CDC42EP4;9
GO:0046649;lymphocyte activation;8/67;212/2237;0,0377358490566038;1,2599267811884;0,698795145742152;0,298742947438529;0,582594774260041;0,520977597834939;NLRP3/CTNNB1/IRF1/IRF4/JAK2/PNP/STAT3/JUNB;8
GO:0008544;epidermis development;3/67;64/2237;0,046875;1,56506529850746;0,805753490089369;0,299993334836428;0,582594774260041;0,520977597834939;CTNNB1/KLF4/ZFP36;3
GO:0043491;phosphatidylinositol 3-kinase/protein kinase B signal transduction;3/67;64/2237;0,046875;1,56506529850746;0,805753490089369;0,299993334836428;0,582594774260041;0,520977597834939;JAK2/STAT3/PHLPP1;3
GO:0050804;modulation of chemical synaptic transmission;3/67;64/2237;0,046875;1,56506529850746;0,805753490089369;0,299993334836428;0,582594774260041;0,520977597834939;JAK2/ADORA2B/ATF4;3
GO:0099177;regulation of trans-synaptic signaling;3/67;64/2237;0,046875;1,56506529850746;0,805753490089369;0,299993334836428;0,582594774260041;0,520977597834939;JAK2/ADORA2B/ATF4;3
GO:0019725;cellular homeostasis;5/67;122/2237;0,040983606557377;1,36836310252019;0,735096382693367;0,300746575286478;0,582594774260041;0,520977597834939;MCL1/HK2/NR1D1/TGM2/ATF4;5
GO:0001503;ossification;4/67;93/2237;0,043010752688172;1,43604557855882;0,754578462047124;0,302856503156621;0,582594774260041;0,520977597834939;CTNNB1/SGMS2/JUNB/ATF4;4
GO:0001667;ameboidal-type cell migration;4/67;93/2237;0,043010752688172;1,43604557855882;0,754578462047124;0,302856503156621;0,582594774260041;0,520977597834939;GADD45A/KLF4/ARID5B/TIMP1;4
GO:0031400;negative regulation of protein modification process;4/67;93/2237;0,043010752688172;1,43604557855882;0,754578462047124;0,302856503156621;0,582594774260041;0,520977597834939;GADD45A/CTNNB1/DUSP1/HSPA1A;4
GO:0046651;lymphocyte proliferation;4/67;93/2237;0,043010752688172;1,43604557855882;0,754578462047124;0,302856503156621;0,582594774260041;0,520977597834939;CTNNB1/IRF1/JAK2/PNP;4
GO:0007565;female pregnancy;2/67;37/2237;0,0540540540540541;1,80475998386446;0,867160184119965;0,304782057200711;0,582594774260041;0,520977597834939;JUNB/TIMP1;2
GO:0030856;regulation of epithelial cell differentiation;2/67;37/2237;0,0540540540540541;1,80475998386446;0,867160184119965;0,304782057200711;0,582594774260041;0,520977597834939;CTNNB1/ZFP36;2
GO:0032602;chemokine production;2/67;37/2237;0,0540540540540541;1,80475998386446;0,867160184119965;0,304782057200711;0,582594774260041;0,520977597834939;KLF4/ADORA2B;2
GO:0046328;regulation of JNK cascade;2/67;37/2237;0,0540540540540541;1,80475998386446;0,867160184119965;0,304782057200711;0,582594774260041;0,520977597834939;GADD45A/PHLPP1;2
GO:0048469;cell maturation;2/67;37/2237;0,0540540540540541;1,80475998386446;0,867160184119965;0,304782057200711;0,582594774260041;0,520977597834939;NR4A2/CTNNB1;2
GO:1901617;organic hydroxy compound biosynthetic process;2/67;37/2237;0,0540540540540541;1,80475998386446;0,867160184119965;0,304782057200711;0,582594774260041;0,520977597834939;NR4A2/NR1D1;2
GO:0000271;polysaccharide biosynthetic process;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;NR1D1;1
GO:0000288;nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;ZFP36;1
GO:0000422;autophagy of mitochondrion;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;HK2;1
GO:0001655;urogenital system development;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0001708;cell fate specification;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0001974;blood vessel remodeling;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;TMBIM1;1
GO:0002448;mast cell mediated immunity;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;ADORA2B;1
GO:0002828;regulation of type 2 immune response;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;NLRP3;1
GO:0005977;glycogen metabolic process;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;NR1D1;1
GO:0006919;activation of cysteine-type endopeptidase activity involved in apoptotic process;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;JAK2;1
GO:0006998;nuclear envelope organization;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;NEK6;1
GO:0007200;phospholipase C-activating G protein-coupled receptor signaling pathway;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;TGM2;1
GO:0007405;neuroblast proliferation;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0007585;respiratory gaseous exchange by respiratory system;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;NR4A2;1
GO:0007631;feeding behavior;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;STAT3;1
GO:0008543;fibroblast growth factor receptor signaling pathway;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0010658;striated muscle cell apoptotic process;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;JAK2;1
GO:0030858;positive regulation of epithelial cell differentiation;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0031098;stress-activated protein kinase signaling cascade;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;FAS;1
GO:0031571;mitotic G1 DNA damage checkpoint signaling;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;SDE2;1
GO:0032436;positive regulation of proteasomal ubiquitin-dependent protein catabolic process;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;HSPA1A;1
GO:0032691;negative regulation of interleukin-1 beta production;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;NLRP3;1
GO:0035272;exocrine system development;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;TGM2;1
GO:0035335;peptidyl-tyrosine dephosphorylation;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;DUSP1;1
GO:0035987;endodermal cell differentiation;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0044819;mitotic G1/S transition checkpoint signaling;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;SDE2;1
GO:0045616;regulation of keratinocyte differentiation;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;ZFP36;1
GO:0046578;regulation of Ras protein signal transduction;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;SH2B2;1
GO:0048483;autonomic nervous system development;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0048546;digestive tract morphogenesis;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0048645;animal organ formation;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0048662;negative regulation of smooth muscle cell proliferation;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;KLF4;1
GO:0048704;embryonic skeletal system morphogenesis;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0060563;neuroepithelial cell differentiation;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0061077;chaperone-mediated protein folding;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;HSPA1A;1
GO:0072028;nephron morphogenesis;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0072088;nephron epithelium morphogenesis;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0090049;regulation of cell migration involved in sprouting angiogenesis;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;KLF4;1
GO:0090279;regulation of calcium ion import;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;CTNNB1;1
GO:0098869;cellular oxidant detoxification;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;PTGES;1
GO:1900745;positive regulation of p38MAPK cascade;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;GADD45A;1
GO:1901657;glycosyl compound metabolic process;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;PNP;1
GO:2000027;regulation of animal organ morphogenesis;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;CTNNB1;1
GO:2001251;negative regulation of chromosome organization;1/67;12/2237;0,0833333333333333;2,78233830845771;1,08757493766981;0,306369796812566;0,582594774260041;0,520977597834939;DUSP1;1
GO:0006259;DNA metabolic process;5/67;123/2237;0,040650406504065;1,35723819924766;0,715980822299739;0,306742587091671;0,582718615799022;0,521088341477589;GADD45A/SDE2/INO80D/CTNNB1/KLF4;5
GO:0006091;generation of precursor metabolites and energy;3/67;65/2237;0,0461538461538462;1,54098737083812;0,777601927911834;0,308328342723738;0,583089439369922;0,521419945504476;HK2/NR1D1/STAT3;3
GO:0051047;positive regulation of secretion;3/67;65/2237;0,0461538461538462;1,54098737083812;0,777601927911834;0,308328342723738;0,583089439369922;0,521419945504476;JAK2/PTGES/ADORA2B;3
GO:0030030;cell projection organization;9/67;245/2237;0,036734693877551;1,22650015229973;0,660009683639338;0,308699975728074;0,583089439369922;0,521419945504476;NR4A2/CTNNB1/APBB2/JAK2/KLF4/CDC42EP2/NDEL1/UBB/CDC42EP4;9
GO:0051223;regulation of protein transport;4/67;94/2237;0,0425531914893617;1,42076849793585;0,732216469251735;0,309751261395729;0,583089439369922;0,521419945504476;JAK2/SAR1A/NDEL1/NR1D1;4
GO:0000075;cell cycle checkpoint signaling;2/67;38/2237;0,0526315789473684;1,75726630007855;0,827125190945625;0,315990242417703;0,583089439369922;0,521419945504476;SDE2/DUSP1;2
GO:0007018;microtubule-based movement;2/67;38/2237;0,0526315789473684;1,75726630007855;0,827125190945625;0,315990242417703;0,583089439369922;0,521419945504476;NDEL1/UBB;2
GO:0031099;regeneration;2/67;38/2237;0,0526315789473684;1,75726630007855;0,827125190945625;0,315990242417703;0,583089439369922;0,521419945504476;JAK2/KLF4;2
GO:0033673;negative regulation of kinase activity;2/67;38/2237;0,0526315789473684;1,75726630007855;0,827125190945625;0,315990242417703;0,583089439369922;0,521419945504476;GADD45A/DUSP1;2
GO:0034614;cellular response to reactive oxygen species;2/67;38/2237;0,0526315789473684;1,75726630007855;0,827125190945625;0,315990242417703;0,583089439369922;0,521419945504476;KLF4/OSER1;2
GO:0042102;positive regulation of T cell proliferation;2/67;38/2237;0,0526315789473684;1,75726630007855;0,827125190945625;0,315990242417703;0,583089439369922;0,521419945504476;JAK2/PNP;2
GO:0099536;synaptic signaling;4/67;95/2237;0,0421052631578947;1,40581304006284;0,710103252095428;0,316663944811248;0,583089439369922;0,521419945504476;CTNNB1/JAK2/ADORA2B/ATF4;4
GO:1903320;regulation of protein modification by small protein conjugation or removal;3/67;66/2237;0,0454545454545455;1,51763907734057;0,749915870188964;0,316674558490928;0,583089439369922;0,521419945504476;CTNNB1/HSPA1A/UBB;3
GO:0006974;DNA damage response;5/67;125/2237;0,04;1,3355223880597;0,67822374062267;0,318792302533058;0,583089439369922;0,521419945504476;GADD45A/MCL1/SDE2/INO80D/BCL2L1;5
GO:0044087;regulation of cellular component biogenesis;7/67;186/2237;0,0376344086021505;1,25653988123897;0,641906783639034;0,32071512891303;0,583089439369922;0,521419945504476;GBP5/CTNNB1/HSPA1A/SAR1A/CDC42EP2/NDEL1/CDC42EP4;7
GO:0032989;cellular anatomical entity morphogenesis;5/67;126/2237;0,0396825396825397;1,32492300402748;0,659576311557015;0,32484270403317;0,583089439369922;0,521419945504476;NR4A2/CTNNB1/APBB2/NDEL1/UBB;5
GO:0040008;regulation of growth;5/67;126/2237;0,0396825396825397;1,32492300402748;0,659576311557015;0,32484270403317;0,583089439369922;0,521419945504476;SERTAD2/HSPA1A/STAT3/H3-3B/BCL2L1;5
GO:0050808;synapse organization;3/67;67/2237;0,0447761194029851;1,49498774782802;0,722678971257087;0,325027862390463;0,583089439369922;0,521419945504476;CTNNB1/APBB2/PPFIBP1;3
GO:1901873;regulation of post-translational protein modification;3/67;67/2237;0,0447761194029851;1,49498774782802;0,722678971257087;0,325027862390463;0,583089439369922;0,521419945504476;CTNNB1/HSPA1A/UBB;3
GO:0006470;protein dephosphorylation;2/67;39/2237;0,0512820512820513;1,71220818982013;0,788258852749387;0,32716109594592;0,583089439369922;0,521419945504476;DUSP1/PHLPP1;2
GO:0008360;regulation of cell shape;2/67;39/2237;0,0512820512820513;1,71220818982013;0,788258852749387;0,32716109594592;0,583089439369922;0,521419945504476;CDC42EP2/CDC42EP4;2
GO:0008654;phospholipid biosynthetic process;2/67;39/2237;0,0512820512820513;1,71220818982013;0,788258852749387;0,32716109594592;0,583089439369922;0,521419945504476;SGMS2/PGS1;2
GO:0016053;organic acid biosynthetic process;2/67;39/2237;0,0512820512820513;1,71220818982013;0,788258852749387;0,32716109594592;0,583089439369922;0,521419945504476;PTGES/NR1D1;2
GO:0022613;ribonucleoprotein complex biogenesis;2/67;39/2237;0,0512820512820513;1,71220818982013;0,788258852749387;0,32716109594592;0,583089439369922;0,521419945504476;SDE2/SRFBP1;2
GO:0030072;peptide hormone secretion;2/67;39/2237;0,0512820512820513;1,71220818982013;0,788258852749387;0,32716109594592;0,583089439369922;0,521419945504476;JAK2/NR1D1;2
GO:0030879;mammary gland development;2/67;39/2237;0,0512820512820513;1,71220818982013;0,788258852749387;0,32716109594592;0,583089439369922;0,521419945504476;HK2/JAK2;2
GO:0046394;carboxylic acid biosynthetic process;2/67;39/2237;0,0512820512820513;1,71220818982013;0,788258852749387;0,32716109594592;0,583089439369922;0,521419945504476;PTGES/NR1D1;2
GO:0071453;cellular response to oxygen levels;2/67;39/2237;0,0512820512820513;1,71220818982013;0,788258852749387;0,32716109594592;0,583089439369922;0,521419945504476;FAS/ATF4;2
GO:1902806;regulation of cell cycle G1/S phase transition;2/67;39/2237;0,0512820512820513;1,71220818982013;0,788258852749387;0,32716109594592;0,583089439369922;0,521419945504476;SDE2/KLF4;2
GO:0001773;myeloid dendritic cell activation;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;IRF4;1
GO:0001782;B cell homeostasis;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;SH2B2;1
GO:0001914;regulation of T cell mediated cytotoxicity;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;PVR;1
GO:0006110;regulation of glycolytic process;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;STAT3;1
GO:0006140;regulation of nucleotide metabolic process;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;STAT3;1
GO:0006690;icosanoid metabolic process;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;PTGES;1
GO:0007595;lactation;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;HK2;1
GO:0009582;detection of abiotic stimulus;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;CTNNB1;1
GO:0009948;anterior/posterior axis specification;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;CTNNB1;1
GO:0009953;dorsal/ventral pattern formation;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;CTNNB1;1
GO:0010761;fibroblast migration;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;ARID5B;1
GO:0016925;protein sumoylation;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;CTNNB1;1
GO:0019674;NAD metabolic process;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;HK2;1
GO:0030811;regulation of nucleotide catabolic process;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;STAT3;1
GO:0032692;negative regulation of interleukin-1 production;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;NLRP3;1
GO:0032814;regulation of natural killer cell activation;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;JAK2;1
GO:0033121;regulation of purine nucleotide catabolic process;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;STAT3;1
GO:0034143;regulation of toll-like receptor 4 signaling pathway;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;NR1D1;1
GO:0035850;epithelial cell differentiation involved in kidney development;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;CTNNB1;1
GO:0042149;cellular response to glucose starvation;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;ATF4;1
GO:0042832;defense response to protozoan;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;IRF4;1
GO:0043029;T cell homeostasis;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;FAS;1
GO:0043154;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;KLF4;1
GO:0043266;regulation of potassium ion transport;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;ATF4;1
GO:0043543;protein acylation;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;ARID5A;1
GO:0045912;negative regulation of carbohydrate metabolic process;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;STAT3;1
GO:0046323;glucose import;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;HK2;1
GO:0046889;positive regulation of lipid biosynthetic process;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;NR1D1;1
GO:0050873;brown fat cell differentiation;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;SH2B2;1
GO:0061035;regulation of cartilage development;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;CTNNB1;1
GO:0071277;cellular response to calcium ion;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;JUNB;1
GO:0090025;regulation of monocyte chemotaxis;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;DUSP1;1
GO:1900542;regulation of purine nucleotide metabolic process;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;STAT3;1
GO:1903018;regulation of glycoprotein metabolic process;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;CTNNB1;1
GO:1903578;regulation of ATP metabolic process;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;STAT3;1
GO:1904707;positive regulation of vascular associated smooth muscle cell proliferation;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;JAK2;1
GO:1905330;regulation of morphogenesis of an epithelium;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;CTNNB1;1
GO:2000379;positive regulation of reactive oxygen species metabolic process;1/67;13/2237;0,0769230769230769;2,5683122847302;0,996277364142626;0,327256638886075;0,583089439369922;0,521419945504476;GADD45A;1
GO:1902533;positive regulation of intracellular signal transduction;9/67;250/2237;0,036;1,20197014925373;0,595253134811188;0,330492456679898;0,588301421947112;0,526080691331575;GADD45A/MCL1/NLRP3/CTNNB1/JAK2/NEK6/ADORA2B/UBB/TGM2;9
GO:0031329;regulation of cellular catabolic process;5/67;127/2237;0,0393700787401575;1,31449053942884;0,641079149810069;0,330907953029022;0,588487946513585;0,52624748843459;TENT5C/MCL1/STAT3/ZFP36/TIMP1;5
GO:0007178;transmembrane receptor protein serine/threonine kinase signaling pathway;3/67;68/2237;0,0441176470588235;1,47300263388938;0,695875703661906;0,33338424584904;0,591500384149257;0,528941320566973;HSPA1A/JAK2/STAT3;3
GO:0010721;negative regulation of cell development;3/67;68/2237;0,0441176470588235;1,47300263388938;0,695875703661906;0,33338424584904;0,591500384149257;0,528941320566973;CTNNB1/IRF1/NR1D1;3
GO:0009611;response to wounding;5/67;128/2237;0,0390625;1,30422108208955;0,622729494395801;0,336986429516616;0,591500384149257;0,528941320566973;JAK2/KLF4/STAT3/ZFP36/TIMP1;5
GO:0023061;signal release;4/67;98/2237;0,0408163265306122;1,3627779469997;0,64519643395371;0,337485162363144;0,591500384149257;0,528941320566973;JAK2/PTGES/NR1D1/TGM2;4
GO:0002790;peptide secretion;2/67;40/2237;0,05;1,66940298507463;0,750491963278393;0,338286877666764;0,591500384149257;0,528941320566973;JAK2/NR1D1;2
GO:0006606;protein import into nucleus;2/67;40/2237;0,05;1,66940298507463;0,750491963278393;0,338286877666764;0,591500384149257;0,528941320566973;JAK2/STAT3;2
GO:0042542;response to hydrogen peroxide;2/67;40/2237;0,05;1,66940298507463;0,750491963278393;0,338286877666764;0,591500384149257;0,528941320566973;KLF4/OSER1;2
GO:0044703;multi-organism reproductive process;2/67;40/2237;0,05;1,66940298507463;0,750491963278393;0,338286877666764;0,591500384149257;0,528941320566973;JUNB/TIMP1;2
GO:0002573;myeloid leukocyte differentiation;3/67;69/2237;0,0434782608695652;1,45165476963011;0,669491305561097;0,341739812080235;0,591500384149257;0,528941320566973;CTNNB1/IRF4/JUNB;3
GO:0007159;leukocyte cell-cell adhesion;5/67;129/2237;0,0387596899224806;1,29411084114312;0,604524656752116;0,343076527619116;0,591500384149257;0,528941320566973;NLRP3/IRF1/JAK2/KLF4/PNP;5
GO:0007417;central nervous system development;6/67;160/2237;0,0375;1,25205223880597;0,581267092035715;0,345375624750807;0,591500384149257;0,528941320566973;NR4A2/CTNNB1/NDEL1/UBB/NR1D1/STAT3;6
GO:0001541;ovarian follicle development;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;BCL2L1;1
GO:0001562;response to protozoan;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;IRF4;1
GO:0002507;tolerance induction;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;PHLPP1;1
GO:0006509;membrane protein ectodomain proteolysis;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;TIMP1;1
GO:0006940;regulation of smooth muscle contraction;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;ADORA2B;1
GO:0006953;acute-phase response;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;PTGES;1
GO:0006984;ER-nucleus signaling pathway;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;ATF4;1
GO:0008347;glial cell migration;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;CTNNB1;1
GO:0009581;detection of external stimulus;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;CTNNB1;1
GO:0015698;inorganic anion transport;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;ATF4;1
GO:0018958;phenol-containing compound metabolic process;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;NR4A2;1
GO:0019083;viral transcription;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;ZFP36;1
GO:0030166;proteoglycan biosynthetic process;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;CTNNB1;1
GO:0032892;positive regulation of organic acid transport;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;PTGES;1
GO:0034332;adherens junction organization;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;CTNNB1;1
GO:0035872;nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;HSPA1A;1
GO:0040014;regulation of multicellular organism growth;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;STAT3;1
GO:0042307;positive regulation of protein import into nucleus;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;JAK2;1
GO:0043470;regulation of carbohydrate catabolic process;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;STAT3;1
GO:0043627;response to estrogen;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;ARID5A;1
GO:0044042;glucan metabolic process;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;NR1D1;1
GO:0050000;chromosome localization;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;NDEL1;1
GO:0051057;positive regulation of small GTPase mediated signal transduction;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;TGM2;1
GO:0051145;smooth muscle cell differentiation;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;CTNNB1;1
GO:0070266;necroptotic process;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;FAS;1
GO:0071300;cellular response to retinoic acid;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;KLF4;1
GO:0071715;icosanoid transport;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;PTGES;1
GO:0090100;positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;JAK2;1
GO:0150077;regulation of neuroinflammatory response;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;NR1D1;1
GO:1901532;regulation of hematopoietic progenitor cell differentiation;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;ZFP36;1
GO:2000060;positive regulation of ubiquitin-dependent protein catabolic process;1/67;14/2237;0,0714285714285714;2,38486140724947;0,913154015494381;0,347523637624669;0,591500384149257;0,528941320566973;HSPA1A;1
GO:0007179;transforming growth factor beta receptor signaling pathway;2/67;41/2237;0,0487804878048781;1,6286858390972;0,713761095805703;0,349360330570532;0,591500384149257;0,528941320566973;HSPA1A/STAT3;2
GO:0007281;germ cell development;2/67;41/2237;0,0487804878048781;1,6286858390972;0,713761095805703;0,349360330570532;0,591500384149257;0,528941320566973;CTNNB1/BCL2L1;2
GO:0010594;regulation of endothelial cell migration;2/67;41/2237;0,0487804878048781;1,6286858390972;0,713761095805703;0,349360330570532;0,591500384149257;0,528941320566973;GADD45A/KLF4;2
GO:0030308;negative regulation of cell growth;2/67;41/2237;0,0487804878048781;1,6286858390972;0,713761095805703;0,349360330570532;0,591500384149257;0,528941320566973;SERTAD2/HSPA1A;2
GO:0044282;small molecule catabolic process;2/67;41/2237;0,0487804878048781;1,6286858390972;0,713761095805703;0,349360330570532;0,591500384149257;0,528941320566973;HK2/PNP;2
GO:0044706;multi-multicellular organism process;2/67;41/2237;0,0487804878048781;1,6286858390972;0,713761095805703;0,349360330570532;0,591500384149257;0,528941320566973;JUNB/TIMP1;2
GO:0045582;positive regulation of T cell differentiation;2/67;41/2237;0,0487804878048781;1,6286858390972;0,713761095805703;0,349360330570532;0,591500384149257;0,528941320566973;NLRP3/PNP;2
GO:0045861;negative regulation of proteolysis;2/67;41/2237;0,0487804878048781;1,6286858390972;0,713761095805703;0,349360330570532;0,591500384149257;0,528941320566973;KLF4/TIMP1;2
GO:0051170;import into nucleus;2/67;41/2237;0,0487804878048781;1,6286858390972;0,713761095805703;0,349360330570532;0,591500384149257;0,528941320566973;JAK2/STAT3;2
GO:0051346;negative regulation of hydrolase activity;2/67;41/2237;0,0487804878048781;1,6286858390972;0,713761095805703;0,349360330570532;0,591500384149257;0,528941320566973;KLF4/TIMP1;2
GO:0072593;reactive oxygen species metabolic process;2/67;41/2237;0,0487804878048781;1,6286858390972;0,713761095805703;0,349360330570532;0,591500384149257;0,528941320566973;GADD45A/HK2;2
GO:0007409;axonogenesis;3/67;70/2237;0,0428571428571429;1,43091684434968;0,643511732226154;0,350090776468489;0,591500384149257;0,528941320566973;NR4A2/APBB2/NDEL1;3
GO:0043161;proteasome-mediated ubiquitin-dependent protein catabolic process;3/67;70/2237;0,0428571428571429;1,43091684434968;0,643511732226154;0,350090776468489;0,591500384149257;0,528941320566973;CTNNB1/FEM1C/HSPA1A;3
GO:0051052;regulation of DNA metabolic process;3/67;70/2237;0,0428571428571429;1,43091684434968;0,643511732226154;0,350090776468489;0,591500384149257;0,528941320566973;INO80D/CTNNB1/KLF4;3
GO:0005975;carbohydrate metabolic process;4/67;100/2237;0,04;1,3355223880597;0,603062990734021;0,351411518098072;0,592674457059437;0,529991219590193;HK2/NR1D1/STAT3/ATF4;4
GO:0048609;multicellular organismal reproductive process;4/67;100/2237;0,04;1,3355223880597;0,603062990734021;0,351411518098072;0,592674457059437;0,529991219590193;CTNNB1/UBB/JUNB/BCL2L1;4
GO:0001666;response to hypoxia;3/67;71/2237;0,0422535211267606;1,41076308597856;0,617923611269955;0,358433466739633;0,602648014724502;0,538909940361098;HK2/NR4A2/ATF4;3
GO:0045732;positive regulation of protein catabolic process;2/67;42/2237;0,0476190476190476;1,58990760483298;0,678007990053862;0,360374659505585;0,602648014724502;0,538909940361098;TIPARP/HSPA1A;2
GO:0061138;morphogenesis of a branching epithelium;2/67;42/2237;0,0476190476190476;1,58990760483298;0,678007990053862;0,360374659505585;0,602648014724502;0,538909940361098;CTNNB1/TGM2;2
GO:0051338;regulation of transferase activity;5/67;132/2237;0,0378787878787879;1,26469923111714;0,550753200204918;0,361400723061524;0,602648014724502;0,538909940361098;GADD45A/DUSP1/JAK2/KLF4/ZFP36;5
GO:0002443;leukocyte mediated immunity;4/67;102/2237;0,0392156862745098;1,30933567456833;0,561790755906177;0,365352834995508;0,602648014724502;0,538909940361098;NLRP3/ARID5A/ADORA2B/PVR;4
GO:0042063;gliogenesis;3/67;72/2237;0,0416666666666667;1,39116915422886;0,59271420126529;0,366764322932482;0,602648014724502;0,538909940361098;CTNNB1/NR1D1/STAT3;3
GO:0001775;cell activation;10/67;290/2237;0,0344827586206897;1,15131240349974;0,485214741688424;0,36712496725066;0,602648014724502;0,538909940361098;NLRP3/CTNNB1/IRF1/IRF4/JAK2/PNP/ADORA2B/NR1D1/STAT3/JUNB;10
GO:0001913;T cell mediated cytotoxicity;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;PVR;1
GO:0002042;cell migration involved in sprouting angiogenesis;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;KLF4;1
GO:0002715;regulation of natural killer cell mediated immunity;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;PVR;1
GO:0002762;negative regulation of myeloid leukocyte differentiation;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;CTNNB1;1
GO:0006112;energy reserve metabolic process;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;NR1D1;1
GO:0006900;vesicle budding from membrane;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;SAR1A;1
GO:0007127;meiosis I;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;UBB;1
GO:0009880;embryonic pattern specification;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;CTNNB1;1
GO:0019935;cyclic-nucleotide-mediated signaling;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;ADORA2B;1
GO:0032024;positive regulation of insulin secretion;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;JAK2;1
GO:0035456;response to interferon-beta;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;IRF1;1
GO:0042269;regulation of natural killer cell mediated cytotoxicity;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;PVR;1
GO:0042475;odontogenesis of dentin-containing tooth;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;CTNNB1;1
GO:0043299;leukocyte degranulation;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;ADORA2B;1
GO:0043648;dicarboxylic acid metabolic process;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;ADSS2;1
GO:0045624;positive regulation of T-helper cell differentiation;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;NLRP3;1
GO:0045921;positive regulation of exocytosis;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;ADORA2B;1
GO:0046427;positive regulation of receptor signaling pathway via JAK-STAT;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;JAK2;1
GO:0060993;kidney morphogenesis;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;CTNNB1;1
GO:0061756;leukocyte adhesion to vascular endothelial cell;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;KLF4;1
GO:0061982;meiosis I cell cycle process;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;UBB;1
GO:0070509;calcium ion import;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;CTNNB1;1
GO:2000117;negative regulation of cysteine-type endopeptidase activity;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;KLF4;1
GO:2000177;regulation of neural precursor cell proliferation;1/67;15/2237;0,0666666666666667;2,22587064676617;0,836877096503406;0,367188917102469;0,602648014724502;0,538909940361098;CTNNB1;1
GO:0001763;morphogenesis of a branching structure;2/67;43/2237;0,0465116279069767;1,55293300937175;0,643179017188669;0,371323510736542;0,606804770780854;0,54262706396176;CTNNB1/TGM2;2
GO:0031214;biomineral tissue development;2/67;43/2237;0,0465116279069767;1,55293300937175;0,643179017188669;0,371323510736542;0,606804770780854;0,54262706396176;SGMS2/ATF4;2
GO:0032609;type II interferon production;2/67;43/2237;0,0465116279069767;1,55293300937175;0,643179017188669;0,371323510736542;0,606804770780854;0,54262706396176;ARID5A/JAK2;2
GO:0032649;regulation of type II interferon production;2/67;43/2237;0,0465116279069767;1,55293300937175;0,643179017188669;0,371323510736542;0,606804770780854;0,54262706396176;ARID5A/JAK2;2
GO:1903828;negative regulation of protein localization;2/67;43/2237;0,0465116279069767;1,55293300937175;0,643179017188669;0,371323510736542;0,606804770780854;0,54262706396176;TMBIM1/BCL2L1;2
GO:0032504;multicellular organism reproduction;4/67;103/2237;0,0388349514563107;1,29662367772787;0,54146533012742;0,372323549978964;0,607390873092298;0,543151178127887;CTNNB1/UBB/JUNB/BCL2L1;4
GO:0055082;intracellular chemical homeostasis;4/67;103/2237;0,0388349514563107;1,29662367772787;0,54146533012742;0,372323549978964;0,607390873092298;0,543151178127887;HK2/NR1D1/TGM2/ATF4;4
GO:0048568;embryonic organ development;3/67;73/2237;0,0410958904109589;1,37211204252709;0,567871353453952;0,375079897185235;0,610680743174539;0,546093100521221;CTNNB1/JUNB/ATF4;3
GO:1901135;carbohydrate derivative metabolic process;6/67;166/2237;0,036144578313253;1,20679733860816;0,486465867662686;0,37851829726691;0,610680743174539;0,546093100521221;ADSS2/HK2/CTNNB1/HSPA1A/PNP/STAT3;6
GO:0061024;membrane organization;5/67;135/2237;0,037037037037037;1,23659480375898;0,498194770624838;0,379773235920362;0,610680743174539;0,546093100521221;HK2/HSPA1A/NEK6/SAR1A/BCL2L1;5
GO:0002702;positive regulation of production of molecular mediator of immune response;2/67;44/2237;0,0454545454545455;1,51763907734057;0,60922471136638;0,382200952283188;0,610680743174539;0,546093100521221;NLRP3/ARID5A;2
GO:0009636;response to toxic substance;2/67;44/2237;0,0454545454545455;1,51763907734057;0,60922471136638;0,382200952283188;0,610680743174539;0,546093100521221;PTGES/ATF4;2
GO:0048588;developmental cell growth;2/67;44/2237;0,0454545454545455;1,51763907734057;0,60922471136638;0,382200952283188;0,610680743174539;0,546093100521221;CTNNB1/NDEL1;2
GO:1903038;negative regulation of leukocyte cell-cell adhesion;2/67;44/2237;0,0454545454545455;1,51763907734057;0,60922471136638;0,382200952283188;0,610680743174539;0,546093100521221;IRF1/KLF4;2
GO:0050767;regulation of neurogenesis;3/67;74/2237;0,0405405405405405;1,35356998789835;0,543383476276282;0,383376853349791;0,610680743174539;0,546093100521221;CTNNB1/NR1D1/TGM2;3
GO:0097435;supramolecular fiber organization;5/67;136/2237;0,0367647058823529;1,22750219490781;0,480933969099185;0,385901083572415;0,610680743174539;0,546093100521221;HSPA1A/JAK2/CDC42EP2/NDEL1/CDC42EP4;5
GO:0000079;regulation of cyclin-dependent protein serine/threonine kinase activity;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;GADD45A;1
GO:0001912;positive regulation of leukocyte mediated cytotoxicity;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;PVR;1
GO:0002886;regulation of myeloid leukocyte mediated immunity;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;ADORA2B;1
GO:0003151;outflow tract morphogenesis;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;CTNNB1;1
GO:0006029;proteoglycan metabolic process;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;CTNNB1;1
GO:0006446;regulation of translational initiation;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;ATF4;1
GO:0006835;dicarboxylic acid transport;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;SLC13A3;1
GO:0006888;endoplasmic reticulum to Golgi vesicle-mediated transport;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;SAR1A;1
GO:0030857;negative regulation of epithelial cell differentiation;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;CTNNB1;1
GO:0031343;positive regulation of cell killing;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;PVR;1
GO:0031640;killing of cells of another organism;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;GBP5;1
GO:0033619;membrane protein proteolysis;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;TIMP1;1
GO:0034110;regulation of homotypic cell-cell adhesion;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;JAK2;1
GO:0035050;embryonic heart tube development;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;CTNNB1;1
GO:0045185;maintenance of protein location;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;HK2;1
GO:0045600;positive regulation of fat cell differentiation;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;ZFP36;1
GO:0048706;embryonic skeletal system development;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;CTNNB1;1
GO:0050853;B cell receptor signaling pathway;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;SH2B2;1
GO:0061005;cell differentiation involved in kidney development;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;CTNNB1;1
GO:0061157;mRNA destabilization;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;ZFP36;1
GO:0061326;renal tubule development;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;CTNNB1;1
GO:0070527;platelet aggregation;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;JAK2;1
GO:0072080;nephron tubule development;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;CTNNB1;1
GO:0072655;establishment of protein localization to mitochondrion;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;HK2;1
GO:0141060;disruption of anatomical structure in another organism;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;GBP5;1
GO:0141061;disruption of cell in another organism;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;GBP5;1
GO:1904029;regulation of cyclin-dependent protein kinase activity;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;GADD45A;1
GO:1990748;cellular detoxification;1/67;16/2237;0,0625;2,08675373134328;0,766408453004023;0,386270079368056;0,610680743174539;0,546093100521221;PTGES;1
GO:0036293;response to decreased oxygen levels;3/67;75/2237;0,04;1,3355223880597;0,51923950247806;0,391651966446415;0,615792217882228;0,550663968528041;HK2/NR4A2/ATF4;3
GO:0031669;cellular response to nutrient levels;2/67;45/2237;0,0444444444444444;1,48391376451078;0,576099358237765;0,393001455012757;0,615792217882228;0,550663968528041;FAS/ATF4;2
GO:0010647;positive regulation of cell communication;13/67;393/2237;0,0330788804071247;1,10443963389161;0,400612588088488;0,394025670225097;0,615792217882228;0,550663968528041;GADD45A/GBP5/MCL1/NLRP3/CTNNB1/HSPA1A/JAK2/NEK6/FAS/ADORA2B/UBB/STAT3/TGM2;13
GO:0023056;positive regulation of signaling;13/67;393/2237;0,0330788804071247;1,10443963389161;0,400612588088488;0,394025670225097;0,615792217882228;0,550663968528041;GADD45A/GBP5/MCL1/NLRP3/CTNNB1/HSPA1A/JAK2/NEK6/FAS/ADORA2B/UBB/STAT3/TGM2;13
GO:0009607;response to biotic stimulus;14/67;427/2237;0,0327868852459016;1,09469048201615;0,382141682522718;0,400011456086847;0,615792217882228;0,550663968528041;GBP5/NLRP3/ARID5A/IRF1/IRF4/HSPA1A/JAK2/KLF4/CDC42EP2/NR1D1/CDC42EP4/ZFP36/PVR/BCL2L1;14
GO:0010720;positive regulation of cell development;4/67;107/2237;0,0373831775700935;1,24815176454178;0,462128644786506;0,400157140692433;0,615792217882228;0,550663968528041;NLRP3/CTNNB1/PNP/TGM2;4
GO:0009887;animal organ morphogenesis;6/67;170/2237;0,0352941176470588;1,1784021071115;0,425106392754797;0,400704826543261;0,615792217882228;0,550663968528041;CTNNB1/TIPARP/ARID5B/STAT3/TGM2/ATF4;6
GO:0002718;regulation of cytokine production involved in immune response;2/67;46/2237;0,0434782608695652;1,45165476963011;0,54376063237726;0,403719874459097;0,615792217882228;0,550663968528041;NLRP3/ARID5A;2
GO:0042770;signal transduction in response to DNA damage;2/67;46/2237;0,0434782608695652;1,45165476963011;0,54376063237726;0,403719874459097;0,615792217882228;0,550663968528041;GADD45A/SDE2;2
GO:0046718;symbiont entry into host cell;2/67;46/2237;0,0434782608695652;1,45165476963011;0,54376063237726;0,403719874459097;0,615792217882228;0,550663968528041;HSPA1A/PVR;2
GO:0071695;anatomical structure maturation;2/67;46/2237;0,0434782608695652;1,45165476963011;0,54376063237726;0,403719874459097;0,615792217882228;0,550663968528041;NR4A2/CTNNB1;2
GO:0071887;leukocyte apoptotic process;2/67;46/2237;0,0434782608695652;1,45165476963011;0,54376063237726;0,403719874459097;0,615792217882228;0,550663968528041;FAS/BCL2L1;2
GO:0009615;response to virus;5/67;139/2237;0,0359712230215827;1,20100934178031;0,429896920056422;0,404275161840381;0,615792217882228;0,550663968528041;GBP5/NLRP3/IRF1/JAK2/BCL2L1;5
GO:0001707;mesoderm formation;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;KLF4;1
GO:0002793;positive regulation of peptide secretion;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;JAK2;1
GO:0006638;neutral lipid metabolic process;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;PGS1;1
GO:0006639;acylglycerol metabolic process;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;PGS1;1
GO:0007566;embryo implantation;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;TIMP1;1
GO:0009152;purine ribonucleotide biosynthetic process;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;ADSS2;1
GO:0010543;regulation of platelet activation;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;JAK2;1
GO:0010803;regulation of tumor necrosis factor-mediated signaling pathway;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;HSPA1A;1
GO:0010827;regulation of glucose transmembrane transport;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;HK2;1
GO:0019233;sensory perception of pain;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;PTGES;1
GO:0030534;adult behavior;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;NR4A2;1
GO:0033555;multicellular organismal response to stress;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;NR4A2;1
GO:0042092;type 2 immune response;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;NLRP3;1
GO:0042632;cholesterol homeostasis;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;NR1D1;1
GO:0043372;positive regulation of CD4-positive, alpha-beta T cell differentiation;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;NLRP3;1
GO:0045576;mast cell activation;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;ADORA2B;1
GO:0045604;regulation of epidermal cell differentiation;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;ZFP36;1
GO:0048477;oogenesis;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;CTNNB1;1
GO:0048709;oligodendrocyte differentiation;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;CTNNB1;1
GO:0050779;RNA destabilization;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;ZFP36;1
GO:0050810;regulation of steroid biosynthetic process;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;NR1D1;1
GO:0051101;regulation of DNA binding;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;JAK2;1
GO:0055092;sterol homeostasis;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;NR1D1;1
GO:0060395;SMAD protein signal transduction;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;JAK2;1
GO:0065004;protein-DNA complex assembly;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;H3-3B;1
GO:0070585;protein localization to mitochondrion;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;HK2;1
GO:0072091;regulation of stem cell proliferation;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;CTNNB1;1
GO:0090277;positive regulation of peptide hormone secretion;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;JAK2;1
GO:0097300;programmed necrotic cell death;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;FAS;1
GO:0140353;lipid export from cell;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;PTGES;1
GO:1901800;positive regulation of proteasomal protein catabolic process;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;HSPA1A;1
GO:1903052;positive regulation of proteolysis involved in protein catabolic process;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;HSPA1A;1
GO:1904894;positive regulation of receptor signaling pathway via STAT;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;JAK2;1
GO:2000243;positive regulation of reproductive process;1/67;17/2237;0,0588235294117647;1,9640035118525;0,700922535880497;0,404784219252045;0,615792217882228;0,550663968528041;CTNNB1;1
GO:0070201;regulation of establishment of protein localization;4/67;108/2237;0,037037037037037;1,23659480375898;0,442764388363241;0,407093013883146;0,618807518695568;0,553360361018823;JAK2/SAR1A/NDEL1/NR1D1;4
GO:0009410;response to xenobiotic stimulus;3/67;77/2237;0,038961038961039;1,30083349486335;0,471941436480362;0,40812431506306;0,61903452987269;0,553563362732817;RNF149/CTNNB1/PNP;3
GO:0048646;anatomical structure formation involved in morphogenesis;8/67;236/2237;0,0338983050847458;1,1317986339489;0,376085682427302;0,411808303112997;0,61903452987269;0,553563362732817;GADD45A/HK2/CTNNB1/DUSP1/KLF4/STAT3/JUNB/TGM2;8
GO:0002367;cytokine production involved in immune response;2/67;47/2237;0,0425531914893617;1,42076849793585;0,512169276886938;0,414351433343161;0,61903452987269;0,553563362732817;NLRP3/ARID5A;2
GO:0045621;positive regulation of lymphocyte differentiation;2/67;47/2237;0,0425531914893617;1,42076849793585;0,512169276886938;0,414351433343161;0,61903452987269;0,553563362732817;NLRP3/PNP;2
GO:0050769;positive regulation of neurogenesis;2/67;47/2237;0,0425531914893617;1,42076849793585;0,512169276886938;0,414351433343161;0,61903452987269;0,553563362732817;CTNNB1/TGM2;2
GO:1903034;regulation of response to wounding;2/67;47/2237;0,0425531914893617;1,42076849793585;0,512169276886938;0,414351433343161;0,61903452987269;0,553563362732817;KLF4/STAT3;2
GO:0051050;positive regulation of transport;6/67;173/2237;0,0346820809248555;1,15796738849107;0,379996045953888;0,417342616622531;0,61903452987269;0,553563362732817;AZIN1/JAK2/PTGES/SAR1A/ADORA2B/ATF4;6
GO:0071705;nitrogen compound transport;10/67;302/2237;0,033112582781457;1,1055648907779;0,346518099272207;0,418554888511685;0,61903452987269;0,553563362732817;MCL1/AZIN1/JAK2/SAR1A/NDEL1/NR1D1/STAT3/ZFP36/TGM2/SLC13A3;10
GO:0001892;embryonic placenta development;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;JUNB;1
GO:0002686;negative regulation of leukocyte migration;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;DUSP1;1
GO:0002825;regulation of T-helper 1 type immune response;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;ARID5A;1
GO:0006633;fatty acid biosynthetic process;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;PTGES;1
GO:0007043;cell-cell junction assembly;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;CTNNB1;1
GO:0008593;regulation of Notch signaling pathway;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;STAT3;1
GO:0009260;ribonucleotide biosynthetic process;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;ADSS2;1
GO:0009798;axis specification;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;CTNNB1;1
GO:0010332;response to gamma radiation;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;BCL2L1;1
GO:0018205;peptidyl-lysine modification;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;CTNNB1;1
GO:0021545;cranial nerve development;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;CTNNB1;1
GO:0030326;embryonic limb morphogenesis;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;CTNNB1;1
GO:0030500;regulation of bone mineralization;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;SGMS2;1
GO:0030518;intracellular steroid hormone receptor signaling pathway;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;JAK2;1
GO:0030968;endoplasmic reticulum unfolded protein response;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;ATF4;1
GO:0031016;pancreas development;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;CTNNB1;1
GO:0032434;regulation of proteasomal ubiquitin-dependent protein catabolic process;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;HSPA1A;1
GO:0032728;positive regulation of interferon-beta production;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;IRF1;1
GO:0032890;regulation of organic acid transport;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;PTGES;1
GO:0034113;heterotypic cell-cell adhesion;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;KLF4;1
GO:0035113;embryonic appendage morphogenesis;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;CTNNB1;1
GO:0042306;regulation of protein import into nucleus;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;JAK2;1
GO:0043030;regulation of macrophage activation;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;NR1D1;1
GO:0043124;negative regulation of canonical NF-kappaB signal transduction;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;NR1D1;1
GO:0045669;positive regulation of osteoblast differentiation;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;CTNNB1;1
GO:0045682;regulation of epidermis development;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;ZFP36;1
GO:0045834;positive regulation of lipid metabolic process;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;NR1D1;1
GO:0046390;ribose phosphate biosynthetic process;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;ADSS2;1
GO:0046513;ceramide biosynthetic process;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;SGMS2;1
GO:0046824;positive regulation of nucleocytoplasmic transport;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;JAK2;1
GO:0048332;mesoderm morphogenesis;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;KLF4;1
GO:0050764;regulation of phagocytosis;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;TGM2;1
GO:0050922;negative regulation of chemotaxis;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;DUSP1;1
GO:0051100;negative regulation of binding;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;JAK2;1
GO:0072332;intrinsic apoptotic signaling pathway by p53 class mediator;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;UBB;1
GO:0097028;dendritic cell differentiation;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;IRF4;1
GO:0097237;cellular response to toxic substance;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;PTGES;1
GO:1904705;regulation of vascular associated smooth muscle cell proliferation;1/67;18/2237;0,0555555555555556;1,85489220563847;0,639753091100068;0,422747938761105;0,61903452987269;0,553563362732817;JAK2;1
GO:0007276;gamete generation;3/67;79/2237;0,0379746835443038;1,2679010013225;0,425897995794807;0,424473336892624;0,61903452987269;0,553563362732817;CTNNB1/UBB/BCL2L1;3
GO:0006874;intracellular calcium ion homeostasis;2/67;48/2237;0,0416666666666667;1,39116915422886;0,481288819479287;0,424891704770062;0,61903452987269;0,553563362732817;TGM2/ATF4;2
GO:0007254;JNK cascade;2/67;48/2237;0,0416666666666667;1,39116915422886;0,481288819479287;0,424891704770062;0,61903452987269;0,553563362732817;GADD45A/PHLPP1;2
GO:0008202;steroid metabolic process;2/67;48/2237;0,0416666666666667;1,39116915422886;0,481288819479287;0,424891704770062;0,61903452987269;0,553563362732817;TIPARP/NR1D1;2
GO:0021537;telencephalon development;2/67;48/2237;0,0416666666666667;1,39116915422886;0,481288819479287;0,424891704770062;0,61903452987269;0,553563362732817;CTNNB1/NDEL1;2
GO:0043542;endothelial cell migration;2/67;48/2237;0,0416666666666667;1,39116915422886;0,481288819479287;0,424891704770062;0,61903452987269;0,553563362732817;GADD45A/KLF4;2
GO:0044409;symbiont entry into host;2/67;48/2237;0,0416666666666667;1,39116915422886;0,481288819479287;0,424891704770062;0,61903452987269;0,553563362732817;HSPA1A/PVR;2
GO:0060560;developmental growth involved in morphogenesis;2/67;48/2237;0,0416666666666667;1,39116915422886;0,481288819479287;0,424891704770062;0,61903452987269;0,553563362732817;CTNNB1/NDEL1;2
GO:0002683;negative regulation of immune system process;5/67;143/2237;0,034965034965035;1,16741467487736;0,363510230402388;0,428699377723648;0,624101938054258;0,558094824837048;CTNNB1/IRF1/DUSP1/IRF4/NR1D1;5
GO:0001558;regulation of cell growth;3/67;80/2237;0,0375;1,25205223880597;0,403323859411971;0,432594694966029;0,626138421673257;0,559915923121364;SERTAD2/HSPA1A/H3-3B;3
GO:0006511;ubiquitin-dependent protein catabolic process;4/67;112/2237;0,0357142857142857;1,19243070362473;0,367068693497859;0,434688495925272;0,626138421673257;0,559915923121364;RNF149/CTNNB1/FEM1C/HSPA1A;4
GO:0071363;cellular response to growth factor stimulus;5/67;144/2237;0,0347222222222222;1,15930762852405;0,347197539367008;0,434783085151301;0,626138421673257;0,559915923121364;CTNNB1/HSPA1A/KLF4/STAT3/ZFP36;5
GO:0007399;nervous system development;12/67;371/2237;0,032345013477089;1,07993724101863;0,296158174142553;0,434898720107227;0,626138421673257;0,559915923121364;NR4A2/CTNNB1/APBB2/SH2B2/JAK2/KLF4/NDEL1/UBB/NR1D1/STAT3/TGM2/ATF4;12
GO:0071702;organic substance transport;12/67;371/2237;0,032345013477089;1,07993724101863;0,296158174142553;0,434898720107227;0,626138421673257;0,559915923121364;MCL1/HK2/AZIN1/JAK2/PTGES/SAR1A/NDEL1/NR1D1/STAT3/ZFP36/TGM2/SLC13A3;12
GO:0000082;G1/S transition of mitotic cell cycle;2/67;49/2237;0,0408163265306122;1,3627779469997;0,451085320214079;0,435336596078784;0,626138421673257;0,559915923121364;SDE2/KLF4;2
GO:0015849;organic acid transport;2/67;49/2237;0,0408163265306122;1,3627779469997;0,451085320214079;0,435336596078784;0,626138421673257;0,559915923121364;PTGES/SLC13A3;2
GO:0021700;developmental maturation;2/67;49/2237;0,0408163265306122;1,3627779469997;0,451085320214079;0,435336596078784;0,626138421673257;0,559915923121364;NR4A2/CTNNB1;2
GO:0046777;protein autophosphorylation;2/67;49/2237;0,0408163265306122;1,3627779469997;0,451085320214079;0,435336596078784;0,626138421673257;0,559915923121364;JAK2/NEK6;2
GO:0046942;carboxylic acid transport;2/67;49/2237;0,0408163265306122;1,3627779469997;0,451085320214079;0,435336596078784;0,626138421673257;0,559915923121364;PTGES/SLC13A3;2
GO:0090092;regulation of transmembrane receptor protein serine/threonine kinase signaling pathway;2/67;49/2237;0,0408163265306122;1,3627779469997;0,451085320214079;0,435336596078784;0,626138421673257;0,559915923121364;HSPA1A/JAK2;2
GO:0044085;cellular component biogenesis;14/67;437/2237;0,0320366132723112;1,06964035656955;0,28510766026174;0,437165843316573;0,626138421673257;0,559915923121364;GBP5/SDE2/NLRP3/CTNNB1/SRFBP1/HSPA1A/JAK2/NEK6/SAR1A/FAS/CDC42EP2/NDEL1/CDC42EP4/H3-3B;14
GO:0001656;metanephros development;1/67;19/2237;0,0526315789473684;1,75726630007855;0,582355382499808;0,440177361069805;0,626138421673257;0,559915923121364;CTNNB1;1
GO:0006970;response to osmotic stress;1/67;19/2237;0,0526315789473684;1,75726630007855;0,582355382499808;0,440177361069805;0,626138421673257;0,559915923121364;NLRP3;1
GO:0010232;vascular transport;1/67;19/2237;0,0526315789473684;1,75726630007855;0,582355382499808;0,440177361069805;0,626138421673257;0,559915923121364;SLC13A3;1
GO:0032526;response to retinoic acid;1/67;19/2237;0,0526315789473684;1,75726630007855;0,582355382499808;0,440177361069805;0,626138421673257;0,559915923121364;KLF4;1
GO:0045453;bone resorption;1/67;19/2237;0,0526315789473684;1,75726630007855;0,582355382499808;0,440177361069805;0,626138421673257;0,559915923121364;CTNNB1;1
GO:0045581;negative regulation of T cell differentiation;1/67;19/2237;0,0526315789473684;1,75726630007855;0,582355382499808;0,440177361069805;0,626138421673257;0,559915923121364;IRF1;1
GO:0045670;regulation of osteoclast differentiation;1/67;19/2237;0,0526315789473684;1,75726630007855;0,582355382499808;0,440177361069805;0,626138421673257;0,559915923121364;CTNNB1;1
GO:0048644;muscle organ morphogenesis;1/67;19/2237;0,0526315789473684;1,75726630007855;0,582355382499808;0,440177361069805;0,626138421673257;0,559915923121364;ARID5B;1
GO:0051963;regulation of synapse assembly;1/67;19/2237;0,0526315789473684;1,75726630007855;0,582355382499808;0,440177361069805;0,626138421673257;0,559915923121364;CTNNB1;1
GO:0061014;positive regulation of mRNA catabolic process;1/67;19/2237;0,0526315789473684;1,75726630007855;0,582355382499808;0,440177361069805;0,626138421673257;0,559915923121364;ZFP36;1
GO:0062014;negative regulation of small molecule metabolic process;1/67;19/2237;0,0526315789473684;1,75726630007855;0,582355382499808;0,440177361069805;0,626138421673257;0,559915923121364;STAT3;1
GO:0072089;stem cell proliferation;1/67;19/2237;0,0526315789473684;1,75726630007855;0,582355382499808;0,440177361069805;0,626138421673257;0,559915923121364;CTNNB1;1
GO:0150104;transport across blood-brain barrier;1/67;19/2237;0,0526315789473684;1,75726630007855;0,582355382499808;0,440177361069805;0,626138421673257;0,559915923121364;SLC13A3;1
GO:1901796;regulation of signal transduction by p53 class mediator;1/67;19/2237;0,0526315789473684;1,75726630007855;0,582355382499808;0,440177361069805;0,626138421673257;0,559915923121364;UBB;1
GO:1903008;organelle disassembly;1/67;19/2237;0,0526315789473684;1,75726630007855;0,582355382499808;0,440177361069805;0,626138421673257;0,559915923121364;HK2;1
GO:1990874;vascular associated smooth muscle cell proliferation;1/67;19/2237;0,0526315789473684;1,75726630007855;0,582355382499808;0,440177361069805;0,626138421673257;0,559915923121364;JAK2;1
GO:2000516;positive regulation of CD4-positive, alpha-beta T cell activation;1/67;19/2237;0,0526315789473684;1,75726630007855;0,582355382499808;0,440177361069805;0,626138421673257;0,559915923121364;NLRP3;1
GO:0002449;lymphocyte mediated immunity;3/67;81/2237;0,037037037037037;1,23659480375898;0,381036664986204;0,44067714682706;0,626138421673257;0,559915923121364;NLRP3/ARID5A/PVR;3
GO:0050870;positive regulation of T cell activation;3/67;81/2237;0,037037037037037;1,23659480375898;0,381036664986204;0,44067714682706;0,626138421673257;0,559915923121364;NLRP3/JAK2/PNP;3
GO:0072594;establishment of protein localization to organelle;3/67;81/2237;0,037037037037037;1,23659480375898;0,381036664986204;0,44067714682706;0,626138421673257;0,559915923121364;HK2/JAK2/STAT3;3
GO:0008610;lipid biosynthetic process;4/67;113/2237;0,0353982300884956;1,18187821952186;0,348566859567708;0,441541277264026;0,626895936385356;0,560593320538008;SGMS2/PTGES/NR1D1/PGS1;4
GO:0001906;cell killing;2/67;50/2237;0,04;1,3355223880597;0,421527146787623;0,445682333321439;0,630412501352356;0,563737961805114;GBP5/PVR;2
GO:0018105;peptidyl-serine phosphorylation;2/67;50/2237;0,04;1,3355223880597;0,421527146787623;0,445682333321439;0,630412501352356;0,563737961805114;GADD45A/NEK6;2
GO:0032868;response to insulin;2/67;50/2237;0,04;1,3355223880597;0,421527146787623;0,445682333321439;0,630412501352356;0,563737961805114;SH2B2/NDEL1;2
GO:0046883;regulation of hormone secretion;2/67;50/2237;0,04;1,3355223880597;0,421527146787623;0,445682333321439;0,630412501352356;0,563737961805114;JAK2/NR1D1;2
GO:0110053;regulation of actin filament organization;2/67;50/2237;0,04;1,3355223880597;0,421527146787623;0,445682333321439;0,630412501352356;0,563737961805114;CDC42EP2/CDC42EP4;2
GO:0051604;protein maturation;3/67;82/2237;0,0365853658536585;1,2215143793229;0,359028269762084;0,448718219328618;0,633302812703609;0,566322584138336;SDE2/NLRP3/HSPA1A;3
GO:0050679;positive regulation of epithelial cell proliferation;2/67;51/2237;0,0392156862745098;1,30933567456833;0,392584773875248;0,455925446349681;0,633302812703609;0,566322584138336;CTNNB1/STAT3;2
GO:0072659;protein localization to plasma membrane;2/67;51/2237;0,0392156862745098;1,30933567456833;0,392584773875248;0,455925446349681;0,633302812703609;0,566322584138336;TMBIM1/BCL2L1;2
GO:0140694;non-membrane-bounded organelle assembly;2/67;51/2237;0,0392156862745098;1,30933567456833;0,392584773875248;0,455925446349681;0,633302812703609;0,566322584138336;HSPA1A/NEK6;2
GO:1903311;regulation of mRNA metabolic process;2/67;51/2237;0,0392156862745098;1,30933567456833;0,392584773875248;0,455925446349681;0,633302812703609;0,566322584138336;TENT5C/ZFP36;2
GO:0001818;negative regulation of cytokine production;3/67;83/2237;0,036144578313253;1,20679733860816;0,337290862562247;0,456715541679327;0,633302812703609;0,566322584138336;NLRP3/KLF4/ZFP36;3
GO:0010817;regulation of hormone levels;3/67;83/2237;0,036144578313253;1,20679733860816;0,337290862562247;0,456715541679327;0,633302812703609;0,566322584138336;TIPARP/JAK2/NR1D1;3
GO:0001657;ureteric bud development;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;CTNNB1;1
GO:0001838;embryonic epithelial tube formation;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;CTNNB1;1
GO:0006413;translational initiation;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;ATF4;1
GO:0007041;lysosomal transport;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;HSPA1A;1
GO:0007088;regulation of mitotic nuclear division;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;DUSP1;1
GO:0007626;locomotory behavior;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;NR4A2;1
GO:0009566;fertilization;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;BCL2L1;1
GO:0009799;specification of symmetry;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;CTNNB1;1
GO:0009855;determination of bilateral symmetry;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;CTNNB1;1
GO:0010469;regulation of signaling receptor activity;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;JAK2;1
GO:0019218;regulation of steroid metabolic process;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;NR1D1;1
GO:0030512;negative regulation of transforming growth factor beta receptor signaling pathway;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;HSPA1A;1
GO:0032147;activation of protein kinase activity;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;JAK2;1
GO:0044773;mitotic DNA damage checkpoint signaling;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;SDE2;1
GO:0044774;mitotic DNA integrity checkpoint signaling;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;SDE2;1
GO:0070231;T cell apoptotic process;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;FAS;1
GO:0070507;regulation of microtubule cytoskeleton organization;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;HSPA1A;1
GO:0072163;mesonephric epithelium development;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;CTNNB1;1
GO:0072164;mesonephric tubule development;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;CTNNB1;1
GO:0097194;execution phase of apoptosis;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;BCL2L1;1
GO:0098754;detoxification;1/67;20/2237;0,05;1,66940298507463;0,52827885757193;0,457088144121348;0,633302812703609;0,566322584138336;PTGES;1
GO:0051130;positive regulation of cellular component organization;7/67;214/2237;0,0327102803738318;1,09213279397405;0,248981237341747;0,463183933998897;0,641279510960461;0,573455640046342;GBP5/INO80D/CTNNB1/HSPA1A/CDC42EP2/NDEL1/CDC42EP4;7
GO:0002520;immune system development;2/67;52/2237;0,0384615384615385;1,2841561423651;0,364230603531788;0,466062754486717;0,6438532873799;0,575757205243294;CTNNB1/PHLPP1;2
GO:0006936;muscle contraction;2/67;52/2237;0,0384615384615385;1,2841561423651;0,364230603531788;0,466062754486717;0,6438532873799;0,575757205243294;APBB2/ADORA2B;2
GO:0044843;cell cycle G1/S phase transition;2/67;52/2237;0,0384615384615385;1,2841561423651;0,364230603531788;0,466062754486717;0,6438532873799;0,575757205243294;SDE2/KLF4;2
GO:0019221;cytokine-mediated signaling pathway;6/67;182/2237;0,032967032967033;1,10070526488437;0,249014932578269;0,466947146590732;0,644604880206156;0,576429307092595;IRF1/HSPA1A/SH2B2/JAK2/FAS/STAT3;6
GO:0048667;cell morphogenesis involved in neuron differentiation;3/67;85/2237;0,0352941176470588;1,1784021071115;0,294599321943763;0,472569955370155;0,645644683475891;0,577359137282671;NR4A2/APBB2/NDEL1;3
GO:0001823;mesonephros development;1/67;21/2237;0,0476190476190476;1,58990760483298;0,477147000782412;0,473495493847948;0,645644683475891;0,577359137282671;CTNNB1;1
GO:0001942;hair follicle development;1/67;21/2237;0,0476190476190476;1,58990760483298;0,477147000782412;0,473495493847948;0,645644683475891;0,577359137282671;CTNNB1;1
GO:0005976;polysaccharide metabolic process;1/67;21/2237;0,0476190476190476;1,58990760483298;0,477147000782412;0,473495493847948;0,645644683475891;0,577359137282671;NR1D1;1
GO:0006275;regulation of DNA replication;1/67;21/2237;0,0476190476190476;1,58990760483298;0,477147000782412;0,473495493847948;0,645644683475891;0,577359137282671;INO80D;1
GO:0006282;regulation of DNA repair;1/67;21/2237;0,0476190476190476;1,58990760483298;0,477147000782412;0,473495493847948;0,645644683475891;0,577359137282671;INO80D;1
GO:0014855;striated muscle cell proliferation;1/67;21/2237;0,0476190476190476;1,58990760483298;0,477147000782412;0,473495493847948;0,645644683475891;0,577359137282671;JAK2;1
GO:0021782;glial cell development;1/67;21/2237;0,0476190476190476;1,58990760483298;0,477147000782412;0,473495493847948;0,645644683475891;0,577359137282671;NR1D1;1
GO:0031397;negative regulation of protein ubiquitination;1/67;21/2237;0,0476190476190476;1,58990760483298;0,477147000782412;0,473495493847948;0,645644683475891;0,577359137282671;HSPA1A;1
GO:0032370;positive regulation of lipid transport;1/67;21/2237;0,0476190476190476;1,58990760483298;0,477147000782412;0,473495493847948;0,645644683475891;0,577359137282671;PTGES;1
GO:0045620;negative regulation of lymphocyte differentiation;1/67;21/2237;0,0476190476190476;1,58990760483298;0,477147000782412;0,473495493847948;0,645644683475891;0,577359137282671;IRF1;1
GO:0046849;bone remodeling;1/67;21/2237;0,0476190476190476;1,58990760483298;0,477147000782412;0,473495493847948;0,645644683475891;0,577359137282671;CTNNB1;1
GO:0061180;mammary gland epithelium development;1/67;21/2237;0,0476190476190476;1,58990760483298;0,477147000782412;0,473495493847948;0,645644683475891;0,577359137282671;JAK2;1
GO:0062013;positive regulation of small molecule metabolic process;1/67;21/2237;0,0476190476190476;1,58990760483298;0,477147000782412;0,473495493847948;0,645644683475891;0,577359137282671;NR1D1;1
GO:0071230;cellular response to amino acid stimulus;1/67;21/2237;0,0476190476190476;1,58990760483298;0,477147000782412;0,473495493847948;0,645644683475891;0,577359137282671;BCL2L1;1
GO:0072175;epithelial tube formation;1/67;21/2237;0,0476190476190476;1,58990760483298;0,477147000782412;0,473495493847948;0,645644683475891;0,577359137282671;CTNNB1;1
GO:2000058;regulation of ubiquitin-dependent protein catabolic process;1/67;21/2237;0,0476190476190476;1,58990760483298;0,477147000782412;0,473495493847948;0,645644683475891;0,577359137282671;HSPA1A;1
GO:0120035;regulation of plasma membrane bounded cell projection organization;4/67;118/2237;0,0338983050847458;1,1317986339489;0,258422229091215;0,475444096982368;0,64639213056271;0,578027531859835;KLF4/CDC42EP2/NDEL1/CDC42EP4;4
GO:1903530;regulation of secretion by cell;4/67;118/2237;0,0338983050847458;1,1317986339489;0,258422229091215;0,475444096982368;0,64639213056271;0,578027531859835;JAK2/PTGES/ADORA2B/NR1D1;4
GO:0006417;regulation of translation;2/67;53/2237;0,0377358490566038;1,2599267811884;0,336438804078053;0,476091352763981;0,64639213056271;0,578027531859835;ZFP36/ATF4;2
GO:0018209;peptidyl-serine modification;2/67;53/2237;0,0377358490566038;1,2599267811884;0,336438804078053;0,476091352763981;0,64639213056271;0,578027531859835;GADD45A/NEK6;2
GO:0050671;positive regulation of lymphocyte proliferation;2/67;53/2237;0,0377358490566038;1,2599267811884;0,336438804078053;0,476091352763981;0,64639213056271;0,578027531859835;JAK2/PNP;2
GO:0055074;calcium ion homeostasis;2/67;53/2237;0,0377358490566038;1,2599267811884;0,336438804078053;0,476091352763981;0,64639213056271;0,578027531859835;TGM2/ATF4;2
GO:0006886;intracellular protein transport;4/67;119/2237;0,0336134453781513;1,12228772105857;0,240844530705923;0,482141493391852;0,649124965881215;0,580471333353457;JAK2/SAR1A/NDEL1/STAT3;4
GO:0007420;brain development;4/67;119/2237;0,0336134453781513;1,12228772105857;0,240844530705923;0,482141493391852;0,649124965881215;0,580471333353457;NR4A2/CTNNB1/NDEL1/UBB;4
GO:0022407;regulation of cell-cell adhesion;5/67;152/2237;0,0328947368421053;1,0982914375491;0,220509794837603;0,482934411267587;0,649124965881215;0,580471333353457;NLRP3/IRF1/JAK2/KLF4/PNP;5
GO:0070848;response to growth factor;5/67;152/2237;0,0328947368421053;1,0982914375491;0,220509794837603;0,482934411267587;0,649124965881215;0,580471333353457;CTNNB1/HSPA1A/KLF4/STAT3/ZFP36;5
GO:0044248;cellular catabolic process;8/67;251/2237;0,0318725099601594;1,06416126538622;0,189523729164124;0,483379067252438;0,649124965881215;0,580471333353457;TENT5C/MCL1/HK2/HSPA1A/PNP/STAT3/ZFP36/TIMP1;8
GO:0001894;tissue homeostasis;2/67;54/2237;0,037037037037037;1,23659480375898;0,309185165257819;0,486008598702315;0,649124965881215;0,580471333353457;CTNNB1/APBB2;2
GO:0010632;regulation of epithelial cell migration;2/67;54/2237;0,037037037037037;1,23659480375898;0,309185165257819;0,486008598702315;0,649124965881215;0,580471333353457;GADD45A/KLF4;2
GO:0051896;regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction;2/67;54/2237;0,037037037037037;1,23659480375898;0,309185165257819;0,486008598702315;0,649124965881215;0,580471333353457;JAK2/PHLPP1;2
GO:0060249;anatomical structure homeostasis;2/67;54/2237;0,037037037037037;1,23659480375898;0,309185165257819;0,486008598702315;0,649124965881215;0,580471333353457;CTNNB1/APBB2;2
GO:0010563;negative regulation of phosphorus metabolic process;3/67;87/2237;0,0344827586206897;1,15131240349974;0,252905550103044;0,488223409427875;0,649124965881215;0,580471333353457;GADD45A/DUSP1/STAT3;3
GO:0045936;negative regulation of phosphate metabolic process;3/67;87/2237;0,0344827586206897;1,15131240349974;0,252905550103044;0,488223409427875;0,649124965881215;0,580471333353457;GADD45A/DUSP1/STAT3;3
GO:0030155;regulation of cell adhesion;7/67;219/2237;0,0319634703196347;1,06719825529885;0,183934377945096;0,48843861612061;0,649124965881215;0,580471333353457;NLRP3/IRF1/DUSP1/JAK2/KLF4/PNP/TGM2;7
GO:0002228;natural killer cell mediated immunity;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;PVR;1
GO:0007589;body fluid secretion;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;HK2;1
GO:0008645;hexose transmembrane transport;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;HK2;1
GO:0010718;positive regulation of epithelial to mesenchymal transition;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;CTNNB1;1
GO:0015749;monosaccharide transmembrane transport;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;HK2;1
GO:0015908;fatty acid transport;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;PTGES;1
GO:0021675;nerve development;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;CTNNB1;1
GO:0022404;molting cycle process;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;CTNNB1;1
GO:0022405;hair cycle process;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;CTNNB1;1
GO:0032615;interleukin-12 production;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;IRF1;1
GO:0032655;regulation of interleukin-12 production;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;IRF1;1
GO:0034103;regulation of tissue remodeling;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;TMBIM1;1
GO:0042267;natural killer cell mediated cytotoxicity;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;PVR;1
GO:0042552;myelination;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;CTNNB1;1
GO:0071229;cellular response to acid chemical;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;BCL2L1;1
GO:0071326;cellular response to monosaccharide stimulus;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;NR1D1;1
GO:0071331;cellular response to hexose stimulus;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;NR1D1;1
GO:0071333;cellular response to glucose stimulus;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;NR1D1;1
GO:0140013;meiotic nuclear division;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;UBB;1
GO:1903305;regulation of regulated secretory pathway;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;ADORA2B;1
GO:1904659;glucose transmembrane transport;1/67;22/2237;0,0454545454545455;1,51763907734057;0,428642237817954;0,489414177021317;0,649124965881215;0,580471333353457;HK2;1
GO:0098609;cell-cell adhesion;7/67;220/2237;0,0318181818181818;1,0623473541384;0,171088119649579;0,493456153500193;0,652791504677349;0,583750086714753;NLRP3/CTNNB1/IRF1/JAK2/KLF4/PNP/PVR;7
GO:0031344;regulation of cell projection organization;4/67;121/2237;0,0330578512396694;1,10373751079314;0,206117141214236;0,495441431677561;0,652791504677349;0,583750086714753;KLF4/CDC42EP2/NDEL1/CDC42EP4;4
GO:0006644;phospholipid metabolic process;2/67;55/2237;0,0363636363636364;1,21411126187246;0,282446967751354;0,495812099618132;0,652791504677349;0,583750086714753;SGMS2/PGS1;2
GO:0050708;regulation of protein secretion;2/67;55/2237;0,0363636363636364;1,21411126187246;0,282446967751354;0,495812099618132;0,652791504677349;0,583750086714753;JAK2/NR1D1;2
GO:0051701;biological process involved in interaction with host;2/67;55/2237;0,0363636363636364;1,21411126187246;0,282446967751354;0,495812099618132;0,652791504677349;0,583750086714753;HSPA1A/PVR;2
GO:0071560;cellular response to transforming growth factor beta stimulus;2/67;55/2237;0,0363636363636364;1,21411126187246;0,282446967751354;0,495812099618132;0,652791504677349;0,583750086714753;HSPA1A/STAT3;2
GO:0007610;behavior;3/67;88/2237;0,0340909090909091;1,13822930800543;0,232416360573633;0,495969891885272;0,652791504677349;0,583750086714753;NR4A2/NR1D1/STAT3;3
GO:0016055;Wnt signaling pathway;3/67;88/2237;0,0340909090909091;1,13822930800543;0,232416360573633;0,495969891885272;0,652791504677349;0,583750086714753;NR4A2/CTNNB1/KLF4;3
GO:0031667;response to nutrient levels;3/67;88/2237;0,0340909090909091;1,13822930800543;0,232416360573633;0,495969891885272;0,652791504677349;0,583750086714753;FAS/ZFP36/ATF4;3
GO:0051960;regulation of nervous system development;3/67;88/2237;0,0340909090909091;1,13822930800543;0,232416360573633;0,495969891885272;0,652791504677349;0,583750086714753;CTNNB1/NR1D1/TGM2;3
GO:0090066;regulation of anatomical structure size;3/67;88/2237;0,0340909090909091;1,13822930800543;0,232416360573633;0,495969891885272;0,652791504677349;0,583750086714753;CDC42EP2/ADORA2B/CDC42EP4;3
GO:0043207;response to external biotic stimulus;13/67;420/2237;0,030952380952381;1,03343994314144;0,133584523577347;0,497499541050469;0,653895996356411;0,584737763651123;GBP5/NLRP3/ARID5A/IRF1/IRF4/HSPA1A/JAK2/CDC42EP2/NR1D1/CDC42EP4/ZFP36/PVR/BCL2L1;13
GO:0051707;response to other organism;13/67;420/2237;0,030952380952381;1,03343994314144;0,133584523577347;0,497499541050469;0,653895996356411;0,584737763651123;GBP5/NLRP3/ARID5A/IRF1/IRF4/HSPA1A/JAK2/CDC42EP2/NR1D1/CDC42EP4/ZFP36/PVR/BCL2L1;13
GO:0198738;cell-cell signaling by wnt;3/67;89/2237;0,0337078651685393;1,12544021465705;0,212157352568078;0,503660459706343;0,653972973104663;0,584806599080422;NR4A2/CTNNB1/KLF4;3
GO:0000956;nuclear-transcribed mRNA catabolic process;1/67;23/2237;0,0434782608695652;1,45165476963011;0,38249445594207;0,504858533743471;0,653972973104663;0,584806599080422;ZFP36;1
GO:0001938;positive regulation of endothelial cell proliferation;1/67;23/2237;0,0434782608695652;1,45165476963011;0,38249445594207;0,504858533743471;0,653972973104663;0,584806599080422;STAT3;1
GO:0002931;response to ischemia;1/67;23/2237;0,0434782608695652;1,45165476963011;0,38249445594207;0,504858533743471;0,653972973104663;0,584806599080422;HK2;1
GO:0007272;ensheathment of neurons;1/67;23/2237;0,0434782608695652;1,45165476963011;0,38249445594207;0,504858533743471;0,653972973104663;0,584806599080422;CTNNB1;1
GO:0008366;axon ensheathment;1/67;23/2237;0,0434782608695652;1,45165476963011;0,38249445594207;0,504858533743471;0,653972973104663;0,584806599080422;CTNNB1;1
GO:0016331;morphogenesis of embryonic epithelium;1/67;23/2237;0,0434782608695652;1,45165476963011;0,38249445594207;0,504858533743471;0,653972973104663;0,584806599080422;CTNNB1;1
GO:0030101;natural killer cell activation;1/67;23/2237;0,0434782608695652;1,45165476963011;0,38249445594207;0,504858533743471;0,653972973104663;0,584806599080422;JAK2;1
GO:0032608;interferon-beta production;1/67;23/2237;0,0434782608695652;1,45165476963011;0,38249445594207;0,504858533743471;0,653972973104663;0,584806599080422;IRF1;1
GO:0032648;regulation of interferon-beta production;1/67;23/2237;0,0434782608695652;1,45165476963011;0,38249445594207;0,504858533743471;0,653972973104663;0,584806599080422;IRF1;1
GO:0035107;appendage morphogenesis;1/67;23/2237;0,0434782608695652;1,45165476963011;0,38249445594207;0,504858533743471;0,653972973104663;0,584806599080422;CTNNB1;1
GO:0035108;limb morphogenesis;1/67;23/2237;0,0434782608695652;1,45165476963011;0,38249445594207;0,504858533743471;0,653972973104663;0,584806599080422;CTNNB1;1
GO:0042088;T-helper 1 type immune response;1/67;23/2237;0,0434782608695652;1,45165476963011;0,38249445594207;0,504858533743471;0,653972973104663;0,584806599080422;ARID5A;1
GO:0042303;molting cycle;1/67;23/2237;0,0434782608695652;1,45165476963011;0,38249445594207;0,504858533743471;0,653972973104663;0,584806599080422;CTNNB1;1
GO:0042633;hair cycle;1/67;23/2237;0,0434782608695652;1,45165476963011;0,38249445594207;0,504858533743471;0,653972973104663;0,584806599080422;CTNNB1;1
GO:0060041;retina development in camera-type eye;1/67;23/2237;0,0434782608695652;1,45165476963011;0,38249445594207;0,504858533743471;0,653972973104663;0,584806599080422;STAT3;1
GO:0072009;nephron epithelium development;1/67;23/2237;0,0434782608695652;1,45165476963011;0,38249445594207;0,504858533743471;0,653972973104663;0,584806599080422;CTNNB1;1
GO:2000107;negative regulation of leukocyte apoptotic process;1/67;23/2237;0,0434782608695652;1,45165476963011;0,38249445594207;0,504858533743471;0,653972973104663;0,584806599080422;BCL2L1;1
GO:0002695;negative regulation of leukocyte activation;2/67;56/2237;0,0357142857142857;1,19243070362473;0,256202865387234;0,505499700435706;0,653972973104663;0,584806599080422;IRF1/NR1D1;2
GO:0003018;vascular process in circulatory system;2/67;56/2237;0,0357142857142857;1,19243070362473;0,256202865387234;0,505499700435706;0,653972973104663;0,584806599080422;ADORA2B/SLC13A3;2
GO:0016311;dephosphorylation;2/67;56/2237;0,0357142857142857;1,19243070362473;0,256202865387234;0,505499700435706;0,653972973104663;0,584806599080422;DUSP1/PHLPP1;2
GO:0048232;male gamete generation;2/67;56/2237;0,0357142857142857;1,19243070362473;0,256202865387234;0,505499700435706;0,653972973104663;0,584806599080422;UBB/BCL2L1;2
GO:0062012;regulation of small molecule metabolic process;2/67;56/2237;0,0357142857142857;1,19243070362473;0,256202865387234;0,505499700435706;0,653972973104663;0,584806599080422;NR1D1/STAT3;2
GO:0048878;chemical homeostasis;5/67;156/2237;0,032051282051282;1,07013011863758;0,159541718851576;0,506544499777619;0,654877325992362;0,585615304574952;HK2/NR1D1/STAT3/TGM2/ATF4;5
GO:0007015;actin filament organization;3/67;90/2237;0,0333333333333333;1,11293532338308;0,192122604858478;0,511293412879467;0,659907289061099;0,590113281887016;JAK2/CDC42EP2/CDC42EP4;3
GO:0120031;plasma membrane bounded cell projection assembly;3/67;90/2237;0,0333333333333333;1,11293532338308;0,192122604858478;0,511293412879467;0,659907289061099;0,590113281887016;CDC42EP2/NDEL1/CDC42EP4;3
GO:0007155;cell adhesion;10/67;324/2237;0,0308641975308642;1,03049566979915;0,104278945464688;0,512816289604578;0,659907289061099;0,590113281887016;NLRP3/CTNNB1/IRF1/DUSP1/JAK2/KLF4/PPFIBP1/PNP/PVR/TGM2;10
GO:0000302;response to reactive oxygen species;2/67;57/2237;0,0350877192982456;1,17151086671904;0,230432778611883;0,515069471987365;0,659907289061099;0,590113281887016;KLF4/OSER1;2
GO:0046879;hormone secretion;2/67;57/2237;0,0350877192982456;1,17151086671904;0,230432778611883;0,515069471987365;0,659907289061099;0,590113281887016;JAK2/NR1D1;2
GO:0050729;positive regulation of inflammatory response;2/67;57/2237;0,0350877192982456;1,17151086671904;0,230432778611883;0,515069471987365;0,659907289061099;0,590113281887016;NLRP3/ADORA2B;2
GO:0051222;positive regulation of protein transport;2/67;57/2237;0,0350877192982456;1,17151086671904;0,230432778611883;0,515069471987365;0,659907289061099;0,590113281887016;JAK2/SAR1A;2
GO:0051962;positive regulation of nervous system development;2/67;57/2237;0,0350877192982456;1,17151086671904;0,230432778611883;0,515069471987365;0,659907289061099;0,590113281887016;CTNNB1/TGM2;2
GO:0071559;response to transforming growth factor beta;2/67;57/2237;0,0350877192982456;1,17151086671904;0,230432778611883;0,515069471987365;0,659907289061099;0,590113281887016;HSPA1A/STAT3;2
GO:1990778;protein localization to cell periphery;2/67;57/2237;0,0350877192982456;1,17151086671904;0,230432778611883;0,515069471987365;0,659907289061099;0,590113281887016;TMBIM1/BCL2L1;2
GO:0072359;circulatory system development;7/67;225/2237;0,0311111111111111;1,03873963515755;0,107640630063369;0,518339023293509;0,659907289061099;0,590113281887016;GADD45A/HK2/CTNNB1/TIPARP/KLF4/STAT3/JUNB;7
GO:0051493;regulation of cytoskeleton organization;3/67;91/2237;0,032967032967033;1,10070526488437;0,172306415350927;0,518867140127665;0,659907289061099;0,590113281887016;HSPA1A/CDC42EP2/CDC42EP4;3
GO:0001910;regulation of leukocyte mediated cytotoxicity;1/67;24/2237;0,0416666666666667;1,39116915422886;0,338472156915585;0,51984248958773;0,659907289061099;0,590113281887016;PVR;1
GO:0002275;myeloid cell activation involved in immune response;1/67;24/2237;0,0416666666666667;1,39116915422886;0,338472156915585;0,51984248958773;0,659907289061099;0,590113281887016;ADORA2B;1
GO:0010565;regulation of cellular ketone metabolic process;1/67;24/2237;0,0416666666666667;1,39116915422886;0,338472156915585;0,51984248958773;0,659907289061099;0,590113281887016;NR1D1;1
GO:0033135;regulation of peptidyl-serine phosphorylation;1/67;24/2237;0,0416666666666667;1,39116915422886;0,338472156915585;0,51984248958773;0,659907289061099;0,590113281887016;GADD45A;1
GO:0034219;carbohydrate transmembrane transport;1/67;24/2237;0,0416666666666667;1,39116915422886;0,338472156915585;0,51984248958773;0,659907289061099;0,590113281887016;HK2;1
GO:0035270;endocrine system development;1/67;24/2237;0,0416666666666667;1,39116915422886;0,338472156915585;0,51984248958773;0,659907289061099;0,590113281887016;ARID5B;1
GO:0042476;odontogenesis;1/67;24/2237;0,0416666666666667;1,39116915422886;0,338472156915585;0,51984248958773;0,659907289061099;0,590113281887016;CTNNB1;1
GO:0048145;regulation of fibroblast proliferation;1/67;24/2237;0,0416666666666667;1,39116915422886;0,338472156915585;0,51984248958773;0,659907289061099;0,590113281887016;CTNNB1;1
GO:0051028;mRNA transport;1/67;24/2237;0,0416666666666667;1,39116915422886;0,338472156915585;0,51984248958773;0,659907289061099;0,590113281887016;ZFP36;1
GO:0051592;response to calcium ion;1/67;24/2237;0,0416666666666667;1,39116915422886;0,338472156915585;0,51984248958773;0,659907289061099;0,590113281887016;JUNB;1
GO:0051783;regulation of nuclear division;1/67;24/2237;0,0416666666666667;1,39116915422886;0,338472156915585;0,51984248958773;0,659907289061099;0,590113281887016;DUSP1;1
GO:1900182;positive regulation of protein localization to nucleus;1/67;24/2237;0,0416666666666667;1,39116915422886;0,338472156915585;0,51984248958773;0,659907289061099;0,590113281887016;JAK2;1
GO:1903035;negative regulation of response to wounding;1/67;24/2237;0,0416666666666667;1,39116915422886;0,338472156915585;0,51984248958773;0,659907289061099;0,590113281887016;STAT3;1
GO:1903825;organic acid transmembrane transport;1/67;24/2237;0,0416666666666667;1,39116915422886;0,338472156915585;0,51984248958773;0,659907289061099;0,590113281887016;SLC13A3;1
GO:1905039;carboxylic acid transmembrane transport;1/67;24/2237;0,0416666666666667;1,39116915422886;0,338472156915585;0,51984248958773;0,659907289061099;0,590113281887016;SLC13A3;1
GO:0046903;secretion;6/67;192/2237;0,03125;1,04337686567164;0,110434701019777;0,520863495503224;0,660760522761625;0,590876274730982;HK2/JAK2/PTGES/ADORA2B/NR1D1/TGM2;6
GO:0016477;cell migration;11/67;360/2237;0,0305555555555556;1,02019071310116;0,0734707047708918;0,523535771219555;0,663620782492217;0,593434023803689;GADD45A/NR4A2/CTNNB1/APBB2/DUSP1/JAK2/KLF4/ARID5B/NDEL1/STAT3/TIMP1;11
GO:0002700;regulation of production of molecular mediator of immune response;2/67;58/2237;0,0344827586206897;1,15131240349974;0,205117797961997;0,524519699783975;0,663620782492217;0,593434023803689;NLRP3/ARID5A;2
GO:0015711;organic anion transport;2/67;58/2237;0,0344827586206897;1,15131240349974;0,205117797961997;0,524519699783975;0,663620782492217;0,593434023803689;PTGES/SLC13A3;2
GO:0060759;regulation of response to cytokine stimulus;2/67;58/2237;0,0344827586206897;1,15131240349974;0,205117797961997;0,524519699783975;0,663620782492217;0,593434023803689;HSPA1A/KLF4;2
GO:0070727;cellular macromolecule localization;12/67;394/2237;0,0304568527918782;1,0168952193348;0,064907175609752;0,525722756103205;0,664698865193238;0,59439808486407;GBP5/MCL1/HK2/TMBIM1/CTNNB1/JAK2/SAR1A/NDEL1/NR1D1/STAT3/ZFP36/BCL2L1;12
GO:1903039;positive regulation of leukocyte cell-cell adhesion;3/67;92/2237;0,0326086956521739;1,08874107722258;0,152703290590463;0,526380117037401;0,664990079273851;0,594658499167247;NLRP3/JAK2/PNP;3
GO:0051649;establishment of localization in cell;9/67;294/2237;0,0306122448979592;1,02208346024977;0,0713752796414699;0,527617072958403;0,664990079273851;0,594658499167247;CTNNB1/HSPA1A/JAK2/SAR1A/NDEL1/ADORA2B/UBB/NR1D1/STAT3;9
GO:0051046;regulation of secretion;4/67;126/2237;0,0317460317460317;1,05993840322199;0,121671751238735;0,528076682291014;0,664990079273851;0,594658499167247;JAK2/PTGES/ADORA2B/NR1D1;4
GO:0007267;cell-cell signaling;9/67;295/2237;0,0305084745762712;1,01861877055401;0,0602949347110856;0,531995807270434;0,664990079273851;0,594658499167247;NR4A2/CTNNB1/JAK2/KLF4/PTGES/ADORA2B/NR1D1/TGM2/ATF4;9
GO:0045926;negative regulation of growth;2/67;59/2237;0,0338983050847458;1,1317986339489;0,1802400964441;0,533848873238707;0,664990079273851;0,594658499167247;SERTAD2/HSPA1A;2
GO:0001961;positive regulation of cytokine-mediated signaling pathway;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;HSPA1A;1
GO:0006164;purine nucleotide biosynthetic process;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;ADSS2;1
GO:0006457;protein folding;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;HSPA1A;1
GO:0006997;nucleus organization;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;NEK6;1
GO:0007189;adenylate cyclase-activating G protein-coupled receptor signaling pathway;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;ADORA2B;1
GO:0030148;sphingolipid biosynthetic process;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;SGMS2;1
GO:0033077;T cell differentiation in thymus;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;CTNNB1;1
GO:0034109;homotypic cell-cell adhesion;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;JAK2;1
GO:0035150;regulation of tube size;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;ADORA2B;1
GO:0035296;regulation of tube diameter;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;ADORA2B;1
GO:0035725;sodium ion transmembrane transport;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;SLC13A3;1
GO:0046330;positive regulation of JNK cascade;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;GADD45A;1
GO:0051302;regulation of cell division;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;BCL2L1;1
GO:0060761;negative regulation of response to cytokine stimulus;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;KLF4;1
GO:0061351;neural precursor cell proliferation;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;CTNNB1;1
GO:0071322;cellular response to carbohydrate stimulus;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;NR1D1;1
GO:0097746;blood vessel diameter maintenance;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;ADORA2B;1
GO:1903046;meiotic cell cycle process;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;UBB;1
GO:1903313;positive regulation of mRNA metabolic process;1/67;25/2237;0,04;1,3355223880597;0,296375555676914;0,534379567399579;0,664990079273851;0,594658499167247;ZFP36;1
GO:0030031;cell projection assembly;3/67;94/2237;0,0319148936170213;1,06557637345189;0,114115245962629;0,541218145137234;0,67305789027572;0,601873031430908;CDC42EP2/NDEL1/CDC42EP4;3
GO:0006281;DNA repair;2/67;60/2237;0,0333333333333333;1,11293532338308;0,155782849861979;0,54305567532763;0,674015366363388;0,602729241637688;GADD45A/INO80D;2
GO:0009914;hormone transport;2/67;60/2237;0,0333333333333333;1,11293532338308;0,155782849861979;0,54305567532763;0,674015366363388;0,602729241637688;JAK2/NR1D1;2
GO:0022604;regulation of cell morphogenesis;2/67;60/2237;0,0333333333333333;1,11293532338308;0,155782849861979;0,54305567532763;0,674015366363388;0,602729241637688;CDC42EP2/CDC42EP4;2
GO:0033036;macromolecule localization;14/67;467/2237;0,0299785867237687;1,00092684329956;0,00395568368204323;0,548077342972857;0,675510942501025;0,604066640629217;GBP5/MCL1/HK2/TMBIM1/CTNNB1/JAK2/PTGES/SAR1A/NDEL1/NR1D1/STAT3/ZFP36/BCL2L1/SLC13A3;14
GO:0006672;ceramide metabolic process;1/67;26/2237;0,0384615384615385;1,2841561423651;0,256031137075915;0,54848289876677;0,675510942501025;0,604066640629217;SGMS2;1
GO:0006813;potassium ion transport;1/67;26/2237;0,0384615384615385;1,2841561423651;0,256031137075915;0,54848289876677;0,675510942501025;0,604066640629217;ATF4;1
GO:0007416;synapse assembly;1/67;26/2237;0,0384615384615385;1,2841561423651;0,256031137075915;0,54848289876677;0,675510942501025;0,604066640629217;CTNNB1;1
GO:0019080;viral gene expression;1/67;26/2237;0,0384615384615385;1,2841561423651;0,256031137075915;0,54848289876677;0,675510942501025;0,604066640629217;ZFP36;1
GO:0034142;toll-like receptor 4 signaling pathway;1/67;26/2237;0,0384615384615385;1,2841561423651;0,256031137075915;0,54848289876677;0,675510942501025;0,604066640629217;NR1D1;1
GO:0042531;positive regulation of tyrosine phosphorylation of STAT protein;1/67;26/2237;0,0384615384615385;1,2841561423651;0,256031137075915;0,54848289876677;0,675510942501025;0,604066640629217;JAK2;1
GO:0043271;negative regulation of monoatomic ion transport;1/67;26/2237;0,0384615384615385;1,2841561423651;0,256031137075915;0,54848289876677;0,675510942501025;0,604066640629217;ATF4;1
GO:0090090;negative regulation of canonical Wnt signaling pathway;1/67;26/2237;0,0384615384615385;1,2841561423651;0,256031137075915;0,54848289876677;0,675510942501025;0,604066640629217;CTNNB1;1
GO:0090398;cellular senescence;1/67;26/2237;0,0384615384615385;1,2841561423651;0,256031137075915;0,54848289876677;0,675510942501025;0,604066640629217;NEK6;1
GO:1905954;positive regulation of lipid localization;1/67;26/2237;0,0384615384615385;1,2841561423651;0,256031137075915;0,54848289876677;0,675510942501025;0,604066640629217;PTGES;1
GO:0009896;positive regulation of catabolic process;3/67;95/2237;0,0315789473684211;1,05435978004713;0,0951202962543624;0,548540564713082;0,675510942501025;0,604066640629217;TIPARP/HSPA1A/ZFP36;3
GO:0002009;morphogenesis of an epithelium;3/67;96/2237;0,03125;1,04337686567164;0,0763183345485909;0,555796966871993;0,684002245130315;0,611659874626064;CTNNB1/KLF4/TGM2;3
GO:0001933;negative regulation of protein phosphorylation;2/67;62/2237;0,032258064516129;1,07703418391911;0,108067009674406;0,56109780602173;0,685602675729408;0,61309103831969;GADD45A/DUSP1;2
GO:0034248;regulation of amide metabolic process;2/67;62/2237;0,032258064516129;1,07703418391911;0,108067009674406;0,56109780602173;0,685602675729408;0,61309103831969;ZFP36/ATF4;2
GO:0043547;positive regulation of GTPase activity;2/67;62/2237;0,032258064516129;1,07703418391911;0,108067009674406;0,56109780602173;0,685602675729408;0,61309103831969;NDEL1/TGM2;2
GO:0000910;cytokinesis;1/67;27/2237;0,037037037037037;1,23659480375898;0,217287319006752;0,562165235167778;0,685602675729408;0,61309103831969;BCL2L1;1
GO:0007034;vacuolar transport;1/67;27/2237;0,037037037037037;1,23659480375898;0,217287319006752;0,562165235167778;0,685602675729408;0,61309103831969;HSPA1A;1
GO:0007229;integrin-mediated signaling pathway;1/67;27/2237;0,037037037037037;1,23659480375898;0,217287319006752;0,562165235167778;0,685602675729408;0,61309103831969;TIMP1;1
GO:0030902;hindbrain development;1/67;27/2237;0,037037037037037;1,23659480375898;0,217287319006752;0,562165235167778;0,685602675729408;0,61309103831969;CTNNB1;1
GO:0031341;regulation of cell killing;1/67;27/2237;0,037037037037037;1,23659480375898;0,217287319006752;0,562165235167778;0,685602675729408;0,61309103831969;PVR;1
GO:0046467;membrane lipid biosynthetic process;1/67;27/2237;0,037037037037037;1,23659480375898;0,217287319006752;0,562165235167778;0,685602675729408;0,61309103831969;SGMS2;1
GO:0048144;fibroblast proliferation;1/67;27/2237;0,037037037037037;1,23659480375898;0,217287319006752;0,562165235167778;0,685602675729408;0,61309103831969;CTNNB1;1
GO:0048534;hematopoietic or lymphoid organ development;1/67;27/2237;0,037037037037037;1,23659480375898;0,217287319006752;0,562165235167778;0,685602675729408;0,61309103831969;CTNNB1;1
GO:0048736;appendage development;1/67;27/2237;0,037037037037037;1,23659480375898;0,217287319006752;0,562165235167778;0,685602675729408;0,61309103831969;CTNNB1;1
GO:0060173;limb development;1/67;27/2237;0,037037037037037;1,23659480375898;0,217287319006752;0,562165235167778;0,685602675729408;0,61309103831969;CTNNB1;1
GO:0071466;cellular response to xenobiotic stimulus;1/67;27/2237;0,037037037037037;1,23659480375898;0,217287319006752;0,562165235167778;0,685602675729408;0,61309103831969;RNF149;1
GO:1901137;carbohydrate derivative biosynthetic process;3/67;97/2237;0,0309278350515464;1,03262040313894;0,0577047732023053;0,56298623287053;0,686162113936154;0,613591308466221;ADSS2/CTNNB1/PNP;3
GO:0002440;production of molecular mediator of immune response;2/67;63/2237;0,0317460317460317;1,05993840322199;0,0847791597431051;0,56993138114069;0,691988182845321;0,618801192796155;NLRP3/ARID5A;2
GO:0010038;response to metal ion;2/67;63/2237;0,0317460317460317;1,05993840322199;0,0847791597431051;0,56993138114069;0,691988182845321;0,618801192796155;JUNB/ATF4;2
GO:0090287;regulation of cellular response to growth factor stimulus;2/67;63/2237;0,0317460317460317;1,05993840322199;0,0847791597431051;0,56993138114069;0,691988182845321;0,618801192796155;CTNNB1/HSPA1A;2
GO:1902107;positive regulation of leukocyte differentiation;2/67;63/2237;0,0317460317460317;1,05993840322199;0,0847791597431051;0,56993138114069;0,691988182845321;0,618801192796155;NLRP3/PNP;2
GO:1903708;positive regulation of hemopoiesis;2/67;63/2237;0,0317460317460317;1,05993840322199;0,0847791597431051;0,56993138114069;0,691988182845321;0,618801192796155;NLRP3/PNP;2
GO:0051301;cell division;3/67;98/2237;0,0306122448979592;1,02208346024977;0,0392751817478118;0,570107319307605;0,691988182845321;0,618801192796155;SDE2/NEK6/BCL2L1;3
GO:0048589;developmental growth;4/67;133/2237;0,0300751879699248;1,00415217147346;0,00867404492578313;0,572066171120114;0,691988182845321;0,618801192796155;CTNNB1/ARID5B/NDEL1/STAT3;4
GO:0032940;secretion by cell;5/67;168/2237;0,0297619047619048;0,993692253020611;-0,0149345483717677;0,574749721771385;0,691988182845321;0,618801192796155;JAK2/PTGES/ADORA2B/NR1D1/TGM2;5
GO:0008643;carbohydrate transport;1/67;28/2237;0,0357142857142857;1,19243070362473;0,180010964818294;0,575438958807487;0,691988182845321;0,618801192796155;HK2;1
GO:0010811;positive regulation of cell-substrate adhesion;1/67;28/2237;0,0357142857142857;1,19243070362473;0,180010964818294;0,575438958807487;0,691988182845321;0,618801192796155;JAK2;1
GO:0015718;monocarboxylic acid transport;1/67;28/2237;0,0357142857142857;1,19243070362473;0,180010964818294;0,575438958807487;0,691988182845321;0,618801192796155;PTGES;1
GO:0017015;regulation of transforming growth factor beta receptor signaling pathway;1/67;28/2237;0,0357142857142857;1,19243070362473;0,180010964818294;0,575438958807487;0,691988182845321;0,618801192796155;HSPA1A;1
GO:0030278;regulation of ossification;1/67;28/2237;0,0357142857142857;1,19243070362473;0,180010964818294;0,575438958807487;0,691988182845321;0,618801192796155;SGMS2;1
GO:0032368;regulation of lipid transport;1/67;28/2237;0,0357142857142857;1,19243070362473;0,180010964818294;0,575438958807487;0,691988182845321;0,618801192796155;PTGES;1
GO:0032481;positive regulation of type I interferon production;1/67;28/2237;0,0357142857142857;1,19243070362473;0,180010964818294;0,575438958807487;0,691988182845321;0,618801192796155;IRF1;1
GO:0032722;positive regulation of chemokine production;1/67;28/2237;0,0357142857142857;1,19243070362473;0,180010964818294;0,575438958807487;0,691988182845321;0,618801192796155;ADORA2B;1
GO:0046822;regulation of nucleocytoplasmic transport;1/67;28/2237;0,0357142857142857;1,19243070362473;0,180010964818294;0,575438958807487;0,691988182845321;0,618801192796155;JAK2;1
GO:0046887;positive regulation of hormone secretion;1/67;28/2237;0,0357142857142857;1,19243070362473;0,180010964818294;0,575438958807487;0,691988182845321;0,618801192796155;JAK2;1
GO:0055088;lipid homeostasis;1/67;28/2237;0,0357142857142857;1,19243070362473;0,180010964818294;0,575438958807487;0,691988182845321;0,618801192796155;NR1D1;1
GO:0060760;positive regulation of response to cytokine stimulus;1/67;28/2237;0,0357142857142857;1,19243070362473;0,180010964818294;0,575438958807487;0,691988182845321;0,618801192796155;HSPA1A;1
GO:0140895;cell surface toll-like receptor signaling pathway;1/67;28/2237;0,0357142857142857;1,19243070362473;0,180010964818294;0,575438958807487;0,691988182845321;0,618801192796155;NR1D1;1
GO:0010506;regulation of autophagy;2/67;64/2237;0,03125;1,04337686567164;0,0618531362594398;0,578639060053731;0,694513548632298;0,621059467431428;MCL1/STAT3;2
GO:0032535;regulation of cellular component size;2/67;64/2237;0,03125;1,04337686567164;0,0618531362594398;0,578639060053731;0,694513548632298;0,621059467431428;CDC42EP2/CDC42EP4;2
GO:0050866;negative regulation of cell activation;2/67;64/2237;0,03125;1,04337686567164;0,0618531362594398;0,578639060053731;0,694513548632298;0,621059467431428;IRF1/NR1D1;2
GO:0022607;cellular component assembly;12/67;410/2237;0,0292682926829268;0,977211503458318;-0,0896977940488448;0,586777253077839;0,697727414166421;0,623933423772451;GBP5/NLRP3/CTNNB1/HSPA1A/JAK2/NEK6/SAR1A/FAS/CDC42EP2/NDEL1/CDC42EP4/H3-3B;12
GO:0071900;regulation of protein serine/threonine kinase activity;2/67;65/2237;0,0307692307692308;1,02732491389208;0,0392761584980936;0,587220352667382;0,697727414166421;0,623933423772451;GADD45A/DUSP1;2
GO:0141091;transforming growth factor beta receptor superfamily signaling pathway;2/67;65/2237;0,0307692307692308;1,02732491389208;0,0392761584980936;0,587220352667382;0,697727414166421;0,623933423772451;HSPA1A/STAT3;2
GO:0009617;response to bacterium;6/67;205/2237;0,0292682926829268;0,977211503458318;-0,0601414904210749;0,587785947208389;0,697727414166421;0,623933423772451;GBP5/NLRP3/ARID5A/JAK2/NR1D1/ZFP36;6
GO:0002444;myeloid leukocyte mediated immunity;1/67;29/2237;0,0344827586206897;1,15131240349974;0,144084554575667;0,588316093148772;0,697727414166421;0,623933423772451;ADORA2B;1
GO:0002752;cell surface pattern recognition receptor signaling pathway;1/67;29/2237;0,0344827586206897;1,15131240349974;0,144084554575667;0,588316093148772;0,697727414166421;0,623933423772451;NR1D1;1
GO:0007265;Ras protein signal transduction;1/67;29/2237;0,0344827586206897;1,15131240349974;0,144084554575667;0,588316093148772;0,697727414166421;0,623933423772451;SH2B2;1
GO:0009749;response to glucose;1/67;29/2237;0,0344827586206897;1,15131240349974;0,144084554575667;0,588316093148772;0,697727414166421;0,623933423772451;NR1D1;1
GO:0010717;regulation of epithelial to mesenchymal transition;1/67;29/2237;0,0344827586206897;1,15131240349974;0,144084554575667;0,588316093148772;0,697727414166421;0,623933423772451;CTNNB1;1
GO:0030010;establishment of cell polarity;1/67;29/2237;0,0344827586206897;1,15131240349974;0,144084554575667;0,588316093148772;0,697727414166421;0,623933423772451;NDEL1;1
GO:0043200;response to amino acid;1/67;29/2237;0,0344827586206897;1,15131240349974;0,144084554575667;0,588316093148772;0,697727414166421;0,623933423772451;BCL2L1;1
GO:0050657;nucleic acid transport;1/67;29/2237;0,0344827586206897;1,15131240349974;0,144084554575667;0,588316093148772;0,697727414166421;0,623933423772451;ZFP36;1
GO:0050658;RNA transport;1/67;29/2237;0,0344827586206897;1,15131240349974;0,144084554575667;0,588316093148772;0,697727414166421;0,623933423772451;ZFP36;1
GO:0050821;protein stabilization;1/67;29/2237;0,0344827586206897;1,15131240349974;0,144084554575667;0,588316093148772;0,697727414166421;0,623933423772451;HSPA1A;1
GO:0051236;establishment of RNA localization;1/67;29/2237;0,0344827586206897;1,15131240349974;0,144084554575667;0,588316093148772;0,697727414166421;0,623933423772451;ZFP36;1
GO:0070227;lymphocyte apoptotic process;1/67;29/2237;0,0344827586206897;1,15131240349974;0,144084554575667;0,588316093148772;0,697727414166421;0,623933423772451;FAS;1
GO:0099504;synaptic vesicle cycle;1/67;29/2237;0,0344827586206897;1,15131240349974;0,144084554575667;0,588316093148772;0,697727414166421;0,623933423772451;CTNNB1;1
GO:1901224;positive regulation of non-canonical NF-kappaB signal transduction;1/67;29/2237;0,0344827586206897;1,15131240349974;0,144084554575667;0,588316093148772;0,697727414166421;0,623933423772451;NLRP3;1
GO:1903844;regulation of cellular response to transforming growth factor beta stimulus;1/67;29/2237;0,0344827586206897;1,15131240349974;0,144084554575667;0,588316093148772;0,697727414166421;0,623933423772451;HSPA1A;1
GO:0030001;metal ion transport;4/67;136/2237;0,0294117647058824;0,982001755926251;-0,0380478393305673;0,59023930691354;0,699570242361855;0,625581348280012;CTNNB1/ORAI2/ATF4/SLC13A3;4
GO:0048870;cell motility;11/67;377/2237;0,0291777188328912;0,974187418345936;-0,0965581819097953;0,590624599176412;0,699589112470372;0,625598222622591;GADD45A/NR4A2/CTNNB1/APBB2/DUSP1/JAK2/KLF4/ARID5B/NDEL1/STAT3/TIMP1;11
GO:0007517;muscle organ development;2/67;66/2237;0,0303030303030303;1,01175938489371;0,0170360966578532;0,595674908735396;0,705130173215525;0,630553242207402;CTNNB1/ARID5B;2
GO:0051251;positive regulation of lymphocyte activation;3/67;102/2237;0,0294117647058824;0,982001755926251;-0,0326869739718354;0,597891530146722;0,706350679765949;0,63164466389341;NLRP3/JAK2/PNP;3
GO:0000077;DNA damage checkpoint signaling;1/67;30/2237;0,0333333333333333;1,11293532338308;0,109403872466528;0,600808313148334;0,706350679765949;0,63164466389341;SDE2;1
GO:0002040;sprouting angiogenesis;1/67;30/2237;0,0333333333333333;1,11293532338308;0,109403872466528;0,600808313148334;0,706350679765949;0,63164466389341;KLF4;1
GO:0006403;RNA localization;1/67;30/2237;0,0333333333333333;1,11293532338308;0,109403872466528;0,600808313148334;0,706350679765949;0,63164466389341;ZFP36;1
GO:0030168;platelet activation;1/67;30/2237;0,0333333333333333;1,11293532338308;0,109403872466528;0,600808313148334;0,706350679765949;0,63164466389341;JAK2;1
GO:0030178;negative regulation of Wnt signaling pathway;1/67;30/2237;0,0333333333333333;1,11293532338308;0,109403872466528;0,600808313148334;0,706350679765949;0,63164466389341;CTNNB1;1
GO:0042445;hormone metabolic process;1/67;30/2237;0,0333333333333333;1,11293532338308;0,109403872466528;0,600808313148334;0,706350679765949;0,63164466389341;TIPARP;1
GO:0042509;regulation of tyrosine phosphorylation of STAT protein;1/67;30/2237;0,0333333333333333;1,11293532338308;0,109403872466528;0,600808313148334;0,706350679765949;0,63164466389341;JAK2;1
GO:0043467;regulation of generation of precursor metabolites and energy;1/67;30/2237;0,0333333333333333;1,11293532338308;0,109403872466528;0,600808313148334;0,706350679765949;0,63164466389341;STAT3;1
GO:0048284;organelle fusion;1/67;30/2237;0,0333333333333333;1,11293532338308;0,109403872466528;0,600808313148334;0,706350679765949;0,63164466389341;MCL1;1
GO:0072073;kidney epithelium development;1/67;30/2237;0,0333333333333333;1,11293532338308;0,109403872466528;0,600808313148334;0,706350679765949;0,63164466389341;CTNNB1;1
GO:0031399;regulation of protein modification process;8/67;277/2237;0,0288808664259928;0,964276092461879;-0,111587163857817;0,601731665710391;0,706997378942606;0,632222965997139;GADD45A/ARID5A/CTNNB1/DUSP1/HSPA1A/JAK2/FAS/UBB;8
GO:0010631;epithelial cell migration;2/67;67/2237;0,0298507462686567;0,996658498552016;-0,00487857091307676;0,604002510161394;0,708677803670188;0,633725663372051;GADD45A/KLF4;2
GO:0090132;epithelium migration;2/67;67/2237;0,0298507462686567;0,996658498552016;-0,00487857091307676;0,604002510161394;0,708677803670188;0,633725663372051;GADD45A/KLF4;2
GO:0006914;autophagy;3/67;103/2237;0,029126213592233;0,972467758295899;-0,0502581400704493;0,604658569551755;0,708677803670188;0,633725663372051;MCL1/HK2/STAT3;3
GO:0061919;process utilizing autophagic mechanism;3/67;103/2237;0,029126213592233;0,972467758295899;-0,0502581400704493;0,604658569551755;0,708677803670188;0,633725663372051;MCL1/HK2/STAT3;3
GO:0051607;defense response to virus;3/67;104/2237;0,0288461538461538;0,963117106773823;-0,0676689842133637;0,611352643208566;0,710890173397593;0,635704045460305;GBP5/IRF1/BCL2L1;3
GO:0003012;muscle system process;2/67;68/2237;0,0294117647058824;0,982001755926251;-0,0264787970766942;0,612203063625404;0,710890173397593;0,635704045460305;APBB2/ADORA2B;2
GO:0032956;regulation of actin cytoskeleton organization;2/67;68/2237;0,0294117647058824;0,982001755926251;-0,0264787970766942;0,612203063625404;0,710890173397593;0,635704045460305;CDC42EP2/CDC42EP4;2
GO:0034504;protein localization to nucleus;2/67;68/2237;0,0294117647058824;0,982001755926251;-0,0264787970766942;0,612203063625404;0,710890173397593;0,635704045460305;JAK2/STAT3;2
GO:0090130;tissue migration;2/67;68/2237;0,0294117647058824;0,982001755926251;-0,0264787970766942;0,612203063625404;0,710890173397593;0,635704045460305;GADD45A/KLF4;2
GO:1904951;positive regulation of establishment of protein localization;2/67;68/2237;0,0294117647058824;0,982001755926251;-0,0264787970766942;0,612203063625404;0,710890173397593;0,635704045460305;JAK2/SAR1A;2
GO:0001101;response to acid chemical;1/67;31/2237;0,032258064516129;1,07703418391911;0,0758761022336423;0,612926955205;0,710890173397593;0,635704045460305;BCL2L1;1
GO:0006694;steroid biosynthetic process;1/67;31/2237;0,032258064516129;1,07703418391911;0,0758761022336423;0,612926955205;0,710890173397593;0,635704045460305;NR1D1;1
GO:0006937;regulation of muscle contraction;1/67;31/2237;0,032258064516129;1,07703418391911;0,0758761022336423;0,612926955205;0,710890173397593;0,635704045460305;ADORA2B;1
GO:0009746;response to hexose;1/67;31/2237;0,032258064516129;1,07703418391911;0,0758761022336423;0,612926955205;0,710890173397593;0,635704045460305;NR1D1;1
GO:0031398;positive regulation of protein ubiquitination;1/67;31/2237;0,032258064516129;1,07703418391911;0,0758761022336423;0,612926955205;0,710890173397593;0,635704045460305;UBB;1
GO:0031570;DNA integrity checkpoint signaling;1/67;31/2237;0,032258064516129;1,07703418391911;0,0758761022336423;0,612926955205;0,710890173397593;0,635704045460305;SDE2;1
GO:0046474;glycerophospholipid biosynthetic process;1/67;31/2237;0,032258064516129;1,07703418391911;0,0758761022336423;0,612926955205;0,710890173397593;0,635704045460305;PGS1;1
GO:0048167;regulation of synaptic plasticity;1/67;31/2237;0,032258064516129;1,07703418391911;0,0758761022336423;0,612926955205;0,710890173397593;0,635704045460305;ATF4;1
GO:0048565;digestive tract development;1/67;31/2237;0,032258064516129;1,07703418391911;0,0758761022336423;0,612926955205;0,710890173397593;0,635704045460305;CTNNB1;1
GO:0048661;positive regulation of smooth muscle cell proliferation;1/67;31/2237;0,032258064516129;1,07703418391911;0,0758761022336423;0,612926955205;0,710890173397593;0,635704045460305;JAK2;1
GO:0050714;positive regulation of protein secretion;1/67;31/2237;0,032258064516129;1,07703418391911;0,0758761022336423;0,612926955205;0,710890173397593;0,635704045460305;JAK2;1
GO:0030036;actin cytoskeleton organization;4/67;140/2237;0,0285714285714286;0,953944562899787;-0,0988756029967192;0,613785479676765;0,711450243884819;0,636204881015213;SH2B2/JAK2/CDC42EP2/CDC42EP4;4
GO:0046907;intracellular transport;6/67;211/2237;0,028436018957346;0,949423498620641;-0,135616872564657;0,617110436101922;0,714866768181676;0,639260062248828;HSPA1A/JAK2/SAR1A/NDEL1/UBB/STAT3;6
GO:0006629;lipid metabolic process;5/67;176/2237;0,0284090909090909;0,948524423337856;-0,124986179382818;0,617528652201836;0,714913977549069;0,639302278595261;TIPARP/SGMS2/PTGES/NR1D1/PGS1;5
GO:0048598;embryonic morphogenesis;3/67;105/2237;0,0285714285714286;0,953944562899787;-0,0849230125388483;0,617973181312763;0,714991573247632;0,63937166751261;CTNNB1/DUSP1/KLF4;3
GO:0045184;establishment of protein localization;8/67;281/2237;0,0284697508896797;0,950549742391247;-0,155733027726246;0,618839990449561;0,715557351594303;0,639877607244614;GBP5/MCL1/HK2/JAK2/SAR1A/NDEL1/NR1D1/STAT3;8
GO:0010959;regulation of metal ion transport;2/67;69/2237;0,0289855072463768;0,967769846420073;-0,0477750021688713;0,620276593522275;0,71678088354557;0,640971734354928;CTNNB1/ATF4;2
GO:0000375;RNA splicing, via transesterification reactions;1/67;32/2237;0,03125;1,04337686567164;0,0434182478872362;0,62468302682842;0,717930614571012;0,641999865972744;SDE2;1
GO:0000377;RNA splicing, via transesterification reactions with bulged adenosine as nucleophile;1/67;32/2237;0,03125;1,04337686567164;0,0434182478872362;0,62468302682842;0,717930614571012;0,641999865972744;SDE2;1
GO:0000398;mRNA splicing, via spliceosome;1/67;32/2237;0,03125;1,04337686567164;0,0434182478872362;0,62468302682842;0,717930614571012;0,641999865972744;SDE2;1
GO:0001936;regulation of endothelial cell proliferation;1/67;32/2237;0,03125;1,04337686567164;0,0434182478872362;0,62468302682842;0,717930614571012;0,641999865972744;STAT3;1
GO:0007260;tyrosine phosphorylation of STAT protein;1/67;32/2237;0,03125;1,04337686567164;0,0434182478872362;0,62468302682842;0,717930614571012;0,641999865972744;JAK2;1
GO:0014074;response to purine-containing compound;1/67;32/2237;0,03125;1,04337686567164;0,0434182478872362;0,62468302682842;0,717930614571012;0,641999865972744;ADSS2;1
GO:0030216;keratinocyte differentiation;1/67;32/2237;0,03125;1,04337686567164;0,0434182478872362;0,62468302682842;0,717930614571012;0,641999865972744;ZFP36;1
GO:0072006;nephron development;1/67;32/2237;0,03125;1,04337686567164;0,0434182478872362;0,62468302682842;0,717930614571012;0,641999865972744;CTNNB1;1
GO:0090101;negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway;1/67;32/2237;0,03125;1,04337686567164;0,0434182478872362;0,62468302682842;0,717930614571012;0,641999865972744;HSPA1A;1
GO:0006913;nucleocytoplasmic transport;2/67;70/2237;0,0285714285714286;0,953944562899787;-0,0687771074521769;0,628223235200328;0,720687345529631;0,644465035823474;JAK2/STAT3;2
GO:0042326;negative regulation of phosphorylation;2/67;70/2237;0,0285714285714286;0,953944562899787;-0,0687771074521769;0,628223235200328;0,720687345529631;0,644465035823474;GADD45A/DUSP1;2
GO:0051169;nuclear transport;2/67;70/2237;0,0285714285714286;0,953944562899787;-0,0687771074521769;0,628223235200328;0,720687345529631;0,644465035823474;JAK2/STAT3;2
GO:0030855;epithelial cell differentiation;4/67;143/2237;0,027972027972028;0,933931739901889;-0,143455097160044;0,630910224604674;0,723331698184778;0,646829712876846;CTNNB1/KLF4/ZFP36/ATF4;4
GO:0140352;export from cell;5/67;179/2237;0,0279329608938547;0,932627365963479;-0,165093810456686;0,632937500222255;0,725216954277647;0,648515577965172;JAK2/PTGES/ADORA2B/NR1D1/TGM2;5
GO:0006412;translation;2/67;71/2237;0,028169014084507;0,940508723985705;-0,0894945660129974;0,636043228489043;0,725665686653508;0,648916850900625;ZFP36/ATF4;2
GO:0009306;protein secretion;2/67;71/2237;0,028169014084507;0,940508723985705;-0,0894945660129974;0,636043228489043;0,725665686653508;0,648916850900625;JAK2/NR1D1;2
GO:0035592;establishment of protein localization to extracellular region;2/67;71/2237;0,028169014084507;0,940508723985705;-0,0894945660129974;0,636043228489043;0,725665686653508;0,648916850900625;JAK2/NR1D1;2
GO:0002220;innate immune response activating cell surface receptor signaling pathway;1/67;33/2237;0,0303030303030303;1,01175938489371;0,0119558157700649;0,636087216035901;0,725665686653508;0,648916850900625;NR1D1;1
GO:0009952;anterior/posterior pattern specification;1/67;33/2237;0,0303030303030303;1,01175938489371;0,0119558157700649;0,636087216035901;0,725665686653508;0,648916850900625;CTNNB1;1
GO:0048754;branching morphogenesis of an epithelial tube;1/67;33/2237;0,0303030303030303;1,01175938489371;0,0119558157700649;0,636087216035901;0,725665686653508;0,648916850900625;CTNNB1;1
GO:0055123;digestive system development;1/67;33/2237;0,0303030303030303;1,01175938489371;0,0119558157700649;0,636087216035901;0,725665686653508;0,648916850900625;CTNNB1;1
GO:0044419;biological process involved in interspecies interaction between organisms;13/67;458/2237;0,0283842794759825;0,947696017727954;-0,220507291602233;0,636394247904687;0,725665686653508;0,648916850900625;GBP5/NLRP3/ARID5A/IRF1/IRF4/HSPA1A/JAK2/CDC42EP2/NR1D1/CDC42EP4/ZFP36/PVR/BCL2L1;13
GO:0043604;amide biosynthetic process;3/67;109/2237;0,0275229357798165;0,918937422976859;-0,152437310325098;0,643710647220711;0,732637125832876;0,655150967301227;SGMS2/ZFP36/ATF4;3
GO:0006869;lipid transport;2/67;72/2237;0,0277777777777778;0,927446102819237;-0,109936391331665;0,643736911504945;0,732637125832876;0,655150967301227;PTGES/SLC13A3;2
GO:0071692;protein localization to extracellular region;2/67;72/2237;0,0277777777777778;0,927446102819237;-0,109936391331665;0,643736911504945;0,732637125832876;0,655150967301227;JAK2/NR1D1;2
GO:0006796;phosphate-containing compound metabolic process;13/67;461/2237;0,0281995661605206;0,941528798523651;-0,247522358142859;0,646626042725307;0,732637125832876;0,655150967301227;GADD45A/ADSS2/HK2/SGMS2/DUSP1/HSPA1A/JAK2/NEK6/FAS/PNP/STAT3/PGS1/PHLPP1;13
GO:0001935;endothelial cell proliferation;1/67;34/2237;0,0294117647058824;0,982001755926251;-0,0185782918475613;0,647149900484901;0,732637125832876;0,655150967301227;STAT3;1
GO:0007219;Notch signaling pathway;1/67;34/2237;0,0294117647058824;0,982001755926251;-0,0185782918475613;0,647149900484901;0,732637125832876;0,655150967301227;STAT3;1
GO:0030307;positive regulation of cell growth;1/67;34/2237;0,0294117647058824;0,982001755926251;-0,0185782918475613;0,647149900484901;0,732637125832876;0,655150967301227;H3-3B;1
GO:0034284;response to monosaccharide;1/67;34/2237;0,0294117647058824;0,982001755926251;-0,0185782918475613;0,647149900484901;0,732637125832876;0,655150967301227;NR1D1;1
GO:0045216;cell-cell junction organization;1/67;34/2237;0,0294117647058824;0,982001755926251;-0,0185782918475613;0,647149900484901;0,732637125832876;0,655150967301227;CTNNB1;1
GO:0071456;cellular response to hypoxia;1/67;34/2237;0,0294117647058824;0,982001755926251;-0,0185782918475613;0,647149900484901;0,732637125832876;0,655150967301227;ATF4;1
GO:0099003;vesicle-mediated transport in synapse;1/67;34/2237;0,0294117647058824;0,982001755926251;-0,0185782918475613;0,647149900484901;0,732637125832876;0,655150967301227;CTNNB1;1
GO:1901222;regulation of non-canonical NF-kappaB signal transduction;1/67;34/2237;0,0294117647058824;0,982001755926251;-0,0185782918475613;0,647149900484901;0,732637125832876;0,655150967301227;NLRP3;1
GO:0045785;positive regulation of cell adhesion;4/67;146/2237;0,0273972602739726;0,914741361684727;-0,18718939371764;0,647561634784147;0,732665314385409;0,655176174537944;NLRP3/JAK2/PNP/TGM2;4
GO:0022409;positive regulation of cell-cell adhesion;3/67;110/2237;0,0272727272727273;0,910583446404342;-0,168956131983046;0,649957000129258;0,734203313952355;0,656551510114677;NLRP3/JAK2/PNP;3
GO:0045859;regulation of protein kinase activity;3/67;110/2237;0,0272727272727273;0,910583446404342;-0,168956131983046;0,649957000129258;0,734203313952355;0,656551510114677;GADD45A/DUSP1/JAK2;3
GO:0008104;protein localization;11/67;393/2237;0,0279898218829517;0,934525844062132;-0,251147673405292;0,650083926873336;0,734203313952355;0,656551510114677;GBP5/MCL1/HK2/TMBIM1/CTNNB1/JAK2/SAR1A/NDEL1/NR1D1/STAT3/BCL2L1;11
GO:0010975;regulation of neuron projection development;2/67;73/2237;0,0273972602739726;0,914741361684727;-0,130111183730933;0,651304714725219;0,735143700649323;0,657392438362008;KLF4/NDEL1;2
GO:0008284;positive regulation of cell population proliferation;6/67;219/2237;0,0273972602739726;0,914741361684727;-0,233369073843118;0,654428623202568;0,735219276472686;0,657460021032931;CTNNB1/JAK2/PNP/STAT3/BCL2L1/TIMP1;6
GO:0001890;placenta development;1/67;35/2237;0,0285714285714286;0,953944562899787;-0,0482447107924874;0,657881156348501;0,735219276472686;0,657460021032931;JUNB;1
GO:0001909;leukocyte mediated cytotoxicity;1/67;35/2237;0,0285714285714286;0,953944562899787;-0,0482447107924874;0,657881156348501;0,735219276472686;0,657460021032931;PVR;1
GO:0002548;monocyte chemotaxis;1/67;35/2237;0,0285714285714286;0,953944562899787;-0,0482447107924874;0,657881156348501;0,735219276472686;0,657460021032931;DUSP1;1
GO:0006631;fatty acid metabolic process;1/67;35/2237;0,0285714285714286;0,953944562899787;-0,0482447107924874;0,657881156348501;0,735219276472686;0,657460021032931;PTGES;1
GO:0006814;sodium ion transport;1/67;35/2237;0,0285714285714286;0,953944562899787;-0,0482447107924874;0,657881156348501;0,735219276472686;0,657460021032931;SLC13A3;1
GO:0007188;adenylate cyclase-modulating G protein-coupled receptor signaling pathway;1/67;35/2237;0,0285714285714286;0,953944562899787;-0,0482447107924874;0,657881156348501;0,735219276472686;0,657460021032931;ADORA2B;1
GO:0007204;positive regulation of cytosolic calcium ion concentration;1/67;35/2237;0,0285714285714286;0,953944562899787;-0,0482447107924874;0,657881156348501;0,735219276472686;0,657460021032931;JAK2;1
GO:0022612;gland morphogenesis;1/67;35/2237;0,0285714285714286;0,953944562899787;-0,0482447107924874;0,657881156348501;0,735219276472686;0,657460021032931;TGM2;1
GO:0043405;regulation of MAP kinase activity;1/67;35/2237;0,0285714285714286;0,953944562899787;-0,0482447107924874;0,657881156348501;0,735219276472686;0,657460021032931;DUSP1;1
GO:0044272;sulfur compound biosynthetic process;1/67;35/2237;0,0285714285714286;0,953944562899787;-0,0482447107924874;0,657881156348501;0,735219276472686;0,657460021032931;CTNNB1;1
GO:0046890;regulation of lipid biosynthetic process;1/67;35/2237;0,0285714285714286;0,953944562899787;-0,0482447107924874;0,657881156348501;0,735219276472686;0,657460021032931;NR1D1;1
GO:0051651;maintenance of location in cell;1/67;35/2237;0,0285714285714286;0,953944562899787;-0,0482447107924874;0,657881156348501;0,735219276472686;0,657460021032931;HK2;1
GO:0072331;signal transduction by p53 class mediator;1/67;35/2237;0,0285714285714286;0,953944562899787;-0,0482447107924874;0,657881156348501;0,735219276472686;0,657460021032931;UBB;1
GO:1900180;regulation of protein localization to nucleus;1/67;35/2237;0,0285714285714286;0,953944562899787;-0,0482447107924874;0,657881156348501;0,735219276472686;0,657460021032931;JAK2;1
GO:2000106;regulation of leukocyte apoptotic process;1/67;35/2237;0,0285714285714286;0,953944562899787;-0,0482447107924874;0,657881156348501;0,735219276472686;0,657460021032931;BCL2L1;1
GO:0006812;monoatomic cation transport;4/67;148/2237;0,027027027027027;0,902379991932231;-0,21589565942862;0,658394345945484;0,735219276472686;0,657460021032931;CTNNB1/ORAI2/ATF4/SLC13A3;4
GO:0031589;cell-substrate adhesion;2/67;74/2237;0,027027027027027;0,902379991932231;-0,150027154887462;0,65874715531898;0,735219276472686;0,657460021032931;CTNNB1/JAK2;2
GO:1901615;organic hydroxy compound metabolic process;2/67;74/2237;0,027027027027027;0,902379991932231;-0,150027154887462;0,65874715531898;0,735219276472686;0,657460021032931;NR4A2/NR1D1;2
GO:0006793;phosphorus metabolic process;13/67;466/2237;0,0278969957081545;0,931426558196144;-0,292269205968444;0,663371593542094;0,739907723897129;0,661652602540144;GADD45A/ADSS2/HK2/SGMS2/DUSP1/HSPA1A/JAK2/NEK6/FAS/PNP/STAT3/PGS1/PHLPP1;13
GO:0043603;amide metabolic process;4/67;149/2237;0,0268456375838926;0,896323750375639;-0,230118004727251;0,66372926235545;0,739907723897129;0,661652602540144;SGMS2/PNP/ZFP36/ATF4;4
GO:0032970;regulation of actin filament-based process;2/67;75/2237;0,0266666666666667;0,890348258706468;-0,169692150572604;0,666064831726448;0,740200416717091;0,661914339186239;CDC42EP2/CDC42EP4;2
GO:0034762;regulation of transmembrane transport;2/67;75/2237;0,0266666666666667;0,890348258706468;-0,169692150572604;0,666064831726448;0,740200416717091;0,661914339186239;HK2/AZIN1;2
GO:0043269;regulation of monoatomic ion transport;2/67;75/2237;0,0266666666666667;0,890348258706468;-0,169692150572604;0,666064831726448;0,740200416717091;0,661914339186239;CTNNB1/ATF4;2
GO:0043410;positive regulation of MAPK cascade;3/67;113/2237;0,0265486725663717;0,886408664641395;-0,217696077870899;0,668240823333113;0,740200416717091;0,661914339186239;GADD45A/CTNNB1/JAK2;3
GO:0002761;regulation of myeloid leukocyte differentiation;1/67;36/2237;0,0277777777777778;0,927446102819237;-0,0770984076331237;0,668290766940985;0,740200416717091;0,661914339186239;CTNNB1;1
GO:0006665;sphingolipid metabolic process;1/67;36/2237;0,0277777777777778;0,927446102819237;-0,0770984076331237;0,668290766940985;0,740200416717091;0,661914339186239;SGMS2;1
GO:0017157;regulation of exocytosis;1/67;36/2237;0,0277777777777778;0,927446102819237;-0,0770984076331237;0,668290766940985;0,740200416717091;0,661914339186239;ADORA2B;1
GO:0036294;cellular response to decreased oxygen levels;1/67;36/2237;0,0277777777777778;0,927446102819237;-0,0770984076331237;0,668290766940985;0,740200416717091;0,661914339186239;ATF4;1
GO:0045017;glycerolipid biosynthetic process;1/67;36/2237;0,0277777777777778;0,927446102819237;-0,0770984076331237;0,668290766940985;0,740200416717091;0,661914339186239;PGS1;1
GO:0045446;endothelial cell differentiation;1/67;36/2237;0,0277777777777778;0,927446102819237;-0,0770984076331237;0,668290766940985;0,740200416717091;0,661914339186239;CTNNB1;1
GO:1905952;regulation of lipid localization;1/67;36/2237;0,0277777777777778;0,927446102819237;-0,0770984076331237;0,668290766940985;0,740200416717091;0,661914339186239;PTGES;1
GO:0044403;biological process involved in symbiotic interaction;2/67;76/2237;0,0263157894736842;0,878633150039277;-0,189113671772485;0,673258418476607;0,745266770657331;0,666444858549239;HSPA1A/PVR;2
GO:0002244;hematopoietic progenitor cell differentiation;1/67;37/2237;0,027027027027027;0,902379991932231;-0,105189355667685;0,678388231100437;0,74745044194545;0,668397577441354;ZFP36;1
GO:0006109;regulation of carbohydrate metabolic process;1/67;37/2237;0,027027027027027;0,902379991932231;-0,105189355667685;0,678388231100437;0,74745044194545;0,668397577441354;STAT3;1
GO:0007411;axon guidance;1/67;37/2237;0,027027027027027;0,902379991932231;-0,105189355667685;0,678388231100437;0,74745044194545;0,668397577441354;APBB2;1
GO:0007519;skeletal muscle tissue development;1/67;37/2237;0,027027027027027;0,902379991932231;-0,105189355667685;0,678388231100437;0,74745044194545;0,668397577441354;CTNNB1;1
GO:0042180;cellular ketone metabolic process;1/67;37/2237;0,027027027027027;0,902379991932231;-0,105189355667685;0,678388231100437;0,74745044194545;0,668397577441354;NR1D1;1
GO:0048525;negative regulation of viral process;1/67;37/2237;0,027027027027027;0,902379991932231;-0,105189355667685;0,678388231100437;0,74745044194545;0,668397577441354;ZFP36;1
GO:0097485;neuron projection guidance;1/67;37/2237;0,027027027027027;0,902379991932231;-0,105189355667685;0,678388231100437;0,74745044194545;0,668397577441354;APBB2;1
GO:1903322;positive regulation of protein modification by small protein conjugation or removal;1/67;37/2237;0,027027027027027;0,902379991932231;-0,105189355667685;0,678388231100437;0,74745044194545;0,668397577441354;UBB;1
GO:0002696;positive regulation of leukocyte activation;3/67;115/2237;0,0260869565217391;0,870992861778066;-0,249536112961167;0,680049392253919;0,74784822076481;0,668753285839259;NLRP3/JAK2/PNP;3
GO:0006816;calcium ion transport;2/67;77/2237;0,025974025974026;0,867222329908897;-0,20829889432284;0,680328661234302;0,74784822076481;0,668753285839259;CTNNB1/ORAI2;2
GO:0022411;cellular component disassembly;2/67;77/2237;0,025974025974026;0,867222329908897;-0,20829889432284;0,680328661234302;0,74784822076481;0,668753285839259;HK2/NEK6;2
GO:0043087;regulation of GTPase activity;2/67;77/2237;0,025974025974026;0,867222329908897;-0,20829889432284;0,680328661234302;0,74784822076481;0,668753285839259;NDEL1/TGM2;2
GO:0033365;protein localization to organelle;4/67;153/2237;0,0261437908496732;0,872890449712223;-0,286166290781123;0,684520198364377;0,752019289850424;0,672483208675225;GBP5/HK2/JAK2/STAT3;4
GO:0030003;intracellular monoatomic cation homeostasis;2/67;78/2237;0,0256410256410256;0,856104094910065;-0,227254687181156;0,687276372067985;0,752985655059902;0,673347367860491;TGM2/ATF4;2
GO:0006310;DNA recombination;1/67;38/2237;0,0263157894736842;0,878633150039277;-0,132563114109024;0,688182771335106;0,752985655059902;0,673347367860491;INO80D;1
GO:0015931;nucleobase-containing compound transport;1/67;38/2237;0,0263157894736842;0,878633150039277;-0,132563114109024;0,688182771335106;0,752985655059902;0,673347367860491;ZFP36;1
GO:0034764;positive regulation of transmembrane transport;1/67;38/2237;0,0263157894736842;0,878633150039277;-0,132563114109024;0,688182771335106;0,752985655059902;0,673347367860491;AZIN1;1
GO:0048193;Golgi vesicle transport;1/67;38/2237;0,0263157894736842;0,878633150039277;-0,132563114109024;0,688182771335106;0,752985655059902;0,673347367860491;SAR1A;1
GO:0048562;embryonic organ morphogenesis;1/67;38/2237;0,0263157894736842;0,878633150039277;-0,132563114109024;0,688182771335106;0,752985655059902;0,673347367860491;CTNNB1;1
GO:1901875;positive regulation of post-translational protein modification;1/67;38/2237;0,0263157894736842;0,878633150039277;-0,132563114109024;0,688182771335106;0,752985655059902;0,673347367860491;UBB;1
GO:0030029;actin filament-based process;4/67;154/2237;0,025974025974026;0,867222329908897;-0,299974406737424;0,689579790874962;0,754078593485669;0,674324713454367;SH2B2/JAK2/CDC42EP2/CDC42EP4;4
GO:0060429;epithelium development;6/67;228/2237;0,0263157894736842;0,878633150039277;-0,339719885679551;0,693777519691878;0,758148784784786;0,677964427676719;CTNNB1/JAK2/KLF4/ZFP36/TGM2/ATF4;6
GO:0043043;peptide biosynthetic process;2/67;79/2237;0,0253164556962025;0,845267334215001;-0,245987629447071;0,694102424929683;0,758148784784786;0,677964427676719;ZFP36/ATF4;2
GO:0001889;liver development;1/67;39/2237;0,0256410256410256;0,856104094910065;-0,159261326509279;0,697683341740084;0,75943232715846;0,679112218305987;ARID5B;1
GO:0002688;regulation of leukocyte chemotaxis;1/67;39/2237;0,0256410256410256;0,856104094910065;-0,159261326509279;0,697683341740084;0,75943232715846;0,679112218305987;DUSP1;1
GO:0006643;membrane lipid metabolic process;1/67;39/2237;0,0256410256410256;0,856104094910065;-0,159261326509279;0,697683341740084;0,75943232715846;0,679112218305987;SGMS2;1
GO:0060538;skeletal muscle organ development;1/67;39/2237;0,0256410256410256;0,856104094910065;-0,159261326509279;0,697683341740084;0,75943232715846;0,679112218305987;CTNNB1;1
GO:0061008;hepaticobiliary system development;1/67;39/2237;0,0256410256410256;0,856104094910065;-0,159261326509279;0,697683341740084;0,75943232715846;0,679112218305987;ARID5B;1
GO:0071675;regulation of mononuclear cell migration;1/67;39/2237;0,0256410256410256;0,856104094910065;-0,159261326509279;0,697683341740084;0,75943232715846;0,679112218305987;DUSP1;1
GO:0006873;intracellular monoatomic ion homeostasis;2/67;80/2237;0,025;0,834701492537314;-0,264504026231685;0,700807751339008;0,761520298930625;0,680979359183781;TGM2/ATF4;2
GO:0050878;regulation of body fluid levels;2/67;80/2237;0,025;0,834701492537314;-0,264504026231685;0,700807751339008;0,761520298930625;0,680979359183781;HK2/JAK2;2
GO:0051347;positive regulation of transferase activity;2/67;80/2237;0,025;0,834701492537314;-0,264504026231685;0,700807751339008;0,761520298930625;0,680979359183781;JAK2/KLF4;2
GO:0043549;regulation of kinase activity;3/67;119/2237;0,0252100840336134;0,84171579079393;-0,311739279744488;0,702752323800952;0,76319547091686;0,68247735936488;GADD45A/DUSP1/JAK2;3
GO:0009743;response to carbohydrate;1/67;40/2237;0,025;0,834701492537314;-0,185322151467296;0,706898635690682;0,764629363791064;0,683759598921704;NR1D1;1
GO:0015850;organic hydroxy compound transport;1/67;40/2237;0,025;0,834701492537314;-0,185322151467296;0,706898635690682;0,764629363791064;0,683759598921704;TGM2;1
GO:0045055;regulated exocytosis;1/67;40/2237;0,025;0,834701492537314;-0,185322151467296;0,706898635690682;0,764629363791064;0,683759598921704;ADORA2B;1
GO:0050803;regulation of synapse structure or activity;1/67;40/2237;0,025;0,834701492537314;-0,185322151467296;0,706898635690682;0,764629363791064;0,683759598921704;CTNNB1;1
GO:0050807;regulation of synapse organization;1/67;40/2237;0,025;0,834701492537314;-0,185322151467296;0,706898635690682;0,764629363791064;0,683759598921704;CTNNB1;1
GO:0060348;bone development;1/67;40/2237;0,025;0,834701492537314;-0,185322151467296;0,706898635690682;0,764629363791064;0,683759598921704;TGM2;1
GO:1902115;regulation of organelle assembly;1/67;40/2237;0,025;0,834701492537314;-0,185322151467296;0,706898635690682;0,764629363791064;0,683759598921704;HSPA1A;1
GO:0050867;positive regulation of cell activation;3/67;120/2237;0,025;0,834701492537314;-0,326996090416091;0,708238082567814;0,765640940858127;0,684664188206929;NLRP3/JAK2/PNP;3
GO:0055085;transmembrane transport;5/67;196/2237;0,0255102040816327;0,85173621687481;-0,381755273305755;0,713115018817712;0,769732134471663;0,688322683468518;MCL1/HK2/ORAI2/AZIN1/SLC13A3;5
GO:0016032;viral process;3/67;121/2237;0,0247933884297521;0,827803133094856;-0,342139749268815;0,713648166912481;0,769732134471663;0,688322683468518;HSPA1A/ZFP36/PVR;3
GO:0034330;cell junction organization;3/67;121/2237;0,0247933884297521;0,827803133094856;-0,342139749268815;0,713648166912481;0,769732134471663;0,688322683468518;CTNNB1/APBB2/PPFIBP1;3
GO:0044255;cellular lipid metabolic process;3/67;121/2237;0,0247933884297521;0,827803133094856;-0,342139749268815;0,713648166912481;0,769732134471663;0,688322683468518;SGMS2/PTGES/PGS1;3
GO:0006605;protein targeting;1/67;41/2237;0,024390243902439;0,814342919548598;-0,210780636283097;0,715837093318686;0,770776267621144;0,689256385595743;GBP5;1
GO:0015980;energy derivation by oxidation of organic compounds;1/67;41/2237;0,024390243902439;0,814342919548598;-0,210780636283097;0,715837093318686;0,770776267621144;0,689256385595743;NR1D1;1
GO:0090257;regulation of muscle system process;1/67;41/2237;0,024390243902439;0,814342919548598;-0,210780636283097;0,715837093318686;0,770776267621144;0,689256385595743;ADORA2B;1
GO:0048729;tissue morphogenesis;3/67;122/2237;0,0245901639344262;0,821017861512112;-0,357172370601261;0,718982794885453;0,773723530405141;0,691891935987257;CTNNB1/KLF4/TGM2;3
GO:0010876;lipid localization;2/67;83/2237;0,0240963855421687;0,804531559072109;-0,31881318922188;0,720209465359751;0,774603479495383;0,692678818711761;PTGES/SLC13A3;2
GO:0001837;epithelial to mesenchymal transition;1/67;42/2237;0,0238095238095238;0,794953802416489;-0,235669042325951;0,724506908777542;0,777459538370915;0,695232811225923;CTNNB1;1
GO:0003158;endothelium development;1/67;42/2237;0,0238095238095238;0,794953802416489;-0,235669042325951;0,724506908777542;0,777459538370915;0,695232811225923;CTNNB1;1
GO:0030324;lung development;1/67;42/2237;0,0238095238095238;0,794953802416489;-0,235669042325951;0,724506908777542;0,777459538370915;0,695232811225923;CTNNB1;1
GO:0050868;negative regulation of T cell activation;1/67;42/2237;0,0238095238095238;0,794953802416489;-0,235669042325951;0,724506908777542;0,777459538370915;0,695232811225923;IRF1;1
GO:0006650;glycerophospholipid metabolic process;1/67;43/2237;0,0232558139534884;0,776466504685873;-0,260017129359387;0,732916037302328;0,784261567599214;0,701315435039813;PGS1;1
GO:0007163;establishment or maintenance of cell polarity;1/67;43/2237;0,0232558139534884;0,776466504685873;-0,260017129359387;0,732916037302328;0,784261567599214;0,701315435039813;NDEL1;1
GO:0051897;positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction;1/67;43/2237;0,0232558139534884;0,776466504685873;-0,260017129359387;0,732916037302328;0,784261567599214;0,701315435039813;JAK2;1
GO:1990868;response to chemokine;1/67;43/2237;0,0232558139534884;0,776466504685873;-0,260017129359387;0,732916037302328;0,784261567599214;0,701315435039813;DUSP1;1
GO:1990869;cellular response to chemokine;1/67;43/2237;0,0232558139534884;0,776466504685873;-0,260017129359387;0,732916037302328;0,784261567599214;0,701315435039813;DUSP1;1
GO:0015031;protein transport;6/67;238/2237;0,0252100840336134;0,84171579079393;-0,453798552555621;0,734038707059582;0,785019373896583;0,701993093202691;MCL1/JAK2/SAR1A/NDEL1/NR1D1/STAT3;6
GO:0006811;monoatomic ion transport;4/67;164/2237;0,024390243902439;0,814342919548598;-0,433887585023324;0,737112395385645;0,787861668657117;0,7045347773408;CTNNB1/ORAI2/ATF4/SLC13A3;4
GO:0098771;inorganic ion homeostasis;2/67;86/2237;0,0232558139534884;0,776466504685873;-0,371377051212959;0,738562873457819;0,788966769503163;0,705522999016612;TGM2/ATF4;2
GO:0030323;respiratory tube development;1/67;44/2237;0,0227272727272727;0,758819538670285;-0,283852404837154;0,741072202070215;0,791201099617242;0,707521018887424;CTNNB1;1
GO:0030334;regulation of cell migration;6/67;240/2237;0,025;0,834701492537314;-0,476133736617961;0,741643573453136;0,791365029926896;0,707667611377967;GADD45A/DUSP1/JAK2/KLF4/STAT3/TIMP1;6
GO:0060537;muscle tissue development;2/67;87/2237;0,0229885057471264;0,767541602333162;-0,388534036722931;0,744453213787935;0,793554986904901;0,709625951164334;CTNNB1/TIPARP;2
GO:0051129;negative regulation of cellular component organization;3/67;127/2237;0,0236220472440945;0,788694323657304;-0,430740026666108;0,744533902708558;0,793554986904901;0,709625951164334;DUSP1/HSPA1A/BCL2L1;3
GO:0051924;regulation of calcium ion transport;1/67;45/2237;0,0222222222222222;0,74195688225539;-0,307200343186416;0,748982900866975;0,797847927020277;0,713464855541391;CTNNB1;1
GO:0032479;regulation of type I interferon production;1/67;46/2237;0,0217391304347826;0,725827384815055;-0,330084579280736;0,756655412564928;0,804663307915763;0,719559418905387;IRF1;1
GO:0032606;type I interferon production;1/67;46/2237;0,0217391304347826;0,725827384815055;-0,330084579280736;0,756655412564928;0,804663307915763;0,719559418905387;IRF1;1
GO:0060828;regulation of canonical Wnt signaling pathway;1/67;46/2237;0,0217391304347826;0,725827384815055;-0,330084579280736;0,756655412564928;0,804663307915763;0,719559418905387;CTNNB1;1
GO:0018193;peptidyl-amino acid modification;4/67;169/2237;0,0236686390532544;0,790249933763137;-0,498211359847702;0,758795589929058;0,806486446310682;0,721189736071743;GADD45A/CTNNB1/JAK2/NEK6;4
GO:0016310;phosphorylation;8/67;319/2237;0,0250783699059561;0,837318111636176;-0,551256443758546;0,760941619344058;0,808313756050279;0,72282378340738;GADD45A/HK2/SGMS2/DUSP1/JAK2/NEK6/FAS/STAT3;8
GO:0002429;immune response-activating cell surface receptor signaling pathway;2/67;90/2237;0,0222222222222222;0,74195688225539;-0,43897617204081;0,761459449831497;0,808410424877161;0,722910228215057;SH2B2/NR1D1;2
GO:2000145;regulation of cell motility;6/67;246/2237;0,024390243902439;0,814342919548598;-0,542234160240201;0,763557392006907;0,809848542626126;0,724196245809725;GADD45A/DUSP1/JAK2/KLF4/STAT3/TIMP1;6
GO:0016485;protein processing;1/67;47/2237;0,0212765957446809;0,710384248967926;-0,352527079638405;0,764096803417575;0,809848542626126;0,724196245809725;SDE2;1
GO:1901888;regulation of cell junction assembly;1/67;47/2237;0,0212765957446809;0,710384248967926;-0,352527079638405;0,764096803417575;0,809848542626126;0,724196245809725;CTNNB1;1
GO:0006397;mRNA processing;1/67;48/2237;0,0208333333333333;0,695584577114428;-0,37454829433245;0,771313933176033;0,815672020901958;0,729403813500389;SDE2;1
GO:0007160;cell-matrix adhesion;1/67;48/2237;0,0208333333333333;0,695584577114428;-0,37454829433245;0,771313933176033;0,815672020901958;0,729403813500389;CTNNB1;1
GO:0038061;non-canonical NF-kappaB signal transduction;1/67;48/2237;0,0208333333333333;0,695584577114428;-0,37454829433245;0,771313933176033;0,815672020901958;0,729403813500389;NLRP3;1
GO:0051098;regulation of binding;1/67;48/2237;0,0208333333333333;0,695584577114428;-0,37454829433245;0,771313933176033;0,815672020901958;0,729403813500389;JAK2;1
GO:0055080;monoatomic cation homeostasis;2/67;92/2237;0,0217391304347826;0,725827384815055;-0,471788959959565;0,77225609230626;0,815757411504772;0,729480172906785;TGM2/ATF4;2
GO:1903829;positive regulation of protein localization;2/67;92/2237;0,0217391304347826;0,725827384815055;-0,471788959959565;0,77225609230626;0,815757411504772;0,729480172906785;JAK2/SAR1A;2
GO:0040012;regulation of locomotion;6/67;250/2237;0,024;0,801313432835821;-0,585575652572165;0,777417302539272;0,820377612697209;0,733611726132279;GADD45A/DUSP1/JAK2/KLF4/STAT3/TIMP1;6
GO:0043122;regulation of canonical NF-kappaB signal transduction;2/67;93/2237;0,021505376344086;0,718022789279409;-0,487962590289583;0,777496206331304;0,820377612697209;0,733611726132279;NEK6/NR1D1;2
GO:0060541;respiratory system development;1/67;49/2237;0,0204081632653061;0,681388973499848;-0,396167292144355;0,778313461032226;0,820782681066278;0,733973953112678;CTNNB1;1
GO:0050801;monoatomic ion homeostasis;2/67;94/2237;0,0212765957446809;0,710384248967926;-0,503985977326477;0,78263268592248;0,824878301133654;0,737636406671511;TGM2/ATF4;2
GO:0019216;regulation of lipid metabolic process;1/67;50/2237;0,02;0,667761194029851;-0,417401881116214;0,78510185139367;0,827020526440273;0,739552063048074;NR1D1;1
GO:0006518;peptide metabolic process;2/67;95/2237;0,0210526315789474;0,702906520031422;-0,519862659586704;0,787666925088273;0,829261343033457;0,741555883366216;ZFP36/ATF4;2
GO:0006909;phagocytosis;1/67;51/2237;0,0196078431372549;0,654667837284167;-0,438268716341337;0,79168537949455;0,832566412416812;0,744511397531624;TGM2;1
GO:0051250;negative regulation of lymphocyte activation;1/67;51/2237;0,0196078431372549;0,654667837284167;-0,438268716341337;0,79168537949455;0,832566412416812;0,744511397531624;IRF1;1
GO:0002768;immune response-regulating cell surface receptor signaling pathway;2/67;97/2237;0,0206185567010309;0,68841360209263;-0,551189461012586;0,797434309414241;0,836957275298693;0,748437868035123;SH2B2/NR1D1;2
GO:0019058;viral life cycle;2/67;97/2237;0,0206185567010309;0,68841360209263;-0,551189461012586;0,797434309414241;0,836957275298693;0,748437868035123;HSPA1A/PVR;2
GO:0006790;sulfur compound metabolic process;1/67;52/2237;0,0192307692307692;0,642078071182549;-0,458783396569838;0,798070136847645;0,836957275298693;0,748437868035123;CTNNB1;1
GO:0050851;antigen receptor-mediated signaling pathway;1/67;52/2237;0,0192307692307692;0,642078071182549;-0,458783396569838;0,798070136847645;0,836957275298693;0,748437868035123;SH2B2;1
GO:0070588;calcium ion transmembrane transport;1/67;52/2237;0,0192307692307692;0,642078071182549;-0,458783396569838;0,798070136847645;0,836957275298693;0,748437868035123;ORAI2;1
GO:0072657;protein localization to membrane;2/67;98/2237;0,0204081632653061;0,681388973499848;-0,566646070458086;0,802170288374796;0,840194317269563;0,751332549595246;TMBIM1/BCL2L1;2
GO:0000209;protein polyubiquitination;1/67;53/2237;0,0188679245283019;0,629963390594199;-0,478960550984356;0,804262036541562;0,840194317269563;0,751332549595246;CTNNB1;1
GO:0003007;heart morphogenesis;1/67;53/2237;0,0188679245283019;0,629963390594199;-0,478960550984356;0,804262036541562;0,840194317269563;0,751332549595246;CTNNB1;1
GO:0007596;blood coagulation;1/67;53/2237;0,0188679245283019;0,629963390594199;-0,478960550984356;0,804262036541562;0,840194317269563;0,751332549595246;JAK2;1
GO:0007599;hemostasis;1/67;53/2237;0,0188679245283019;0,629963390594199;-0,478960550984356;0,804262036541562;0,840194317269563;0,751332549595246;JAK2;1
GO:0010810;regulation of cell-substrate adhesion;1/67;53/2237;0,0188679245283019;0,629963390594199;-0,478960550984356;0,804262036541562;0,840194317269563;0,751332549595246;JAK2;1
GO:0030100;regulation of endocytosis;1/67;53/2237;0,0188679245283019;0,629963390594199;-0,478960550984356;0,804262036541562;0,840194317269563;0,751332549595246;TGM2;1
GO:0042060;wound healing;2/67;99/2237;0,0202020202020202;0,674506256595809;-0,581968965724294;0,806809691100276;0,842391154875371;0,753297042291153;JAK2/TIMP1;2
GO:0001959;regulation of cytokine-mediated signaling pathway;1/67;54/2237;0,0185185185185185;0,618297401879491;-0,498813917314309;0,810266818387585;0,843211732981366;0,75403083330574;HSPA1A;1
GO:0007283;spermatogenesis;1/67;54/2237;0,0185185185185185;0,618297401879491;-0,498813917314309;0,810266818387585;0,843211732981366;0,75403083330574;BCL2L1;1
GO:0045927;positive regulation of growth;1/67;54/2237;0,0185185185185185;0,618297401879491;-0,498813917314309;0,810266818387585;0,843211732981366;0,75403083330574;H3-3B;1
GO:0046486;glycerolipid metabolic process;1/67;54/2237;0,0185185185185185;0,618297401879491;-0,498813917314309;0,810266818387585;0,843211732981366;0,75403083330574;PGS1;1
GO:0050817;coagulation;1/67;54/2237;0,0185185185185185;0,618297401879491;-0,498813917314309;0,810266818387585;0,843211732981366;0,75403083330574;JAK2;1
GO:0071347;cellular response to interleukin-1;1/67;54/2237;0,0185185185185185;0,618297401879491;-0,498813917314309;0,810266818387585;0,843211732981366;0,75403083330574;NR1D1;1
GO:0007249;canonical NF-kappaB signal transduction;2/67;101/2237;0,0198019801980198;0,661149697059258;-0,612225444199152;0,815804488363086;0,848339496226755;0,758616267119907;NEK6/NR1D1;2
GO:0007600;sensory perception;1/67;55/2237;0,0181818181818182;0,607055630936228;-0,518356412299063;0,816090053920353;0,848339496226755;0,758616267119907;PTGES;1
GO:0003002;regionalization;1/67;56/2237;0,0178571428571429;0,596215351812367;-0,53760019537626;0,821737151256437;0,852822524209514;0,76262515503424;CTNNB1;1
GO:0050792;regulation of viral process;1/67;56/2237;0,0178571428571429;0,596215351812367;-0,53760019537626;0,821737151256437;0,852822524209514;0,76262515503424;ZFP36;1
GO:0007186;G protein-coupled receptor signaling pathway;3/67;145/2237;0,0206896551724138;0,690787442099846;-0,676400186154641;0,821753488216665;0,852822524209514;0,76262515503424;JAK2/ADORA2B/TGM2;3
GO:0060627;regulation of vesicle-mediated transport;2/67;103/2237;0,0194174757281553;0,648311838863933;-0,641981610268319;0,824430156992277;0,855131827679832;0,764690218827794;ADORA2B/TGM2;2
GO:0050731;positive regulation of peptidyl-tyrosine phosphorylation;1/67;58/2237;0,0172413793103448;0,575656201749871;-0,575236817753969;0,832523774903074;0,863054203429897;0,771774697559442;JAK2;1
GO:0003013;circulatory system process;2/67;106/2237;0,0188679245283019;0,629963390594199;-0,685723976170451;0,836701578967383;0,866910716938853;0,775223333271058;ADORA2B/SLC13A3;2
GO:0007389;pattern specification process;1/67;59/2237;0,0169491525423729;0,56589931697445;-0,593650682337956;0,837673342173149;0,866969021899423;0,775275471703536;CTNNB1;1
GO:0051235;maintenance of location;1/67;59/2237;0,0169491525423729;0,56589931697445;-0,593650682337956;0,837673342173149;0,866969021899423;0,775275471703536;HK2;1
GO:0031401;positive regulation of protein modification process;4/67;192/2237;0,0208333333333333;0,695584577114428;-0,77502202364417;0,84146959901654;0,870422403351899;0,77836361195643;ARID5A/JAK2/FAS/UBB;4
GO:0002064;epithelial cell development;1/67;60/2237;0,0166666666666667;0,556467661691542;-0,611807976440326;0,842666861950192;0,87070978534297;0,778620599464702;ATF4;1
GO:0070555;response to interleukin-1;1/67;60/2237;0,0166666666666667;0,556467661691542;-0,611807976440326;0,842666861950192;0,87070978534297;0,778620599464702;NR1D1;1
GO:0051668;localization within membrane;2/67;108/2237;0,0185185185185185;0,618297401879491;-0,714319649917799;0,844454411774643;0,872081055562254;0,779846839548528;TMBIM1/BCL2L1;2
GO:0048762;mesenchymal cell differentiation;1/67;61/2237;0,0163934426229508;0,547345241008074;-0,629717839439592;0,847508993438174;0,874758601401581;0,782241199163644;CTNNB1;1
GO:0009101;glycoprotein biosynthetic process;1/67;62/2237;0,0161290322580645;0,538517091959557;-0,647388929830737;0,852204258805657;0,87816913284979;0,785291021372374;CTNNB1;1
GO:0030111;regulation of Wnt signaling pathway;1/67;62/2237;0,0161290322580645;0,538517091959557;-0,647388929830737;0,852204258805657;0,87816913284979;0,785291021372374;CTNNB1;1
GO:0031331;positive regulation of cellular catabolic process;1/67;62/2237;0,0161290322580645;0,538517091959557;-0,647388929830737;0,852204258805657;0,87816913284979;0,785291021372374;ZFP36;1
GO:0098662;inorganic cation transmembrane transport;2/67;111/2237;0,018018018018018;0,601586661288154;-0,75640982860371;0,855469670209996;0,881054679378865;0,787871382826984;ORAI2/SLC13A3;2
GO:0060562;epithelial tube morphogenesis;1/67;63/2237;0,0158730158730159;0,529969201610993;-0,664829458222612;0,856757047155092;0,881901003973774;0,788628197295505;CTNNB1;1
GO:0016050;vesicle organization;1/67;64/2237;0,015625;0,521688432835821;-0,68204721757049;0,861171618378923;0,884522258790499;0,79097221941528;SAR1A;1
GO:0030198;extracellular matrix organization;1/67;64/2237;0,015625;0,521688432835821;-0,68204721757049;0,861171618378923;0,884522258790499;0,79097221941528;APBB2;1
GO:0043062;extracellular structure organization;1/67;64/2237;0,015625;0,521688432835821;-0,68204721757049;0,861171618378923;0,884522258790499;0,79097221941528;APBB2;1
GO:0050920;regulation of chemotaxis;1/67;64/2237;0,015625;0,521688432835821;-0,68204721757049;0,861171618378923;0,884522258790499;0,79097221941528;DUSP1;1
GO:0045229;external encapsulating structure organization;1/67;65/2237;0,0153846153846154;0,513662456946039;-0,699049610915647;0,865452106905666;0,888437013809935;0,794472936819978;APBB2;1
GO:0098655;monoatomic cation transmembrane transport;2/67;115/2237;0,0173913043478261;0,580661907852044;-0,811117888307375;0,869068725194713;0,891666395188941;0,797360767998114;ORAI2/SLC13A3;2
GO:0006887;exocytosis;1/67;66/2237;0,0151515151515152;0,505879692446857;-0,715843676873258;0,869602525339054;0,891731014072641;0,797418552572045;ADORA2B;1
GO:0045860;positive regulation of protein kinase activity;1/67;67/2237;0,0149253731343284;0,498329249276008;-0,73243611308324;0,873626767993261;0,895372888841579;0,800675250456344;JAK2;1
GO:0098660;inorganic ion transmembrane transport;2/67;117/2237;0,0170940170940171;0,570736063273377;-0,83790125046997;0,875426409747423;0,896732082239924;0,8018906910043;ORAI2/SLC13A3;2
GO:0043123;positive regulation of canonical NF-kappaB signal transduction;1/67;69/2237;0,0144927536231884;0,483884923210037;-0,765041309898839;0,881311732280122;0,901785208502729;0,806409381693376;NEK6;1
GO:0071674;mononuclear cell migration;1/67;69/2237;0,0144927536231884;0,483884923210037;-0,765041309898839;0,881311732280122;0,901785208502729;0,806409381693376;DUSP1;1
GO:0060485;mesenchyme development;1/67;70/2237;0,0142857142857143;0,476972281449893;-0,781065947130508;0,884979681513163;0,905049415111193;0,809328354867954;CTNNB1;1
GO:0033674;positive regulation of kinase activity;1/67;71/2237;0,0140845070422535;0,470254361992853;-0,79691274329595;0,888535916556364;0,907346952810192;0,811382897277608;JAK2;1
GO:0048638;regulation of developmental growth;1/67;71/2237;0,0140845070422535;0,470254361992853;-0,79691274329595;0,888535916556364;0,907346952810192;0,811382897277608;STAT3;1
GO:0001932;regulation of protein phosphorylation;4/67;210/2237;0,019047619047619;0,635963041933191;-0,973580089750922;0,888663462229623;0,907346952810192;0,811382897277608;GADD45A/DUSP1/JAK2/FAS;4
GO:0019220;regulation of phosphate metabolic process;5/67;252/2237;0,0198412698412698;0,662461502013741;-0,999279003736209;0,889699254855675;0,907915080116729;0,811890937535606;GADD45A/DUSP1/JAK2/FAS/STAT3;5
GO:0051174;regulation of phosphorus metabolic process;5/67;253/2237;0,0197628458498024;0,659843077104596;-1,009281179581;0,89176131128405;0,908288869896774;0,812225194055415;GADD45A/DUSP1/JAK2/FAS/STAT3;5
GO:0009100;glycoprotein metabolic process;1/67;72/2237;0,0138888888888889;0,463723051409619;-0,81258698392862;0,891983789866948;0,908288869896774;0,812225194055415;CTNNB1;1
GO:0034329;cell junction assembly;1/67;72/2237;0,0138888888888889;0,463723051409619;-0,81258698392862;0,891983789866948;0,908288869896774;0,812225194055415;CTNNB1;1
GO:0042742;defense response to bacterium;1/67;72/2237;0,0138888888888889;0,463723051409619;-0,81258698392862;0,891983789866948;0,908288869896774;0,812225194055415;GBP5;1
GO:0002685;regulation of leukocyte migration;1/67;73/2237;0,0136986301369863;0,457370680842364;-0,828093720915818;0,895326554799472;0,911202845131757;0,814830977500693;DUSP1;1
GO:0050730;regulation of peptidyl-tyrosine phosphorylation;1/67;74/2237;0,0135135135135135;0,451189995966115;-0,843437786051206;0,898567368490985;0,914009987068704;0,817341226695684;JAK2;1
GO:0040011;locomotion;6/67;302/2237;0,0198675496688742;0,663338934466739;-1,10509423794114;0,907193954686948;0,92228950626789;0,824745076187981;GADD45A/DUSP1/JAK2/KLF4/STAT3/TIMP1;6
GO:0034220;monoatomic ion transmembrane transport;2/67;130/2237;0,0153846153846154;0,513662456946039;-1,00373863007356;0,910366396592043;0,925018216279683;0,827185188681159;ORAI2/SLC13A3;2
GO:0042325;regulation of phosphorylation;4/67;223/2237;0,0179372197309417;0,598888963255471;-1,10899795267189;0,914803711271879;0,928786615110689;0,830555029018562;GADD45A/DUSP1/JAK2/FAS;4
GO:0016192;vesicle-mediated transport;5/67;266/2237;0,018796992481203;0,627595107170912;-1,13672737393314;0,915751407542871;0,928786615110689;0,830555029018562;CTNNB1/SAR1A/ADORA2B/BCL2L1/TGM2;5
GO:0030595;leukocyte chemotaxis;1/67;80/2237;0,0125;0,417350746268657;-0,932331911875341;0,916036640457639;0,928786615110689;0,830555029018562;DUSP1;1
GO:0097529;myeloid leukocyte migration;1/67;80/2237;0,0125;0,417350746268657;-0,932331911875341;0,916036640457639;0,928786615110689;0,830555029018562;DUSP1;1
GO:0042692;muscle cell differentiation;1/67;81/2237;0,0123456790123457;0,412198267919661;-0,946656511920554;0,918644681760067;0,930434773932389;0,832028873037967;CTNNB1;1
GO:0044057;regulation of system process;1/67;81/2237;0,0123456790123457;0,412198267919661;-0,946656511920554;0,918644681760067;0,930434773932389;0,832028873037967;ADORA2B;1
GO:0070925;organelle assembly;2/67;135/2237;0,0148148148148148;0,494637921503593;-1,06413471800287;0,921218082891181;0,932542516833723;0,833913693984028;HSPA1A/NEK6;2
GO:0008015;blood circulation;1/67;84/2237;0,0119047619047619;0,397476901208244;-0,98885989389983;0,925999338549769;0,936881809408794;0,83779404842925;ADORA2B;1
GO:0006897;endocytosis;2/67;138/2237;0,0144927536231884;0,483884923210037;-1,09957106725977;0,927132601674976;0,937527574785053;0,838371515494442;BCL2L1/TGM2;2
GO:0051051;negative regulation of transport;1/67;86/2237;0,0116279069767442;0,388233252342936;-1,01638517509758;0,930534419671155;0,940465416679385;0,840998641381165;ATF4;1
GO:0018108;peptidyl-tyrosine phosphorylation;1/67;87/2237;0,0114942528735632;0,383770801166581;-1,02997362354891;0,932698154623285;0,942149495923468;0,842504606758662;JAK2;1
GO:0061061;muscle structure development;2/67;142/2237;0,0140845070422535;0,470254361992853;-1,1459429099584;0,934379312669801;0,943261915975789;0,843499373536956;CTNNB1/ARID5B;2
GO:0018212;peptidyl-tyrosine modification;1/67;88/2237;0,0113636363636364;0,379409769335142;-1,04344964826862;0,934795467944327;0,943261915975789;0,843499373536956;JAK2;1
GO:0006468;protein phosphorylation;5/67;282/2237;0,0177304964539007;0,591986874139939;-1,28756375265518;0,938899712849173;0,946867074766254;0,846723238647753;GADD45A/DUSP1/JAK2/NEK6/FAS;5
GO:0001934;positive regulation of protein phosphorylation;2/67;145/2237;0,0137931034482759;0,460524961399897;-1,18009766166327;0,939368127500418;0,946867074766254;0,846723238647753;JAK2/FAS;2
GO:0030335;positive regulation of cell migration;2/67;148/2237;0,0135135135135135;0,451189995966115;-1,21374398616792;0,944001444735724;0,951031242728437;0,850446990246237;JAK2/STAT3;2
GO:0042327;positive regulation of phosphorylation;2/67;150/2237;0,0133333333333333;0,445174129353234;-1,2359034437349;0,946904193733606;0,953448454509011;0,852608549605402;JAK2/FAS;2
GO:2000147;positive regulation of cell motility;2/67;152/2237;0,0131578947368421;0,439316575019639;-1,25785307544726;0,949665644610787;0,955720898455276;0,854640652261735;JAK2/STAT3;2
GO:0010256;endomembrane system organization;1/67;98/2237;0,0102040816326531;0,340694486749924;-1,17256732266398;0,952529113068753;0,9580935423007;0,85676235733998;NEK6;1
GO:0040017;positive regulation of locomotion;2/67;155/2237;0,0129032258064516;0,430813673567646;-1,29039710192381;0,953556499822703;0,958617840055308;0,857231203606397;JAK2/STAT3;2
GO:0060326;cell chemotaxis;1/67;100/2237;0,01;0,333880597014925;-1,1972731884546;0,95545707724702;0,960018941276316;0,858484119665199;DUSP1;1
GO:0003008;system process;4/67;257/2237;0,0155642023346304;0,519658516754748;-1,43789606551298;0,95952331137722;0,963593399654536;0,861680531342271;APBB2/PTGES/ADORA2B/SLC13A3;4
GO:0010562;positive regulation of phosphorus metabolic process;2/67;164/2237;0,0121951219512195;0,407171459774299;-1,38546261217742;0,963601271227192;0,966663563402703;0,864425984279969;JAK2/FAS;2
GO:0045937;positive regulation of phosphate metabolic process;2/67;164/2237;0,0121951219512195;0,407171459774299;-1,38546261217742;0,963601271227192;0,966663563402703;0,864425984279969;JAK2/FAS;2
GO:0007507;heart development;1/67;111/2237;0,00900900900900901;0,300793330644077;-1,32748265566631;0,968649838963103;0,971213761247283;0,868494937946356;CTNNB1;1
GO:0098657;import into cell;2/67;171/2237;0,0116959064327485;0,390503622239679;-1,45695943290086;0,969956557674147;0,972009375785627;0,869206405623895;BCL2L1/TGM2;2
GO:0050877;nervous system process;1/67;119/2237;0,00840336134453781;0,280571930264643;-1,41690690064531;0,975745188739756;0,9772931715881;0,873931369468823;PTGES;1
GO:0050900;leukocyte migration;1/67;124/2237;0,00806451612903226;0,269258545979778;-1,47084962158385;0,979349558439199;0,980384811672221;0,876696027333187;DUSP1;1
GO:0006935;chemotaxis;1/67;132/2237;0,00757575757575758;0,252939846223428;-1,55438974530282;0,984048942165464;0,984048942165464;0,879972627101779;DUSP1;1
GO:0042330;taxis;1/67;132/2237;0,00757575757575758;0,252939846223428;-1,55438974530282;0,984048942165464;0,984048942165464;0,879972627101779;DUSP1;1
